<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001319.pub5" GROUP_ID="INJ" ID="540099072011521412" MERGED_FROM="" MODIFIED="2012-10-16 19:26:59 +0100" MODIFIED_BY="Emma Sydenham" REVIEW_NO="INJ0051" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2012-10-16 19:26:15 +0100" MODIFIED_BY="Emma Sydenham">
<TITLE MODIFIED="2012-05-29 21:42:52 +0100" MODIFIED_BY="Anne Lawson">Colloid solutions for fluid resuscitation</TITLE>
<CONTACT>
<PERSON ID="11163" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Frances</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bunn</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Fellow</POSITION>
<EMAIL_1>f.bunn@herts.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Research in Primary and Community Care</DEPARTMENT>
<ORGANISATION>University of Hertfordshire</ORGANISATION>
<ADDRESS_1>College Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hatfield</CITY>
<ZIP>AL10 9AB</ZIP>
<REGION>Hertfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01707 286457</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-10-16 19:24:19 +0100" MODIFIED_BY="Emma Sydenham">
<PERSON ID="11163" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Frances</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bunn</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Research Fellow</POSITION>
<EMAIL_1>f.bunn@herts.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Research in Primary and Community Care</DEPARTMENT>
<ORGANISATION>University of Hertfordshire</ORGANISATION>
<ADDRESS_1>College Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hatfield</CITY>
<ZIP>AL10 9AB</ZIP>
<REGION>Hertfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01707 286457</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8460C44382E26AA2017D2D709AFC4B17" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Daksha</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Trivedi</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>d.trivedi@herts.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Research in Primary and Community Care</DEPARTMENT>
<ORGANISATION>University of Hertfordshire</ORGANISATION>
<ADDRESS_1>College Lane</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hatfield</CITY>
<ZIP>AL10 9AB</ZIP>
<REGION>Hertfordshire</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01707 286389</PHONE_1>
<PHONE_2/>
<FAX_1>01707 286457</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-09-13 14:39:18 +0100" MODIFIED_BY="Deirdre Beecher">
<UP_TO_DATE>
<DATE DAY="1" MONTH="12" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="12" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="7" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="7" YEAR="2012"/>
</DATES>
<WHATS_NEW MODIFIED="2012-10-16 19:26:15 +0100" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-10-16 19:26:15 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="10" YEAR="2012"/>
<DESCRIPTION>
<P>Minor copy edits made to analysis labels</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-10-16 19:25:53 +0100" MODIFIED_BY="Emma M Sydenham">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-10-16 19:25:53 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="12" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>Due to the retraction of four studies (<LINK REF="STD-Boldt-2006" TYPE="STUDY">Boldt 2006</LINK>; <LINK REF="STD-Haisch-2001a" TYPE="STUDY">Haisch 2001a</LINK>; <LINK REF="STD-Haisch-2001b" TYPE="STUDY">Haisch 2001b</LINK>; <LINK REF="STD-Huttner-2000" TYPE="STUDY">Huttner 2000</LINK>), the review has been amended. The retracted studies, and their associated data, are now excluded from the review. </P>
<P>The conclusions of the review have not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-06-12 16:54:09 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="1" MONTH="5" YEAR="2012"/>
<DESCRIPTION>
<P>The review has been updated to December 2011. Twenty additional studies have been included (<LINK REF="STD-Akech-2006" TYPE="STUDY">Akech 2006;</LINK> <LINK REF="STD-Dolecek-2009" TYPE="STUDY">Dolecek 2009</LINK>; <LINK REF="STD-Friedman-2008" TYPE="STUDY">Friedman 2008</LINK>; <LINK REF="STD-Godet-2008" TYPE="STUDY">Godet 2008</LINK>; <LINK REF="STD-Gombocz-2007" TYPE="STUDY">Gombocz 2007</LINK>; <LINK REF="STD-Gondos-2010" TYPE="STUDY">Gondos 2010</LINK>; <LINK REF="STD-Haas-2007" TYPE="STUDY">Haas 2007</LINK>; <LINK REF="STD-Hecht_x002d_Dolnik-2009" TYPE="STUDY">Hecht-Dolnik 2009</LINK>; <LINK REF="STD-Inal-2010" TYPE="STUDY">Inal 2010</LINK>; <LINK REF="STD-Jin-2010" TYPE="STUDY">Jin 2010</LINK>; <LINK REF="STD-Mahmood-2007" TYPE="STUDY">Mahmood 2007</LINK>; <LINK REF="STD-Mittermayr-2007" TYPE="STUDY">Mittermayr 2007</LINK>; <LINK REF="STD-Mukhtar-2009" TYPE="STUDY">Mukhtar 2009</LINK>; <LINK REF="STD-Ooi-2009" TYPE="STUDY">Ooi 2009</LINK>; <LINK REF="STD-Reine-2008" TYPE="STUDY">Reine 2008</LINK>; <LINK REF="STD-Schramko-2009" TYPE="STUDY">Schramko 2009</LINK>; <LINK REF="STD-Schramko-2010" TYPE="STUDY">Schramko 2010</LINK>; <LINK REF="STD-Standl-2008" TYPE="STUDY">Standl 2008</LINK>; <LINK REF="STD-Volta-2007" TYPE="STUDY">Volta 2007</LINK>; <LINK REF="STD-Yang-2011" TYPE="STUDY">Yang 2011</LINK>). The conclusions of the review have not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-06-12 16:52:52 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="30" MONTH="4" YEAR="2012"/>
<DESCRIPTION>
<P>The review has been updated to December 2011.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="10" MONTH="2" YEAR="2011"/>
<DESCRIPTION>
<P>The editorial group is aware that a clinical trial by Prof. Joachim Boldt has been found to have been fabricated (<LINK REF="REF-Boldt-2009" TYPE="REFERENCE">Boldt 2009</LINK>). As the editors who revealed this fabrication point out (<LINK REF="REF-Reinhart-2011" TYPE="REFERENCE">Reinhart 2011</LINK>; <LINK REF="REF-Shafer-2011" TYPE="REFERENCE">Shafer 2011</LINK>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author (<LINK REF="STD-Boldt-1986" TYPE="STUDY">Boldt 1986</LINK>, <LINK REF="STD-Boldt-1993a" TYPE="STUDY">Boldt 1993a</LINK>, <LINK REF="STD-Boldt-1995" TYPE="STUDY">Boldt 1995</LINK>, <LINK REF="STD-Boldt-1996a" TYPE="STUDY">Boldt 1996a</LINK>, <LINK REF="STD-Boldt-1996b" TYPE="STUDY">Boldt 1996b</LINK>, <LINK REF="STD-Boldt-1996c" TYPE="STUDY">Boldt 1996c</LINK>, <LINK REF="STD-Boldt-1998" TYPE="STUDY">Boldt 1998</LINK>, <LINK REF="STD-Boldt-2000" TYPE="STUDY">Boldt 2000</LINK>, <LINK REF="STD-Boldt-2001" TYPE="STUDY">Boldt 2001</LINK>, Boldt 2006a, Haisch 2001c, Haisch 2001c, Huttner 2000a) on the conclusions of the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-02-10 16:25:55 +0000" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="11" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-18 17:53:04 +0100" MODIFIED_BY="Emma M Sydenham">
<DATE DAY="2" MONTH="10" YEAR="2007"/>
<DESCRIPTION>
<P>The search for the review was updated in March 2007 and thirteen new studies were added to the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Hertfordshire</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-06-11 15:20:42 +0100" MODIFIED_BY="Emma M Sydenham">
<SUMMARY MODIFIED="2012-05-30 10:15:22 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-05-30 10:15:22 +0100" MODIFIED_BY="[Empty name]">Are particular types of colloid solution safer for replacing blood fluids than others?</TITLE>
<SUMMARY_BODY>
<P>When a person is bleeding heavily, the loss of fluid volume in their veins can lead to shock, so they need fluid resuscitation. Colloids and crystalloids are two types of solutions used to replace lost blood fluid (plasma). They include blood and synthetic products. Both colloids and crystalloids appear to be similarly effective at resuscitation. There are different types of colloids and these may have different effects. However, the review of trials found there is not enough evidence to be sure that any particular colloid is safer than any other.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-06-11 15:07:37 +0100" MODIFIED_BY="Emma M Sydenham">
<ABS_BACKGROUND MODIFIED="2012-05-29 12:46:04 +0100" MODIFIED_BY="Anne Lawson">
<P>Colloids are widely used in the replacement of fluid volume. However, doubts remain as to which colloid is best. Different colloids vary in their molecular weight and therefore in the length of time they remain in the circulatory system. Because of this, and their other characteristics, they may differ in their safety and efficacy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To compare the effects of different colloid solutions in patients thought to need volume replacement.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-06-11 13:15:25 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Injuries Specialised Register (searched 1 December 2011), the Cochrane Central Register of Controlled Trials 2011, issue 4 (<I>The Cochrane Library</I>); MEDLINE (Ovid) (1948 to November Week 3 2011); EMBASE (Ovid) (1974 to 2011 Week 47); ISI Web of Science: Science Citation Index Expanded (1970 to 1 December 2011); ISI Web of Science: Conference Proceedings Citation Index-Science (1990 to 1 December 2011); CINAHL (EBSCO) (1982 to 1 December 2011); National Research Register (2007, Issue 1) and PubMed (searched 1 December 2011). Bibliographies of trials retrieved were searched, and for the initial version of the review drug companies manufacturing colloids were contacted for information (1999).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-05-03 12:17:04 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Randomised controlled trials comparing colloid solutions in critically ill and surgical patients thought to need volume replacement. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-05-29 19:57:26 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Two review authors independently extracted the data and assessed the quality of the trials. The outcomes sought were death, amount of whole blood transfused, and incidence of adverse reactions.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-06-11 15:07:37 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Eighty-six trials, with a total of 5,484 participants, met the inclusion criteria. Quality of allocation concealment was judged to be adequate in 33 trials and poor or uncertain in the rest.</P>
<P>Deaths were reported in 57 trials. For albumin or plasma protein fraction (PPF) versus hydroxyethyl starch (HES) 31 trials (n = 1719) reported mortality. The pooled relative risk (RR) was 1.06 (95% confidence interval (CI) 0.86 to 1.31). When the trials by Boldt were removed from the analysis the pooled RR was 0.90 (95% CI 0.68 to 1.20). For albumin or PPF versus gelatin, nine trials (n = 824) reported mortality. The RR was 0.89 (95% CI 0.65 to 1.21). Removing the study by Boldt from the analysis did not change the RR or CIs. For albumin or PPF versus dextran four trials (n = 360) reported mortality. The RR was 3.75 (95% CI 0.42 to 33.09). For gelatin versus HES 22 trials (n = 1612) reported mortality and the RR was 1.02 (95% CI 0.84 to 1.26). When the trials by Boldt were removed from the analysis the pooled RR was 1.03 (95% CI 0.84 to 1.27). RR was not estimable in the gelatin versus dextran and HES versus dextran groups.</P>
<P>Forty-one trials recorded the amount of blood transfused; however, quantitative analysis was not possible due to skewness and variable reporting. Twenty-four trials recorded adverse reactions, with two studies reporting possible adverse reactions to gel and one to HES.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-05-29 19:57:26 +0100" MODIFIED_BY="Anne Lawson">
<P>From this review, there is no evidence that one colloid solution is more effective or safe than any other, although the CIs were wide and do not exclude clinically significant differences between colloids. Larger trials of fluid therapy are needed if clinically significant differences in mortality are to be detected or excluded.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-06-11 15:20:42 +0100" MODIFIED_BY="Emma M Sydenham">
<BACKGROUND MODIFIED="2012-06-11 11:34:54 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Colloids are used as plasma substitutes for short-term replacement of fluid volume while the cause of the problem is being addressed (e.g. stopping bleeding). These solutions can be blood products (human albumin solution, plasma protein fraction (PPF)) or synthetic products (modified gelatins, dextrans, etherified starches). Colloid solutions are widely used in fluid resuscitation (<LINK REF="REF-Yim-1995" TYPE="REFERENCE">Yim 1995</LINK>) and they have been recommended in a number of resuscitation guidelines and intensive care management algorithms (<LINK REF="REF-Armstrong-1994" TYPE="REFERENCE">Armstrong 1994</LINK>; <LINK REF="REF-Vermeulen-1995" TYPE="REFERENCE">Vermeulen 1995</LINK>). Previous systematic reviews have suggested that colloids are no more effective than crystalloids in reducing mortality (<LINK REF="REF-Perel-2012" TYPE="REFERENCE">Perel 2012</LINK>; <LINK REF="REF-Roberts-2011" TYPE="REFERENCE">Roberts 2011</LINK>). Despite this, colloid solutions are still widely used as they are thought to remain in the intravascular space for longer than crystalloids and, therefore, be more effective in maintaining osmotic pressure.</P>
<P>It is plausible that colloids may vary in their safety and effectiveness. Different colloids vary in the length of time they remain in the circulatory system. It may be that some low-to-medium molecular weight colloids (e.g. gelatins and albumin) are more likely to leak into the interstitial space (<LINK REF="REF-Traylor-1996" TYPE="REFERENCE">Traylor 1996</LINK>), whereas some larger molecular weight hydroxyethyl starches (HES) are retained for longer (<LINK REF="REF-Boldt-1996" TYPE="REFERENCE">Boldt 1996</LINK>). In addition it is thought that some colloids may affect coagulation or cause other adverse effects.</P>
<P>This review examines direct comparisons of the different colloid solutions in randomised trials to complement the earlier reviews on colloids compared to crystalloids (<LINK REF="REF-Perel-2012" TYPE="REFERENCE">Perel 2012</LINK>) and human albumin (<LINK REF="REF-Roberts-2011" TYPE="REFERENCE">Roberts 2011</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To quantify the relative effects on mortality of different colloid solutions in critically ill and surgical patients requiring volume replacement, by examining direct comparisons of colloid solutions.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-06-11 11:35:25 +0100" MODIFIED_BY="Emma M Sydenham">
<SELECTION_CRITERIA MODIFIED="2012-05-30 10:21:07 +0100" MODIFIED_BY="Emma M Sydenham">
<CRIT_STUDIES MODIFIED="2012-05-03 11:42:37 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-05-15 14:46:43 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Patients clinically assessed as requiring volume replacement or maintenance of colloid osmotic pressure. </P>
<P>Administration of fluid for preoperative haemodilution or volume loading, during plasma exchange, for priming extracorporeal circuits or following paracentesis are excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-05-30 10:21:07 +0100" MODIFIED_BY="Anne Lawson">
<P>The colloid solutions considered are human albumin solutions, PPF, modified gelatins, dextran 70, or etherified starch solutions.</P>
<P>Trials of other blood products not used primarily for volume replacement (e.g. fresh frozen plasma (FFP), pooled serum) were excluded.</P>
<P>The review compares the administration of any regimens of different classes of colloids with each other.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-05-29 19:14:46 +0100" MODIFIED_BY="Anne Lawson">
<P>The primary outcome measure was mortality from any cause at the end of the study period.</P>
<P>We also attempted to find data on incidence of adverse reactions, allergies or anaphylactic shock, and the amount of blood (whole blood or red blood cells) transfused in each group. Some of the synthetic colloids may have anticoagulant properties and, therefore, we felt that some measure of blood loss or haemorrhage was important. However, as blood loss is vulnerable to measurement error, we decided to use the amount of blood products transfused as an outcome measure.</P>
<P>Intermediate physiological outcomes were not used for several reasons. These were that they are subject to intra- and inter-observer variation, they have no face value to patients and relatives, and the ones seen as appropriate are not stable over time. Also there would need to exist a strong predictive relationship between the variable and mortality.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-05-30 11:25:28 +0100" MODIFIED_BY="Emma M Sydenham">
<P>We did not limit the search for trials by language, date, or publication status.</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-05-30 11:11:04 +0100" MODIFIED_BY="Emma M Sydenham">
<P>We searched the following electronic databases:<BR/>
</P>
<UL>
<LI>Cochrane Injuries Specialised Register (searched 1 Dec 2011);</LI>
<LI>the Cochrane Central Register of Controlled Trials (2011, issue 4, <I>The Cochrane Library</I>);</LI>
<LI>MEDLINE (Ovid) (1948 to November Week 3 2011);</LI>
<LI>EMBASE (Ovid) (1974 to 2011 Week 47);</LI>
<LI>ISI Web of Science: Science Citation Index Expanded (1970 to 1 December 2011);</LI>
<LI>ISI Web of Science: Conference Proceedings Citation Index-Science (1990 to 1 December 2011);</LI>
<LI>CINAHL (EBSCO) (1982 to 1 December 2011);</LI>
<LI>PubMed (<A HREF="http://ncbi.nlm.nih.gov/sites/entrez/">ncbi.nlm.nih.gov/sites/entrez/</A>)  (searched 1 December 2011 limit-Humans, published in the last 90 days);</LI>
<LI>National Research Register (issue 1, 2007);</LI>
<LI>Zetoc (searched 23 March 2007).</LI>
</UL>
<P>Full search strategies are listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-05-30 11:25:28 +0100" MODIFIED_BY="Emma M Sydenham">
<P>We searched the bibliographies of the retrieved trials and contacted drug companies manufacturing colloids for information. For the original version of the review in 1999 we also identified trials by using the searches undertaken for the pre-existing review of colloids versus crystalloids (<LINK REF="REF-Perel-2012" TYPE="REFERENCE">Perel 2012</LINK>), which included BIDS Index to Scientific and Technical Proceedings, drawing on the handsearching of 29 international journals and the proceedings of several international meetings on fluid resuscitation, and checking the reference lists of the trials found. There were no language restrictions in any of the searches.</P>
<P>To identify unpublished trials we searched the register of the Medical Editors' Trial Amnesty and we contacted the UK Medicines Control Agency.</P>
<P>For the first version of the review (published 1999) we also contacted the medical directors of the following companies, which all manufacture colloids:<BR/>
</P>
<UL>
<LI>Alpha Therapeutic UK Limited (Albutein),</LI>
<LI>American Critical Care McGraw (Hespan),</LI>
<LI>Bayer (Plasbumin),</LI>
<LI>Baxter (Gentran),</LI>
<LI>Bio Products Laboratory (Zenalb),</LI>
<LI>Cambridge Laboratories (Rheomacrodex),</LI>
<LI>Centeon Ltd (Albuminar),</LI>
<LI>CIS UK Ltd,</LI>
<LI>CP (Lomodex),</LI>
<LI>Common Services Agency,</LI>
<LI>Consolidated (Gelofusine),</LI>
<LI>DuPont (Hespan),</LI>
<LI>Fresenius (eloHAES and HAES-Steril),</LI>
<LI>Geistlich Sons Ltd (Hespan and Pentaspan),</LI>
<LI>Hoechst (Haemaccel),</LI>
<LI>Mallinckrodt Medical GMBH (Infoson),</LI>
<LI>Nycomed, Oxford Nutrition (Elohes),</LI>
<LI>Pharmacia and Upjohn Ltd (Rheomacrodex),</LI>
<LI>Sorin Biomedica Diagnostics Spa.</LI>
</UL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-06-11 11:35:25 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The Injuries Group Trials Search Co-ordinator ran the electronic database searches, collated the results, and removed duplicates before sending them to the review authors for screening.</P>
<STUDY_SELECTION MODIFIED="2012-05-29 19:15:10 +0100" MODIFIED_BY="Emma M Sydenham">
<P>One review author examined the search results for reports of possibly relevant trials and these reports were then retrieved in full. Two review authors applied the selection criteria independently to the trial reports, resolving disagreements by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-05-29 21:20:54 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Two review authors independently extracted information on the following:<BR/>
</P>
<UL>
<LI>method of allocation concealment,</LI>
<LI>number of randomised patients,</LI>
<LI>type of participants,</LI>
<LI>the interventions,</LI>
<LI>outcome data (numbers of deaths, volume of blood transfused, and incidence of adverse or allergic reactions).</LI>
</UL>
<P>The review authors were not blinded to the trial authors or journal when doing this, as the value of this has not been established (<LINK REF="REF-Berlin-1997" TYPE="REFERENCE">Berlin 1997</LINK>). Results were compared and any differences resolved by discussion. Where there was insufficient information in the published report, we attempted to contact the trial authors for clarification.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-05-29 21:20:45 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Since there is evidence that the quality of allocation concealment particularly affects the results of studies (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), two review authors scored this quality on the scale used by <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK> as shown below, assigning 'high risk of bias' to poorest quality and 'low risk of bias' to best quality:</P>
<UL>
<LI>low risk of bias = trials deemed to have taken adequate measures to conceal allocation (i.e. central randomisation; numbered or coded bottles or containers; drugs prepared by the pharmacy; serially numbered, opaque, sealed envelopes; or other description that contained elements convincing of concealment);</LI>
<LI>unclear risk of bias = trials in which the authors either did not report an allocation concealment approach at all or reported an approach that did not fall into one of the other categories;</LI>
<LI>high risk of bias = trials in which concealment was inadequate (such as alternation or reference to case record numbers or to dates of birth).</LI>
</UL>
<P>Where the method used to conceal allocation was not clearly reported, the trial author was contacted, if possible, for clarification. We then compared the scores allocated and resolved differences by discussion.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-06-11 11:35:25 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The following comparisons were made:<BR/>
</P>
<UL>
<LI>albumin or PPF versus etherified starch,</LI>
<LI>albumin or PPF versus modified gelatin,</LI>
<LI>albumin or PPF versus dextran 70,</LI>
<LI>modified gelatin versus etherified starch,</LI>
<LI>modified gelatin versus dextran 70,</LI>
<LI>etherified starch versus dextran 70.</LI>
</UL>
<P>For each trial we calculated the risk ratio (RR) of death and 95% confidence interval (CI), such that a RR of more than 1 indicates a higher risk of death in the first group named. </P>
<P>We examined the groups of trials for statistical evidence of heterogeneity using Chi<SUP>2</SUP> and I<SUP>2</SUP> tests. If there was no obvious heterogeneity on visual inspection or statistical testing, we calculated pooled RRs and 95% CIs using a fixed-effects model.</P>
<P>We assessed the skewness of continuous data by checking the mean and standard deviation (if available). If the standard deviation is more than twice the mean for data with a finite end point (such as 0 in the case of bleeding), the data are likely to be skewed and it is inappropriate to apply parametric tests (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). This is because the mean is unlikely to be a good measure of central tendency. If parametric tests could not be applied, we tabulated the data.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-05-29 19:15:28 +0100" MODIFIED_BY="Emma M Sydenham">
<P>We examined the effect of excluding trials judged to have inadequate (scoring 'high risk of bias') allocation concealment in a sensitivity analysis.</P>
<P>The editorial group is aware that a clinical trial by Professor Joachim Boldt has been found to have been fabricated (<LINK REF="REF-Boldt-2009" TYPE="REFERENCE">Boldt 2009</LINK>). As the editors who revealed this fabrication pointed out (<LINK REF="REF-Reinhart-2011" TYPE="REFERENCE">Reinhart 2011</LINK>; <LINK REF="REF-Shafer-2011" TYPE="REFERENCE">Shafer 2011</LINK>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews that include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author on the conclusions of the review.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-06-11 15:20:42 +0100" MODIFIED_BY="Emma M Sydenham">
<STUDY_DESCRIPTION MODIFIED="2012-06-11 13:46:29 +0100" MODIFIED_BY="Emma M Sydenham">
<P>For more detailed descriptions of individual studies, see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'.</P>
<P>Eighty-six studies met the inclusion criteria, with a total of 5488 participants. The earliest trial was from 1980 and the most recent from 2011. From the drug companies that we contacted in 1999, we were sent information by Baxter Healthcare Ltd, CIS UK Ltd, Fresenius Ltd, Hoechst and Pharmacia. No new trials were identified from the information sent to us.</P>
<P>The trials included the following comparisons.</P>
<SUBSECTION>
<HEADING LEVEL="3">Albumin or PPF versus starch (50 trials with 2458 participants in these groups)</HEADING>
<P>
<LINK REF="STD-Arellano-2005" TYPE="STUDY">Arellano 2005</LINK>; <LINK REF="STD-Boldt-1986" TYPE="STUDY">Boldt 1986</LINK>; <LINK REF="STD-Boldt-1993a" TYPE="STUDY">Boldt 1993a</LINK>; <LINK REF="STD-Boldt-1995" TYPE="STUDY">Boldt 1995</LINK>; <LINK REF="STD-Boldt-1996a" TYPE="STUDY">Boldt 1996a</LINK>; <LINK REF="STD-Boldt-1996b" TYPE="STUDY">Boldt 1996b</LINK>; <LINK REF="STD-Boldt-1996c" TYPE="STUDY">Boldt 1996c</LINK>; <LINK REF="STD-Boldt-1998" TYPE="STUDY">Boldt 1998</LINK>; <LINK REF="STD-Brock-1995" TYPE="STUDY">Brock 1995</LINK>; <LINK REF="STD-Brutocao-1996" TYPE="STUDY">Brutocao 1996</LINK>; <LINK REF="STD-Claes-1992" TYPE="STUDY">Claes 1992</LINK>; <LINK REF="STD-Diehl-1982" TYPE="STUDY">Diehl 1982</LINK>; <LINK REF="STD-Dolecek-2009" TYPE="STUDY">Dolecek 2009</LINK>; <LINK REF="STD-Falk-1988" TYPE="STUDY">Falk 1988</LINK>; <LINK REF="STD-Friedman-2008" TYPE="STUDY">Friedman 2008</LINK>; <LINK REF="STD-Fulachier-1994" TYPE="STUDY">Fulachier 1994</LINK>; <LINK REF="STD-Gahr-1981" TYPE="STUDY">Gahr 1981</LINK>; <LINK REF="STD-Gallagher-1985" TYPE="STUDY">Gallagher 1985</LINK>; <LINK REF="STD-Gold-1990" TYPE="STUDY">Gold 1990</LINK>; <LINK REF="STD-Gondos-2010" TYPE="STUDY">Gondos 2010</LINK>; <LINK REF="STD-Haas-2007" TYPE="STUDY">Haas 2007</LINK>; <LINK REF="STD-Hausdorfer-1986" TYPE="STUDY">Hausdorfer 1986</LINK>; <LINK REF="STD-Hecht_x002d_Dolnik-2009" TYPE="STUDY">Hecht-Dolnik 2009</LINK>; <LINK REF="STD-Hiippala-1995" TYPE="STUDY">Hiippala 1995</LINK>; <LINK REF="STD-Huskisson-1993" TYPE="STUDY">Huskisson 1993</LINK>; <LINK REF="STD-Jones-2004" TYPE="STUDY">Jones 2004</LINK>; <LINK REF="STD-Kirklin-1984" TYPE="STUDY">Kirklin 1984</LINK>; <LINK REF="STD-London-1989" TYPE="STUDY">London 1989</LINK>; <LINK REF="STD-Mastroianni-1994" TYPE="STUDY">Mastroianni 1994</LINK>; <LINK REF="STD-Moggio-1983" TYPE="STUDY">Moggio 1983</LINK>; <LINK REF="STD-Mukhtar-2009" TYPE="STUDY">Mukhtar 2009</LINK>; <LINK REF="STD-Munoz-1980" TYPE="STUDY">Munoz 1980</LINK>; <LINK REF="STD-Munsch-1988" TYPE="STUDY">Munsch 1988</LINK>; <LINK REF="STD-Niemi-2006" TYPE="STUDY">Niemi 2006</LINK>; <LINK REF="STD-Prien-1990" TYPE="STUDY">Prien 1990</LINK>; <LINK REF="STD-Rackow-1983" TYPE="STUDY">Rackow 1983</LINK>; <LINK REF="STD-Rackow-1989" TYPE="STUDY">Rackow 1989</LINK>; <LINK REF="STD-Reine-2008" TYPE="STUDY">Reine 2008</LINK>; <LINK REF="STD-Rosencher-1992" TYPE="STUDY">Rosencher 1992</LINK>; <LINK REF="STD-Schramko-2009" TYPE="STUDY">Schramko 2009</LINK>; <LINK REF="STD-Shatney-1983" TYPE="STUDY">Shatney 1983</LINK>; <LINK REF="STD-Standl-2008" TYPE="STUDY">Standl 2008</LINK>; <LINK REF="STD-Veneman-2004" TYPE="STUDY">Veneman 2004</LINK>; <LINK REF="STD-Verheij-2006" TYPE="STUDY">Verheij 2006</LINK>; <LINK REF="STD-Vogt-1994" TYPE="STUDY">Vogt 1994</LINK>; <LINK REF="STD-Vogt-1996" TYPE="STUDY">Vogt 1996</LINK>; <LINK REF="STD-Vogt-1999" TYPE="STUDY">Vogt 1999</LINK>; <LINK REF="STD-von-Sommoggy-1990" TYPE="STUDY">von Sommoggy 1990</LINK>; <LINK REF="STD-Woittiez-1997" TYPE="STUDY">Woittiez 1997</LINK>; <LINK REF="STD-Yang-2011" TYPE="STUDY">Yang 2011</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Albumin or PPF versus dextran (six trials with 410 participants in these groups)</HEADING>
<P>
<LINK REF="STD-Hedstrand-1987" TYPE="STUDY">Hedstrand 1987</LINK>; <LINK REF="STD-Hiippala-1995" TYPE="STUDY">Hiippala 1995</LINK>; <LINK REF="STD-Jones-2004" TYPE="STUDY">Jones 2004</LINK>; <LINK REF="STD-Karanko-1987" TYPE="STUDY">Karanko 1987</LINK>; <LINK REF="STD-Lisander-1996" TYPE="STUDY">Lisander 1996</LINK>; <LINK REF="STD-Tollofsrud-1995" TYPE="STUDY">Tollofsrud 1995</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Albumin or PPF versus gelatin (14 trials with 1152 participants in these groups)</HEADING>
<P>
<LINK REF="STD-Boldt-1986" TYPE="STUDY">Boldt 1986</LINK>; <LINK REF="STD-Du-Gres-1989" TYPE="STUDY">Du Gres 1989</LINK>; <LINK REF="STD-Evans-2003" TYPE="STUDY">Evans 2003</LINK>; <LINK REF="STD-Gondos-2010" TYPE="STUDY">Gondos 2010</LINK>; <LINK REF="STD-Haas-2007" TYPE="STUDY">Haas 2007</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Huskisson-1993" TYPE="STUDY">Huskisson 1993</LINK>; <LINK REF="STD-Karanko-1987" TYPE="STUDY">Karanko 1987</LINK>; <LINK REF="STD-Niemi-2006" TYPE="STUDY">Niemi 2006</LINK>; <LINK REF="STD-Stockwell-1992" TYPE="STUDY">Stockwell 1992</LINK>; <LINK REF="STD-Stoddart-1996" TYPE="STUDY">Stoddart 1996</LINK>; <LINK REF="STD-Tollofsrud-1995" TYPE="STUDY">Tollofsrud 1995</LINK>; <LINK REF="STD-Verheij-2006" TYPE="STUDY">Verheij 2006</LINK>; <LINK REF="STD-Wahba-1996" TYPE="STUDY">Wahba 1996</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Starch versus gelatin (26 trials with 1883 participants in these groups)</HEADING>
<P>
<LINK REF="STD-Allison-1999" TYPE="STUDY">Allison 1999</LINK>; <LINK REF="STD-Asfar-2000" TYPE="STUDY">Asfar 2000</LINK>; <LINK REF="STD-Beards-1994" TYPE="STUDY">Beards 1994</LINK>; <LINK REF="STD-Berard-1995" TYPE="STUDY">Berard 1995</LINK>; <LINK REF="STD-Beyer-1997" TYPE="STUDY">Beyer 1997</LINK>; <LINK REF="STD-Boldt-1986" TYPE="STUDY">Boldt 1986</LINK>; <LINK REF="STD-Boldt-2000" TYPE="STUDY">Boldt 2000</LINK>; <LINK REF="STD-Boldt-2001" TYPE="STUDY">Boldt 2001</LINK>; <LINK REF="STD-Carli-2000" TYPE="STUDY">Carli 2000</LINK>; <LINK REF="STD-Dytkowska-1998" TYPE="STUDY">Dytkowska 1998</LINK>; <LINK REF="STD-Godet-2008" TYPE="STUDY">Godet 2008</LINK>; <LINK REF="STD-Gondos-2010" TYPE="STUDY">Gondos 2010</LINK>; <LINK REF="STD-Haas-2007" TYPE="STUDY">Haas 2007</LINK>; <LINK REF="STD-Huskisson-1993" TYPE="STUDY">Huskisson 1993</LINK>; <LINK REF="STD-Inal-2010" TYPE="STUDY">Inal 2010</LINK>; <LINK REF="STD-Jin-2010" TYPE="STUDY">Jin 2010</LINK>; <LINK REF="STD-Mahmood-2007" TYPE="STUDY">Mahmood 2007</LINK>; <LINK REF="STD-Molnar-2004" TYPE="STUDY">Molnar 2004</LINK>; <LINK REF="STD-Niemi-2006" TYPE="STUDY">Niemi 2006</LINK>, <LINK REF="STD-Ooi-2009" TYPE="STUDY">Ooi 2009</LINK>; <LINK REF="STD-Rittoo-2004" TYPE="STUDY">Rittoo 2004</LINK>; <LINK REF="STD-Schortgen-2001" TYPE="STUDY">Schortgen 2001</LINK>; <LINK REF="STD-Schramko-2010" TYPE="STUDY">Schramko 2010</LINK>; <LINK REF="STD-Van-der-Linden-2004" TYPE="STUDY">Van der Linden 2004</LINK>; <LINK REF="STD-Van-der-Linden-2005" TYPE="STUDY">Van der Linden 2005</LINK>; <LINK REF="STD-Volta-2007" TYPE="STUDY">Volta 2007</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Starch versus dextran (one trial with 30 participants in these groups)</HEADING>
<P>
<LINK REF="STD-Hiippala-1995" TYPE="STUDY">Hiippala 1995</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dextran versus gelatin (three trials with 82 participants in these groups)</HEADING>
<P>
<LINK REF="STD-Gombocz-2007" TYPE="STUDY">Gombocz 2007</LINK>; <LINK REF="STD-Karanko-1987" TYPE="STUDY">Karanko 1987</LINK>; <LINK REF="STD-Tollofsrud-1995" TYPE="STUDY">Tollofsrud 1995</LINK>.</P>
<P>The trials involved patients with hypovolaemia, sepsis, trauma, and patients who had undergone surgery.</P>
<P>The trials tended to report surrogate outcomes such as haemodynamic variables. Data on death were obtainable from 57 trials. Information on the amount of blood or FFP transfused was available in 41 trials. However, the data were reported in a variety of different ways that made combining the data in a meta-analysis unfeasible.</P>
<P>Inclusion and exclusion criteria varied, but many of the studies excluded patients with previous adverse reactions to colloids, clotting problems, or renal disease.</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-06-11 13:45:07 +0100" MODIFIED_BY="Frances Bunn">
<P>Using the criteria defined in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) the quality of allocation concealment was judged to be adequate (at low risk of bias) in 33 trials, unclear in 42 trials, and inadequate (at high risk of bias) in 10 trials. Where the method of allocation concealment was unclear, we attempted to contact all of the trialists and we obtained information from 16 of them. However, due to the lack of reported information on the process of randomisation and allocation concealment, we were unable to assess the quality in many of the trials properly.</P>
<P>Thirteen trials mentioned that some form of blinding was used. In nine, some, or all, of the staff giving treatment were blinded, in six those giving postoperative care were blinded, in two the outcome assessors were blinded, and in one the statisticians performing the analysis were blinded to treatment group.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-06-11 15:20:42 +0100" MODIFIED_BY="Emma M Sydenham">
<SUBSECTION>
<HEADING LEVEL="3">Mortality</HEADING>
<P>Of the 86 trials identified, 41 reported mortality data. Information on death was obtained from a further 16 trials by contact with the trial authors. We, therefore, had data on death from 57 trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Albumin or PPF versus HES</HEADING>
<P>Thirty-one trials (1719 participants) reported mortality data. The pooled RR was 1.06 (95% CI 0.86 to 1.31). When the trials by Boldt (<LINK REF="STD-Boldt-1993a" TYPE="STUDY">Boldt 1993a</LINK>; <LINK REF="STD-Boldt-1995" TYPE="STUDY">Boldt 1995</LINK>; <LINK REF="STD-Boldt-1996a" TYPE="STUDY">Boldt 1996a</LINK>; <LINK REF="STD-Boldt-1996b" TYPE="STUDY">Boldt 1996b</LINK>; <LINK REF="STD-Boldt-1996c" TYPE="STUDY">Boldt 1996c</LINK>; <LINK REF="STD-Boldt-1998" TYPE="STUDY">Boldt 1998</LINK>; Boldt 2006a) were removed from the analysis the pooled RR was 0.97 (95% CI 0.70 to 1.35).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Albumin or PPF versus gelatin</HEADING>
<P>Nine trials (824 participants) reported mortality but only three of those trials had any deaths. The RR was 0.89 (95% CI 0.65 to 1.21). The Boldt trial included in this analysis had no events (<LINK REF="STD-Boldt-1993a" TYPE="STUDY">Boldt 1993a</LINK>), and therefore contributed no data to the analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Albumin or PPF versus dextran</HEADING>
<P>Four trials (360 participants) reported mortality and were included in the meta-analysis. Only one of these reported any deaths (<LINK REF="STD-Hedstrand-1987" TYPE="STUDY">Hedstrand 1987</LINK>). The RR was 3.75 (95% CI 0.42 to 33.09).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Gelatin versus HES</HEADING>
<P>Twenty-two studies (1612 participants) reported mortality and the pooled RR was 1.02 (95% CI 0.84 to 1.26). The effect was unchanged with removal of the six trials by Boldt (<LINK REF="STD-Boldt-1993a" TYPE="STUDY">Boldt 1993a</LINK>; <LINK REF="STD-Boldt-2000" TYPE="STUDY">Boldt 2000</LINK>; <LINK REF="STD-Boldt-2001" TYPE="STUDY">Boldt 2001</LINK>; Haisch 2001c; Haisch 2001c; Huttner 2000a) (RR 1.00; 95% CI 0.80 to 1.25).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Gelatin versus dextran 70</HEADING>
<P>There were three trials (82 participants) that reported mortality. There were no deaths so the RR was not estimable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">HES versus dextran 70</HEADING>
<P>No trials reported mortality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Amount of blood transfused</HEADING>
<P>Forty-five trials recorded the amount of blood or FFP transfused. As the data were reported in various ways, often lacking a measure of variation, and was also skewed we did not attempt a quantitative synthesis. These data can be seen in the 'other data' tables.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Twenty-four trials reported the incidence of adverse or allergic reactions or anaphylactic shock. The majority reported that there were no such incidents. However, one study (<LINK REF="STD-Akech-2006" TYPE="STUDY">Akech 2006</LINK>) reported a possible adverse reaction to gelatin (Gelufusine) and one (<LINK REF="STD-Godet-2008" TYPE="STUDY">Godet 2008</LINK>) reported two possible adverse reactions in the HES group and one in the gelatin group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sensitivity analysis</HEADING>
<P>The effect of excluding trials judged to have inadequate or unclear allocation concealment was examined in a subgroup analysis. This made no significant difference to the results (albumin or PPF versus HES: pooled RR 1.08; 95% CI 0.86 to 1.36; albumin or PPF versus gelatin pooled RR 0.92; 95% CI 0.47 to 1.81; gelatin versus HES pooled RR 1.10; 95% CI 0.84 to 1.44).</P>
<P>There was also no significant difference when the trials by Boldt were removed from the analysis (albumin or PPF versus HES pooled RR 0.90 (95% CI 0.68 to 1.20), albumin or PPF vs gelatin 0.92 (0.47, 1.81), gelatin versus HES 1.03 (0.84, 1.27).</P>
<P>Removing both the trials with inadequate allocation concealment and the trials by Boldt from the albumin or PPF versus HES analysis gave a pooled effect of RR 0.88 (95% CI 0.63 to 1.24). The RR for gelatin versus HES was 1.12 (95% CI 0.85 to 1.47).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-05-29 21:29:40 +0100" MODIFIED_BY="Frances Bunn">
<P>Despite finding 90 trials we cannot make any conclusions about the relative effectiveness of different colloid solutions. Previous systematic reviews have suggested that colloids are no more effective than crystalloids in reducing mortality (<LINK REF="REF-Perel-2012" TYPE="REFERENCE">Perel 2012</LINK>; <LINK REF="REF-Roberts-2011" TYPE="REFERENCE">Roberts 2011</LINK>), but there are too few data available to show in direct comparisons whether any of the colloids are safer or more effective than another. The CIs are wide and do not exclude clinically significant differences between colloids.</P>
<P>Mortality was selected as the main outcome measure in this systematic review for several reasons. In the context of critical illness, death or survival is a clinically relevant outcome that is of immediate importance to patients, and data on death are reported in many of the studies. Furthermore, one might expect that mortality data would be less prone to measurement error or biased reporting than would data on pathophysiological outcomes. The use of a pathophysiological end point as a surrogate for an adverse outcome assumes a direct relationship between the two, an assumption that may sometimes be inappropriate. Finally, when trials collect data on a number of physiological end points, there is the potential for bias due to the selective publication of end points showing striking treatment effects.</P>
<P>There was wide variation in the participants, intervention regimens, and the length of follow-up. The length of follow-up was not reported in many of the studies. Where it is reported it ranges from a matter of hours to months, which may explain a high proportion of the heterogeneity in overall event rates. The effect of these factors was not examined in a sensitivity analysis, as there was felt to be insufficient data to justify examining subgroups.</P>
<P>Many of the trials were small, and some had been done some time ago. Although older trials will not necessarily be of poorer quality, it may be that treatment protocols have subsequently altered making these trials less relevant to current clinical practice.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-05-29 21:29:55 +0100" MODIFIED_BY="Emma M Sydenham">
<IMPLICATIONS_PRACTICE MODIFIED="2012-05-29 21:29:55 +0100" MODIFIED_BY="Emma M Sydenham">
<P>Previous reviews have not shown a benefit of colloids over crystalloids for volume replacement (<LINK REF="REF-Perel-2012" TYPE="REFERENCE">Perel 2012</LINK>; <LINK REF="REF-Roberts-2011" TYPE="REFERENCE">Roberts 2011</LINK>).</P>
<P>This review does not provide any evidence that one colloid is safer than another, but does not rule out clinically significant differences.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-05-29 14:00:51 +0100" MODIFIED_BY="Anne Lawson">
<P>Trials of fluid therapy need to be larger in order to exclude clinically significant differences between colloids in patient relevant outcomes. However, trials should probably first address the question of whether colloids are any more effective than crystalloid solutions.</P>
<P>Use of surrogate outcomes, such as physiological measurements, should be discouraged unless there is a strong relationship with outcomes of interest to patients and relatives.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-06-11 11:44:06 +0100" MODIFIED_BY="Frances Bunn">
<P>We wish to acknowledge the contribution of Phil Alderson, Victoria Hawkins and Syed Ashraf who were authors of earlier versions of this review. In addition, we acknowledge the help of Ralph Bloch, Olivier Duperrex, Andrew Smith, Peter Smith, and Reinhard Wentz, who assisted with translating articles. Also many thanks to the authors who provided us with details of their studies.</P>
<P>We are grateful to the drug companies, Baxter Healthcare Ltd, CIS Ltd, Fresenius Ltd, Hoechst, and Pharmacia who responded to our request for information.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-05-29 19:58:13 +0100" MODIFIED_BY="Frances Bunn">
<P>FB screened citations for eligibility, obtained references, contacted authors, extracted data, entered data and wrote the review. DT screened citations for eligibility and extracted data. PA, VH, and SA contributed to earlier versions of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="Emma M Sydenham">
<P>The editorial group is aware that a clinical trial by Professor Joachim Boldt has been found to have been fabricated (<LINK REF="REF-Boldt-2009" TYPE="REFERENCE">Boldt 2009</LINK>). As the editors who revealed this fabrication point out (<LINK REF="REF-Reinhart-2011" TYPE="REFERENCE">Reinhart 2011</LINK>; <LINK REF="REF-Shafer-2011" TYPE="REFERENCE">Shafer 2011</LINK>), this casts some doubt on the veracity of other studies by the same author. All Cochrane Injuries Group reviews which include studies by this author have therefore been edited to show the results with this author's trials included and excluded. Readers can now judge the potential impact of trials by this author (<LINK REF="STD-Boldt-1986" TYPE="STUDY">Boldt 1986</LINK>; <LINK REF="STD-Boldt-1993a" TYPE="STUDY">Boldt 1993a;</LINK> <LINK REF="STD-Boldt-1995" TYPE="STUDY">Boldt 1995;</LINK> <LINK REF="STD-Boldt-1996a" TYPE="STUDY">Boldt 1996a;</LINK> <LINK REF="STD-Boldt-1996b" TYPE="STUDY">Boldt 1996b;</LINK> <LINK REF="STD-Boldt-1996c" TYPE="STUDY">Boldt 1996c;</LINK> <LINK REF="STD-Boldt-1998" TYPE="STUDY">Boldt 1998;</LINK> <LINK REF="STD-Boldt-2000" TYPE="STUDY">Boldt 2000;</LINK> <LINK REF="STD-Boldt-2001" TYPE="STUDY">Boldt 2001;</LINK> Boldt 2006a Haisch 2001c Haisch 2001c Huttner 2000a) on the conclusions of the review.</P>
<P>Emma Sydenham, Managing Editor, performed the sensitivity analysis in 2011. The authors agreed with the changes to the manuscript.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akech-2006" MODIFIED="2012-05-03 12:31:17 +0100" MODIFIED_BY="[Empty name]" NAME="Akech 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-03 12:31:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akech S, Gwer S, Idro R, Fegan G, Eziefula AC, Newton CRJC, et al</AU>
<TI>Volume expansion with albumin compared to gelofusine in children with severe malaria: results of a controlled trial</TI>
<SO>PLoS Hub for Clinical Trials</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>5</NO>
<PG>e21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allison-1999" NAME="Allison 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allison KP, Gosling P, Jones S, Pallister I, Porter K</AU>
<TI>Randomized trial of hydroxyethyl starch versus gelatine for trauma resuscitation</TI>
<SO>Journal of Trauma</SO>
<YR>1999</YR>
<VL>47</VL>
<NO>6</NO>
<PG>1114-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arellano-2005" MODIFIED="2012-05-29 18:29:53 +0100" MODIFIED_BY="Anne Lawson" NAME="Arellano 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-05-29 18:29:53 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arellano R, Gan BS, Salpeter MJ, Yeo E, McCluskey S, Pinto R, et al</AU>
<TI>A triple-blinded randomized trial comparing the hemostatic effects of large-dose 10% hydroxyethyl starch 264/0.45 versus 5% albumin during major reconstructive surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2005</YR>
<VL>100</VL>
<PG>1846-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asfar-2000" NAME="Asfar 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asfar P, Kereni N, Labadie F, Gouello JP, Brenet O, Alquier P</AU>
<TI>Assessment of hemodynamic and gastric mucosal acidosis with modified fluid versus 6% hydroxyethyl starch: a prospective, randomized study</TI>
<SO>Intensive Care Medicine</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>9</NO>
<PG>1282-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Beards-1994" NAME="Beards 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Beards SC, Watt T, Edwards JD, Nightingale P, Farragher EB. Comparison of the hemodynamic and oxygen transport responses to modified fluid gelatin and hetastarch in critically ill patients: A prospective, randomized trial. Crit Care Med 1994; 22(4):600-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beards SC, Watt T, Edwards JD, Nightingale P, Farragher EB</AU>
<TI>Comparison of the hemodynamic and oxygen transport responses to modified fluid gelatin and hetastarch in critically ill patients: a prospective, randomized trial</TI>
<SO>Critical Care Medicine</SO>
<YR>1994</YR>
<VL>22</VL>
<NO>4</NO>
<PG>600-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994192356"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berard-1995" MODIFIED="2012-05-30 11:19:18 +0100" MODIFIED_BY="Anne Lawson" NAME="Berard 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-05-30 11:19:18 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Berard J-P, Curt I, Piech J-J,Ruiz F. Hydroxyethylamidons versus gelatines: Impact sur le cout du rempissage dans un service de reanimation. (Hydroxyethylamidons versus gelatines: impact on the cost of replacement in an emergency (resuscitation) service. Annales Francaises d'anaesthesia reanimation 1995;14:R335.&lt;/p&gt;" NOTES_MODIFIED="2012-05-30 11:19:18 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berard JP, Curt I, Piech JJ, Ruiz F</AU>
<TI>Hydroxyethylamidons versus gelatines: impact on the cost of replacement in an emergency (resuscitation) service</TI>
<TO>Hydroxyethylamidons versus gelatines: impact sur le cout du rempissage dans un service de reanimation</TO>
<SO>Annales Francaises d'Anaesthesia et de Reanimation</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>R335</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Beyer-1997" MODIFIED="2012-05-29 18:30:44 +0100" MODIFIED_BY="Anne Lawson" NAME="Beyer 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-05-29 18:30:44 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Beyer R, Harmening U, Rittmeyer O, Zielmann S, Mielck F, Kazmaier S, Kettler D. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. Brit J Anaesth 1997;78:44-50&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:30:44 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beyer R, Harmening U, Rittmeyer O, Zielmann S, Mielck F, Kazmaier S, et al</AU>
<TI>Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>1</NO>
<PG>44-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997212347"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1986" MODIFIED="2012-05-16 11:11:15 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Boldt 1986" YEAR="1986">
<REFERENCE MODIFIED="2012-05-16 11:11:15 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Boldt J, V.Bormann B, Kling D, Borner U, Mulch J, Hempelmann G. Volumenersatz mit einem neuen hydroxyathylstarke - praparat (3% HAS 200/0.5) in der herzchirurgie. Infusionstherapie 1986; 13: 145-151.&lt;/p&gt;" NOTES_MODIFIED="2012-05-16 11:11:15 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt JV, Von Bormann B, Kling D, Borner U, Mulch J, Hempelmann G</AU>
<TI>Volume replacement with a new hydroxyethyl starch preparation (3% HES 200/0.5) in heart surgery</TI>
<TO>Volumenersatz mit einem neuen hydroxyathylstarke - praparat (3% HAS 200/0.5) in der herzchirurgie</TO>
<SO>Infusionstherapie und Klinische Ernahrung</SO>
<YR>1986</YR>
<VL>13</VL>
<NO>3</NO>
<PG>145-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1986302988"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Boldt-1993a" NAME="Boldt 1993a" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Boldt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G. Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass. Anesth Analg 1993;76:1185-90.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Knothe C, Zickmann B, Andres P, Dapper F, Hempelmann G</AU>
<TI>Influence of different intravascular volume therapies on platelet function in patients undergoing cardiopulmonary bypass</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1993</YR>
<VL>76</VL>
<NO>6</NO>
<PG>1185-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1995" NAME="Boldt 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Boldt J, Heesen M, Welters I, Padberg W, Martin K, Hempelmann G. Does the type of volume therapy influence endothelial-related coagulation in the critically ill? British Journal of Anaesthesia 1995;75:740-746.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Heesen M, Welters I, Padberg W, Martin K, Hempelmann G</AU>
<TI>Does the type of volume therapy influence endothelial-related coagulation in the critically ill?</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1995</YR>
<VL>75</VL>
<NO>6</NO>
<PG>740-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996246804"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1996a" NAME="Boldt 1996a" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Boldt J, Heesen M, Muller M, Pabsdorf M, Hempelmann G. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients. Anesth Analg 1996;83:254-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Heesen M, Muller M, Pabsdorf M, Hempelmann G</AU>
<TI>The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>2</NO>
<PG>254-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996302067"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1996b" NAME="Boldt 1996b" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Boldt J, Heesen M, Padberg W, Martin K, Hempelmann G. The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients. Anaesthesia 1996;51:529-535.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Heesen M, Padberg W, Martin K, Hempelmann G</AU>
<TI>The influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients</TI>
<SO>Anaesthesia</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>6</NO>
<PG>529-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996296856"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1996c" NAME="Boldt 1996c" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Boldt J, Mueller M, Menges T, Papsdorf M, Hempelmann G. Influence of different volume therapy regimens on regulators of the circulation in the critically ill. British Journal of Anaesthesia 1996;77:480-487&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Mueller M, Menges T, Papsdorf M, Hempelmann G</AU>
<TI>Influence of different volume therapy regimens on regulators of the circulation in the critically ill</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>4</NO>
<PG>480-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997097789"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1998" NAME="Boldt 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G. Volume therapy in the critically ill: is there a difference? Intensive Care Med 1998;24:28-36&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G</AU>
<TI>Volume therapy in the critically ill: is there a difference?</TI>
<SO>Intensive Care Medicine</SO>
<YR>1998</YR>
<VL>24</VL>
<NO>1</NO>
<PG>28-36</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998163949"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-2000" NAME="Boldt 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Suttner S, Kumle B, Huttner I</AU>
<TI>Cost analysis of different volume replacement strategies in anesthesia</TI>
<SO>Infusionstherapie und Transfusionsmedizin</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>1</NO>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-2001" NAME="Boldt 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Suttner S, Huttner I, Kumle B, Piper S, Krumholz W</AU>
<TI>Are cost of a crystalloid-based volume replacement regimen lower than of a colloid-based volume replacement strategy?</TI>
<SO>Infusionstherapie und transfusionsmedizin</SO>
<YR>2001</YR>
<VL>28</VL>
<NO>3</NO>
<PG>144-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brock-1995" NAME="Brock 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Brock H, Rapf B, Nececk S, Gabriel C, Peterlik C, Polz W. Volume replacement after cardiac surgery. A comparison of small-volume resuscitation and two different colloid solutions. Anaesthesist 1995;44:486-492.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brock H, Rapf B, Necek S, Gabriel C, Peterlik C, Polz W</AU>
<TI>Volume replacement after cardiac surgery. A comparison of small-volume resuscitation and two different colloid solutions</TI>
<TO>Vergleichende untersuchungen zur postoperativen volumentherapie</TO>
<SO>Anaesthesist</SO>
<YR>1995</YR>
<VL>44</VL>
<NO>7</NO>
<PG>486-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995390424"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brutocao-1996" NAME="Brutocao 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Brucato D, Bratton SL, Thomas JR, Schrader P, Coles PG, Lynn A. Comparison of hetastarch with albumin for postoperative volume expansion in children after cardiopulmonary bypass. Journal of Cardiothoracic and Vascular Anesthesia 1996; 10(3): 348-351.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brutocao D, Bratton SL, Thomas JR, Schrader PF, Coles PG, Lynn AM</AU>
<TI>Comparison of hetastarch with albumin for postoperative volume expansion in children after cardiopulmonary bypass</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>3</NO>
<PG>348-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996298754"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carli-2000" NAME="Carli 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carli P, Goldstein P, Lejay M, Facon A, Orliaguet G, Petit P</AU>
<TI>Prehospital care of hypovolemic trauma patients: 6% hydroxyethyl starch versus gelatin</TI>
<TO>Remplissage vasculaire prehospitalier en traumatologie: Hesteril 6% versus Plasmion</TO>
<SO>Journal Europeen des Urgences</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Claes-1992" NAME="Claes 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Claes Y, Van Hemelrijck J, Van Gerven M, Arnout J, Vermylen J, Weidler B, Van Aken H. Influence of hydroxyethyl starch on coagulation in patients during the perioperative period. Anesth Analg 1992;75:24-30.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Claes Y, Van Hemelrijck J, Van Gerven M, Arnout J, Vermylen J, Weidler B, et al</AU>
<TI>Influence of hydroxyethyl starch on coagulation in patients during the perioperative period</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1992</YR>
<VL>75</VL>
<NO>1</NO>
<PG>24-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992312872"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diehl-1982" NAME="Diehl 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Diehl JT, Lester JL, Cosgrove DM. Clinical comparison of hetastarch and albumin in postoperative cardiac patients. Annals Thoracic Surg 1982; 34:674-679&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Diehl JT, Lester JL, Cosgrove DM</AU>
<TI>Clinical comparison of hetastarch and albumin in postoperative cardiac patients</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1982</YR>
<VL>34</VL>
<NO>6</NO>
<PG>674-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1983073643"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dolecek-2009" MODIFIED="2012-05-29 18:33:08 +0100" MODIFIED_BY="[Empty name]" NAME="Dolecek 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-29 18:33:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dolecek M, Svoboda P, Kantorova I, Scheer P, Sas I, Bibrova J, et al</AU>
<TI>Therapeutic influence of 20% albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2009</YR>
<VL>56</VL>
<NO>96</NO>
<PG>1622-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-Gres-1989" NAME="Du Gres 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Du Gres B, Gruner MC, Flamens C. Comparison des effets hemodynamiques de l'Haemaccel et de l'albumine diluee dans la periode postoperatoire immediate apres chirurgie cardiaque. Cahiers d'Anesthesiolotgie;37(5):327-332.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du Gres B, Gruner MC, Flamens C</AU>
<TI>A comparison of the hemodynamic effect of Haemaccel and diluted albumin in the immediate postoperative period after heart surgery</TI>
<TO>Comparaison des effets hemodynamiques de l'Haemaccel et de l'albumine diluee dans la periode postoperatoire immediate apres chirurgie cardiaque</TO>
<SO>Cahiers d'Anesthesiologie</SO>
<YR>1989</YR>
<VL>37</VL>
<NO>5</NO>
<PG>327-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990029584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dytkowska-1998" NAME="Dytkowska 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dytkowska B, Karwacki Z, Suchorzewska J, Wujtewicz M</AU>
<TI>Comparative assessment of 200/0.5 HAES 6% and Gelafundin in the treatment of hypovolaemia in post-coronary bypass patients</TI>
<SO>Medical Science Monitor</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>6</NO>
<PG>1000-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Evans-2003" MODIFIED="2012-05-29 18:33:44 +0100" MODIFIED_BY="Anne Lawson" NAME="Evans 2003" YEAR="2003">
<REFERENCE MODIFIED="2012-05-29 18:33:44 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Evans PA, Heptinstall S, Crowhurst EC, Davies T, Glenn JR, Madira W, et al</AU>
<TI>Prospective double-blind randomized study of the effects of four intravenous fluids on platelet function and hemostasis in elective hip surgery</TI>
<SO>Journal of Thrombosis and Haemostasis</SO>
<YR>2003</YR>
<VL>1</VL>
<PG>2140-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falk-1988" MODIFIED="2012-05-29 18:33:58 +0100" MODIFIED_BY="Anne Lawson" NAME="Falk 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-05-29 18:33:58 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Falk JL, Rackow EC, Astiz ME, Weil MH. Effects of Hetastarch and albumin on coagulation in patients with septic shock. J Clin Pharmacol 1988;28:412-415&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:33:58 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falk JL, Rackow EC, Astiz ME, Weil MH</AU>
<TI>Effects of hetastarch and albumin on coagulation in patients with septic shock</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1988</YR>
<VL>28</VL>
<NO>5</NO>
<PG>412-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988273726"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-2008" MODIFIED="2012-05-29 18:34:12 +0100" MODIFIED_BY="[Empty name]" NAME="Friedman 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-29 18:34:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman G, Jankowski S, Shahla M, Gomez J, Vincent JL</AU>
<TI>Hemodynamic effects of 6% and 10% hydroxyethyl starch solutions versus 4% albumin solution in septic patients</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>2008</YR>
<VL>20</VL>
<NO>7</NO>
<PG>528-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fries-2004" MODIFIED="2012-05-29 18:34:25 +0100" MODIFIED_BY="Anne Lawson" NAME="Fries 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-05-29 18:34:25 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fries D, Streif W, Margreiter J, Klingler A, Kühbacher G, Schobersberger W, et al</AU>
<TI>The effects of perioperative administered crystalloids and colloids on concentrations of molecular markers of activated coagulation and fibrinolysis</TI>
<SO>Blood Coagulation and Fibrinolysis</SO>
<YR>2004</YR>
<VL>15</VL>
<PG>213-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fulachier-1994" NAME="Fulachier 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Fulachier V, Sicard MP, Baille Y, Auffray JP. Effects of fluid expansion using albumin or hydroxyethylstarch on oxygen transport after induction of anesthesia for cardiac surgery. J Cardiothorac Vasc Anesh 1994; 8(3):89&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fulachier V, Sicard MP, Baille Y, Auffray JP</AU>
<TI>Effects of fluid expansion using albumin or hydroxyethylstarch on oxygen transport after induction of anesthesia for cardiac surgery</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>1994</YR>
<VL>8</VL>
<NO>3Supp2</NO>
<PG>89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gahr-1981" NAME="Gahr 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Gahr R, Bock PR. Wirkung von hydroxyathylstarke HAS 450/0.7 und humanalbumin 5% auf den kolloidosmotischen druck und hamodynamische parameter bei hypovolamischen patienten nach groberen abdominalen eingriffen. Infusionstherapie 1981,3:147-152.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gahr R, Bock PR</AU>
<TI>Effect of hydroxyethyl starch HES 450/0.7 and 5% human albumin on the colloid osmotic pressure and hemodynamic parameters in hypovolemic patients after major abdominal procedures</TI>
<TO>Wirkung von hydroxyathylstarke HAS 450/0.7 und humanalbumin 5% auf den kolloidosmotischen druck und hamodynamische parameter bei hypovolamischen patienten nach grosseren abdominalen eingriffen</TO>
<SO>Infusionstherapie und Transfusionsmedizin</SO>
<YR>1981</YR>
<VL>8</VL>
<NO>3</NO>
<PG>147-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1981262968"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gallagher-1985" NAME="Gallagher 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Gallagher JD, Moore RA, Kerns D, Jose AB, Botros SB, Flicker S, Naidech h, Clark DL. Effects of colloid or crystalloid administration on pulmonary extravascular water in the postoperative period after coronary artery bypass grafting. Anesth Analg, 1985;64:753-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallagher JD, Moore RA, Kerns D, Jose AB, Botros SB, Flicker S, et al</AU>
<TI>Effects of colloid or crystalloid administration on pulmonary extravascular water in the postoperative period after coronary artery bypass grafting</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1985</YR>
<VL>64</VL>
<NO>8</NO>
<PG>753-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Godet-2008" MODIFIED="2012-05-30 10:52:05 +0100" MODIFIED_BY="[Empty name]" NAME="Godet 2008" YEAR="2008 12">
<REFERENCE MODIFIED="2012-05-30 10:52:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P</AU>
<TI>Safety of HES 130/0.4 (Voluven(R)) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>12</NO>
<PG>986-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Gold-1990" NAME="Gold 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Gold MS, Russo J, Tissot M, Weinhouse G, Riles T. Comparison of hetastarch to albumin for perioperative bleeding in patients undergoing abdominal aortic aneurysm surgery. Ann. Surg 1989; 211(4):482-485&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gold MS, Russo J, Tissot M, Weinhouse G, Riles T</AU>
<TI>Comparison of hetastarch to albumin for perioperative bleeding in patients undergoing abdominal aortic aneurysm surgery</TI>
<SO>Annals of Surgery</SO>
<YR>1990</YR>
<VL>211</VL>
<NO>4</NO>
<PG>482-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990210743"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gombocz-2007" MODIFIED="2012-05-29 18:36:21 +0100" MODIFIED_BY="[Empty name]" NAME="Gombocz 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-29 18:36:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gombocz K, Beledi A, Alotti N, Kecskes G, Gabor V, Bogar L, et al</AU>
<TI>Influence of dextran-70 on systemic inflammatory response and myocardial ischaemia-reperfusion following cardiac operations</TI>
<SO>Critical Care</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>4</NO>
<PG>R87</PG>
<IDENTIFIERS MODIFIED="2012-05-16 11:12:42 +0100" MODIFIED_BY="Emma M Sydenham">
<IDENTIFIER MODIFIED="2012-05-16 11:12:42 +0100" MODIFIED_BY="Emma M Sydenham" TYPE="DOI" VALUE="10.1186/cc6095"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gondos-2010" MODIFIED="2012-05-29 18:36:48 +0100" MODIFIED_BY="Frances Bunn" NAME="Gondos 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-29 18:36:48 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gondos T, Marjanek Z, Ulakcasi Z, Szabo Z, Bogar L, Karolyi M, et al</AU>
<TI>Short-term effectiveness of different volume replacement therapies in postoperative hypovolaemic patients</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2010</YR>
<VL>27</VL>
<PG>794-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-15 13:42:47 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gondos T, Marjanek Z, Ulakcsai Z, Szabó Z, et al</AU>
<TI>Evaluation of the effectiveness of different volume replacement therapies in postoperative hypovolemic patients using the PiCCO monitoring system</TI>
<SO>Critical Care</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>1</NO>
<PG>Suppl 1: P220</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haas-2007" MODIFIED="2012-02-03 11:12:23 +0000" MODIFIED_BY="[Empty name]" NAME="Haas 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-02-03 11:12:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haas T, Preinreich A, Oswald E, Pajk W, Berger J, Kuehbacher G, et al</AU>
<TI>Effects of albumin 5% and artificial colloids on clot formation in small infants</TI>
<SO>Anaesthesia</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1000-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hausdorfer-1986" NAME="Hausdorfer 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Hausdorfer J, Hagemann H, Heine J. Vergleich der volumenersatzmittel humanalbumin 5% und hydroxathylstarke 6% (40.000/0.5) in der kinderanasthesie (Comparison of plasma substitutes human albumin 5% and hydroxyethyl starch 6% in paediatric anaesthesia). Anasth.Intensivther. Notfallmed. 1986;21:137-142.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hausdorfer J, Hagemann H, Heine J</AU>
<TI>Comparison of volume substitutes human albumin 5% and hydroxyethyl starch 6% in paediatric anaesthesia</TI>
<TO>Vergleich der volumenersatzmittel humanalbumin 5% und hydroxathylstarke 6% (40.000/0.5) in der kinderanasthesie</TO>
<SO>Anasthesie, Intensivtherapie, Notfallmedizin</SO>
<YR>1986</YR>
<VL>21</VL>
<NO>3</NO>
<PG>137-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1986320933"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hecht_x002d_Dolnik-2009" MODIFIED="2012-05-29 18:38:23 +0100" MODIFIED_BY="Frances Bunn" NAME="Hecht-Dolnik 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-29 18:38:23 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hecht-Dolnik M, Barkan H, Taharka A, Loftus J</AU>
<TI>Hetastarch increases the risk of bleeding complications in patients after off-pump bypass surgery: a randomized clinical trial</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>2009</YR>
<VL>138</VL>
<PG>703-11</PG>
<IDENTIFIERS MODIFIED="2012-05-15 11:07:35 +0100" MODIFIED_BY="Frances Bunn"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hedstrand-1987" MODIFIED="2012-05-29 18:38:38 +0100" MODIFIED_BY="Anne Lawson" NAME="Hedstrand 1987" YEAR="1987">
<REFERENCE MODIFIED="2012-05-29 18:38:38 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Hedstrand U, Hogman C, Zaren B, Lundkvist B. Postoperative complications after blood replacement with or without plasma. Acta Chir Scand, 1987; 153: 501-505.&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:38:38 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hedstrand U, Hogman C, Zaren B, Lundkvist B</AU>
<TI>Postoperative complications after blood replacement with or without plasma</TI>
<SO>Acta Chirurgica Scandinavica</SO>
<YR>1987</YR>
<VL>153</VL>
<NO>9</NO>
<PG>501-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiippala-1995" NAME="Hiippala 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Hippala S, Linko K, Myllyla G, Lalla M, Hekali R, Makelainen A. Replacement of major surgical blood loss by hypo-oncotic or conventional plasma substitutes. Acta Anaesthesiol Scand 1995;39:228-235&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiippala S, Linko K, Myllyla G, Lalla M, Hekali R, Makelainen A</AU>
<TI>Replacement of major surgical blood loss by hypo-oncotic or conventional plasma substitutes</TI>
<SO>Acta Anaesthesiologia Scandinavica</SO>
<YR>1995</YR>
<VL>39</VL>
<NO>2</NO>
<PG>228-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995313480"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005" MODIFIED="2012-05-29 21:34:35 +0100" MODIFIED_BY="Anne Lawson" NAME="Huang 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-05-29 21:34:35 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang Y, Yan B, Yang Z</AU>
<TI>Clinical study of a formula for delayed rapid fluid resuscitation for patients with burn shock</TI>
<SO>Burns</SO>
<YR>2005</YR>
<VL>31</VL>
<PG>617-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huskisson-1993" NAME="Huskisson 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Huskisson L, Elliott M, Spitz L. Haemodynamic effects of threee colloids following peadiatric open heart surgery. Clinical Intensive Care 1993;4:302&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huskisson L, Elliott M, Spitz L</AU>
<TI>Haemodynamic effects of three colloids following pediatric open heart surgery</TI>
<SO>Clinical Intensive Care</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inal-2010" MODIFIED="2012-05-29 18:39:16 +0100" MODIFIED_BY="[Empty name]" NAME="Inal 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-29 18:39:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inal MT, Memi, Karamanlioglu B, Sut N</AU>
<TI>Effects of polygeline and hydroxyethyl starch solutions on liver functions assessed with LIMON in hypovolemic patients</TI>
<SO>Journal of Critical Care</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>2</NO>
<PG>361</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-2010" MODIFIED="2012-05-29 18:39:40 +0100" MODIFIED_BY="[Empty name]" NAME="Jin 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-29 18:39:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin SL, Yu BW</AU>
<TI>Effects of acute hypervolemic fluid infusion of hydroxyethyl starch and gelatin on hemostasis and possible mechanisms</TI>
<SO>Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>1</NO>
<PG>91-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2004" NAME="Jones 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones S, Whitten C, Monk T</AU>
<TI>Influence of crystalloid and colloid replacement solutions on hemodynamic variables during acute normovolemic hemodilution</TI>
<SO>Journal of Clinical Anaesthesia</SO>
<YR>2004</YR>
<VL>16</VL>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Karanko-1987" NAME="Karanko 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Karanko MS. Effects of three colloid solutions on plasma volume and hemodynamics after coronary artery bypass surgery. Crit Care Med 1987;15(11):1015-1021.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karanko MS</AU>
<TI>Effects of three colloid solutions on plasma volume and hemodynamics after coronary bypass surgery</TI>
<SO>Critical Care Medicine</SO>
<YR>1987</YR>
<VL>15</VL>
<NO>11</NO>
<PG>1015-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988054051"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirklin-1984" NAME="Kirklin 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Kirklin JK, Lell WA, Kouchoukos NT. Hydroxyethyl starch versus albumin for colloid infusion following cardiopulmonary bypass in patients undergoing myocardial revascularization. Annals Thoracic Surg 1984;37:40-46.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirklin JK, Lell WA, Kouchoukos NT</AU>
<TI>Hydroxyethyl starch versus albumin for colloid infusion following cardiopulmonary bypass in patients undergoing myocardial revascularization</TI>
<SO>Annals of Thoracic Surgery</SO>
<YR>1984</YR>
<VL>37</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1984103384"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lisander-1996" NAME="Lisander 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Lisander B, Jacobsson S, Ivarsson I, Vegfors M, Engdahl O. Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty. Eur J Surg 1996;162:861-866&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lisander B, Jacobsson SA, Ivarsson I, Vegfors M, Engdahl O</AU>
<TI>Giving both enoxaparin and dextran increases the need for transfusion in revision hip arthroplasty</TI>
<SO>European Journal of Surgery</SO>
<YR>1996</YR>
<VL>162</VL>
<NO>11</NO>
<PG>861-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997115584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-London-1989" MODIFIED="2012-05-29 18:40:16 +0100" MODIFIED_BY="Anne Lawson" NAME="London 1989" YEAR="1989">
<REFERENCE MODIFIED="2012-05-29 18:40:16 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH, Hanley FL, Browner WS, Mangano DT. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc surg 1989;97:785-97&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:40:16 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH, et al</AU>
<TI>A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations</TI>
<SO>Journal of Thoracic and Cardiovascular Surgery</SO>
<YR>1989</YR>
<VL>97</VL>
<NO>5</NO>
<PG>785-97</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1989218083"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahmood-2007" MODIFIED="2012-05-29 18:40:39 +0100" MODIFIED_BY="Frances Bunn" NAME="Mahmood 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-29 18:40:39 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahmood A, Gosling P, Vohra RK</AU>
<TI>Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery</TI>
<SO>The British Journal of Surgery</SO>
<YR>2007</YR>
<VL>94</VL>
<NO>4</NO>
<PG>427-33</PG>
<IDENTIFIERS MODIFIED="2012-04-02 11:21:13 +0100" MODIFIED_BY="Frances Bunn">
<IDENTIFIER TYPE="PUBMED" VALUE="17380548"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mastroianni-1994" NAME="Mastroianni 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Mastroianni L, Low HB, Rollman J, Wagle M, Bleske B, Chow MS. A comparison of 10% pentastarch and 5% albumin in patients undergoing open-heart surgery. J clin pharmacol 1994;34:34-40&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mastroianni L, Low HB, Rollman J, Wagle M, Bleske B, Chow MS</AU>
<TI>A comparison of 10% pentastarch and 5% albumin in patients undergoing open-heart surgery</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1994</YR>
<VL>34</VL>
<NO>1</NO>
<PG>34-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994179580"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mittermayr-2007" MODIFIED="2012-05-29 18:40:58 +0100" MODIFIED_BY="Frances Bunn" NAME="Mittermayr 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-29 18:40:58 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mittermayr M, Streif W, Haas T, Fries D, Velik-Salchner C, Klingler A, et al</AU>
<TI>Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2007</YR>
<VL>105</VL>
<NO>4</NO>
<PG>905-17</PG>
<IDENTIFIERS MODIFIED="2012-04-02 11:21:13 +0100" MODIFIED_BY="Frances Bunn">
<IDENTIFIER TYPE="PUBMED" VALUE="17898365"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moggio-1983" NAME="Moggio 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Moggio RA, Chan C, Somberg ED, Praeger P, Pooley RW, Reed GE. Hemodynamic comparison of albumin and hydroxyethyl starch in postoperative cardiac surgery patients. Crit care med 1983; 11(12):943-945&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moggio RA, Rha CC, Somberg ED, Praeger P, Pooley RW, Reed GE</AU>
<TI>Hemodynamic comparison of albumin and hydroxyethyl starch in postoperative cardiac surgery patients</TI>
<SO>Critical Care Medicine</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>12</NO>
<PG>943-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1984056648"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Molnar-2004" NAME="Molnar 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Molnar Z, Mikor A, Leiner T, Szakmany T</AU>
<TI>Fluid resuscitation with colloids of different molecular weight in septic shock</TI>
<SO>Intensive Care Medicine</SO>
<YR>2004</YR>
<VL>30</VL>
<PG>1356-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukhtar-2009" MODIFIED="2012-05-30 10:54:15 +0100" MODIFIED_BY="Frances Bunn" NAME="Mukhtar 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-30 10:54:15 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukhtar A, Aboulfetouh F, Obayah G, Salah M, Emam M, Khater Y, et al</AU>
<TI>The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2009</YR>
<VL>109</VL>
<PG>924-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munoz-1980" MODIFIED="2012-05-30 10:54:49 +0100" MODIFIED_BY="Anne Lawson" NAME="Munoz 1980" YEAR="1980">
<REFERENCE MODIFIED="2012-05-30 10:54:49 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Munoz E, Raciti A, Dove D, Stahl WM, Del Guercio L. Effect of hydroxyethyl starch versus albumin on hemodymanic and respiratory function in patients with shock. Crit Care Med 1980;8(4)&lt;/p&gt;" NOTES_MODIFIED="2012-05-30 10:54:49 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munoz E, Raciti A, Dove D, Stahl WM, Del Guercio L</AU>
<TI>Effect of hydroxyethyl starch versus albumin on hemodynamic and respiratory function in patients with shock</TI>
<SO>Critical Care Medicine</SO>
<YR>1980</YR>
<VL>8</VL>
<NO>4</NO>
<PG>255</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munsch-1988" NAME="Munsch 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Munsch CM, MacIntyre E, Machin SJ, Mackie IJ, Treasure T. Hydroxyethyl starch: an alternative to plasma for postoperative volume expansion after cardiac surgery. Br J Surg 1988;75:675-678&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munsch CM, MacIntyre E, Machin SJ, Mackie IJ, Treasure T</AU>
<TI>Hydroxyethyl starch: an alternative to plasma for postoperative volume expansion after cardiac surgery</TI>
<SO>British Journal of Surgery</SO>
<YR>1988</YR>
<VL>75</VL>
<NO>7</NO>
<PG>675-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988327292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Niemi-2006" MODIFIED="2012-05-29 18:42:59 +0100" MODIFIED_BY="Frances Bunn" NAME="Niemi 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-29 18:42:59 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuitunen A, Suojaranta-Ylinen R, Kukkonen S, Niemi T</AU>
<TI>A comparison of the haemodynamic effects of 4% succinylated gelatin, 6% hydroxyethyl starch (200/0.5) and 4% human albumin after cardiac surgery</TI>
<SO>Scandinavian Journal of Surgery</SO>
<YR>2007</YR>
<VL>96</VL>
<PG>72-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-04-02 09:20:04 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Niemi T, Suojaranta-Ylinen R, Kukkonen S, Kuitunen A</AU>
<TI>Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2006</YR>
<VL>102</VL>
<PG>998-1006</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ooi-2009" MODIFIED="2012-05-29 18:43:27 +0100" MODIFIED_BY="[Empty name]" NAME="Ooi 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-29 18:43:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ooi JS, Ramzisham AR, Zamrin MD</AU>
<TI>Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery?</TI>
<SO>Asian Cardiovascular &amp; Thoracic Annals</SO>
<YR>2009</YR>
<VL>17</VL>
<NO>4</NO>
<PG>368-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Prien-1990" NAME="Prien 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Prien T, Backhaus N, Pelster F, Pircher W, Bunte H, Lawin P. Effect of intraoperative fluid administration and colloid osmotic pressure on the formation of intestinal edema during gastrointestinal surgery. J Clin Anesth 1990;2:317-23.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prien T, Backhaus N, Pelster F, Pircher W, Bunte H, Lawin P</AU>
<TI>Effect of intraoperative fluid administration and colloid osmotic pressure on the formation of intestinal edema during gastrointestinal surgery</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>1990</YR>
<VL>2</VL>
<NO>5</NO>
<PG>317-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991104037"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rackow-1983" MODIFIED="2012-05-29 18:43:49 +0100" MODIFIED_BY="Anne Lawson" NAME="Rackow 1983" YEAR="1983">
<REFERENCE MODIFIED="2012-05-29 18:43:49 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Rackow EC, Falk JL, Fein A, Siegel JS, Packman MI, Haupt MT, Kaufman S, Putnam D. Fluid resuscitation in circulatory shock: A comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 1983; Vol 11: 839-850&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:43:49 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, et al</AU>
<TI>Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock</TI>
<SO>Critical Care Medicine</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>11</NO>
<PG>839-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1984027713"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rackow-1989" NAME="Rackow 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 1989; 17(5): 395-398&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH</AU>
<TI>Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion</TI>
<SO>Critical Care Medicine</SO>
<YR>1989</YR>
<VL>17</VL>
<NO>5</NO>
<PG>395-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1989209912"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reine-2008" MODIFIED="2012-05-30 10:39:58 +0100" MODIFIED_BY="[Empty name]" NAME="Reine 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-30 10:39:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reine PA, Kongsgaard UE, Andersen A, Thogersen AK, Olsen H</AU>
<TI>Infusion of albumin attenuates changes in serum protein binding of drugs in surgical patients compared with volume replacement with HAES</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>2008</YR>
<VL>52</VL>
<NO>3</NO>
<PG>406-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rittoo-2004" MODIFIED="2012-05-30 10:55:44 +0100" MODIFIED_BY="Anne Lawson" NAME="Rittoo 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-05-30 10:55:44 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rittoo D, Gosling P, Burnley S, Bonnici C, Millns P, Simms MH, et al</AU>
<TI>Randomized study comparing the effects of hydroxyethyl starch solution with Gelofusine on pulmonary function in patients undergoing abdominal aortic aneurysm surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2004</YR>
<VL>92</VL>
<PG>61-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rosencher-1992" NAME="Rosencher 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Rosencher N, Vassilieff N, Guigonis V, Toulin P, Conseiller C. Comparison des effets de l'Elohes et de l'albumine sur l'hemostase en chirurgie orthopedique. Ann Fr Anesth Reanim 1992;11:526-530&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosencher N, Vassilieff N, Guigonis V, Toulin P, Conseiller C</AU>
<TI>Comparison of effects of Elohes and albumin on haemostasis in orthopedic surgery</TI>
<TO>Comparaison des effets de l'Elohes et de l'albumine sur l'hemostase en chirurgie orthopedique</TO>
<SO>Annales francaises d'Anesthesie et de Reanimation</SO>
<YR>1992</YR>
<VL>11</VL>
<NO>5</NO>
<PG>526-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993118965"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schortgen-2001" NAME="Schortgen 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schortgen F, Lacherade J, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al</AU>
<TI>Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9260</NO>
<PG>911-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schramko-2009" MODIFIED="2012-05-30 10:56:36 +0100" MODIFIED_BY="Frances Bunn" NAME="Schramko 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-29 18:46:12 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Niemi T, Schramko A, Kukkonen S, Kuitunen A, Suojaranta-Ylinen R</AU>
<TI>Haemodynamics and acid-base equilibrium after cardiac surgery: comparison of rapidly degradable hydroxyethyl starch solutions and albumin</TI>
<SO>Scandinavian Journal of Surgery</SO>
<YR>2008</YR>
<VL>97</VL>
<PG>259-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-30 10:56:36 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schramko A, Suojaranta-Ylinen R, Kuitunen A, Kukkonen S, Niemi T</AU>
<TI>Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: a prospective randomized trial</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2009</YR>
<VL>108</VL>
<PG>30-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schramko-2010" MODIFIED="2012-05-29 18:47:26 +0100" MODIFIED_BY="Frances Bunn" NAME="Schramko 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-15 11:09:15 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schramko A, Suojaranta-Ylinen R, Kuitunen A, Raivio P, Kukkonen S, Niemi T</AU>
<TI>Comparison of the effect of 6% hydroxyethyl starch and gelatine on cardiac and stroke volume index: a randomized, controlled trial after cardiac surgery</TI>
<SO>Perfusion</SO>
<YR>2010</YR>
<VL>25</VL>
<NO>5</NO>
<PG>283-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-29 18:47:26 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schramko A, Suojaranta-Ylinen R, Kuitunen A, Raivio P, Kukkonen S, Niemi T</AU>
<TI>Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2010</YR>
<VL>6</VL>
<PG>691-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shatney-1983" NAME="Shatney 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Shatney CH, Deepika K, Militello PR, Majerus TC, Dawson RB. Efficacy of hetastarch in the resuscitation of patients with multisystem trauma and shock. Arch surg 1983;118:804-809&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shatney CH, Deepika K, Militello PR, Majerus TC, Dawson RB</AU>
<TI>Efficacy of hetastarch in the resuscitation of patients with multisystem trauma and shock</TI>
<SO>Archives of Surgery</SO>
<YR>1983</YR>
<VL>118</VL>
<NO>7</NO>
<PG>804-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1983230251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Standl-2008" MODIFIED="2012-05-29 18:47:59 +0100" MODIFIED_BY="[Empty name]" NAME="Standl 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-29 18:47:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>HES 130/0.4 (Voluven) or human albumin in children younger than 2 yr undergoing non-cardiac surgery</AU>
<TI>A prospective, randomized, open label, multicentre trial</TI>
<SO>European Journal of Anaesthesiology</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>6</NO>
<PG>437-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stockwell-1992" NAME="Stockwell 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Stockwell MA, Scott A, Day A, Riley B, Soni N. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline 2. Anesthesia, 1992; 47:7-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stockwell MA, Scott A, Day A, Riley B, Soni N</AU>
<TI>Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline: 2. Serum albumin concentration and incidences of pulmonary oedema</TI>
<SO>Anesthesia</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>1</NO>
<PG>7-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Stockwell MA, Soni N, Riley B. Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline. 1. Outcome and duration of stay in the intensive care unit. Anaesthesia 1992; Vol 47: 3-6.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Stockwell MA, Soni N, Riley B</AU>
<TI>Colloid solutions in the critically ill. A randomised comparison of albumin and polygeline: 1. Outcome and duration of stay in the intensive care unit</TI>
<SO>Anaesthesia</SO>
<YR>1992</YR>
<VL>47</VL>
<NO>1</NO>
<PG>3-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1992161241"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stoddart-1996" NAME="Stoddart 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Stoddart PA, Rich P, Sury MRJ. A comparison of 4.5% human albumin solution and haemaccel in neonates undergoing major surgery. Paediatric anaesthesia 1996;6:103-106&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stoddart PA, Rich P, Sury MR</AU>
<TI>A comparison of 4.5% human albumin solution and haemaccel in neonates undergoing major surgery</TI>
<SO>Paediatric Anaesthesia</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>2</NO>
<PG>103-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996243349"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollofsrud-1995" MODIFIED="2012-05-30 11:20:56 +0100" MODIFIED_BY="Anne Lawson" NAME="Tollofsrud 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-05-29 18:49:02 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Svennevig JL, Tollofsrud S, Kongsgaard U, Noddeland H, Mohr B, Ozer M, Mollnes TE. Complement activation during and after open-heart surgery is only marginally affected by the choice of fluid for volume replacement. Perfusion 1996;11:326-32.&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:49:02 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Svennevig JL, Tollofsrud S, Kongsgaard U, Noddeland H, Mohr B, Ozer M, et al</AU>
<TI>Complement activation during and after open-heart surgery is only marginally affected by the choice of fluid for volume replacement</TI>
<SO>Perfusion</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>4</NO>
<PG>326-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-30 11:20:56 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Tollofsrud S, Svennevig JL, Breivik H et al. Fluid balance and pulmonary functions during and after coronary artery bypass surgery: Ringer&amp;#8217;s acetate compared with dextran, polygeline, or albumin. Acta Anaesthesiol Scand 1995;39:671-7.&lt;/p&gt;" NOTES_MODIFIED="2012-05-30 11:20:56 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tollofsrud S, Svennevig JL, Breivik H, Kongsgaard U, Ozer M, Hysing E, et al</AU>
<TI>Fluid balance and pulmonary functions during and after coronary artery bypass surgery: Ringer's acetate compared with dextran, polygeline, or albumin</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1995</YR>
<VL>39</VL>
<NO>5</NO>
<PG>671-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Linden-2004" MODIFIED="2012-05-29 18:49:54 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Van der Linden 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-05-29 18:49:54 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Linden PJ, De Hert SG, Daper A, Trenchant A, Schmartz D, Defrance P, et al</AU>
<TI>3.5% Urea linked gelatine is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>3</NO>
<PG>236-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-der-Linden-2005" MODIFIED="2012-05-29 18:50:04 +0100" MODIFIED_BY="Anne Lawson" NAME="Van der Linden 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-05-29 18:50:04 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, et al</AU>
<TI>Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2005</YR>
<VL>101</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Veneman-2004" MODIFIED="2012-05-29 18:51:00 +0100" MODIFIED_BY="Anne Lawson" NAME="Veneman 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-05-29 18:51:00 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Veneman T, Oude Nijhuis J, Woittiez A</AU>
<TI>Human albumin and starch administration in critically ill patients: a prospective RCT</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>2004</YR>
<VL>116</VL>
<NO>9-10</NO>
<PG>283-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verheij-2006" MODIFIED="2012-05-29 18:52:10 +0100" MODIFIED_BY="Anne Lawson" NAME="Verheij 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-29 18:51:17 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verheij J, van Lingen A, Beishuizen A, Christiaans H, de Jong J, Girbes A, et al</AU>
<TI>Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery</TI>
<SO>Intensive Care Medicine</SO>
<YR>2006</YR>
<VL>32</VL>
<PG>1030-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-29 18:52:10 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verheij J, van Lingen A, Raijmakers P, Rijnsburgr E, Veerman D, Wisselink W, et al</AU>
<TI>Effect of fluid loading with saline or colloids on pulmonary permeability, oedema and lung injury score after cardiac and major vascular surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2006</YR>
<VL>96</VL>
<NO>1</NO>
<PG>21-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogt-1994" NAME="Vogt 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Vogt N, Bothner U, Georgieff M. Vergleich von human albumin 5% and 6% HES 200/0.5 als ausschliebliche kolloidkomponente bei groben chirurgischen eingriffen. Anasthesiol Intensivmed Notfallmed Schmerzther 1994;29:150-156&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogt N, Bothner U, Georgieff M</AU>
<TI>Comparison of 5% human albumin and 6% 200/0.5 HES as exclusive colloid components in large surgical interventions</TI>
<TO>Vergleich von humanalbumin 5% und 6% HES 200/0.5 als ausschliessliche kolloidkomponente bei grossen chirurgischen eingriffen</TO>
<SO>Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie</SO>
<YR>1994</YR>
<VL>29</VL>
<NO>3</NO>
<PG>150-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogt-1996" MODIFIED="2012-05-29 18:52:35 +0100" MODIFIED_BY="Anne Lawson" NAME="Vogt 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-05-29 18:52:35 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Vogt NH, Bothner U, Lerch G, Linder KH, Georgieff M. Large-dose administration of 6% hydroxyethyl starch 200/0.5 for total hip arthroplasty: Plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin. Anesth Analg 1996;83:262-8.&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:52:35 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogt NH, Bothner U, Lerch G, Linder KH, Georgieff M</AU>
<TI>Large-dose administration of 6% hydroxyethyl starch 200/0.5 for total hip arthroplasty: plasma homeostasis, hemostasis, and renal function compared to use of 5% human albumin</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1996</YR>
<VL>83</VL>
<NO>2</NO>
<PG>262-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996302068"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogt-1999" MODIFIED="2012-05-16 11:28:44 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Vogt 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vogt N, Bothner U, Brinkmann A, De Petriconi R, Georgieff M</AU>
<TI>Peri-operative tolerance to large-dose 6% HES 200/0.5 in major urological procedures compared with 5% human albumin</TI>
<SO>Anaesthesia</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>2</NO>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-05-16 11:28:44 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogt N, Bothner U, Lerch G, Georgieff M</AU>
<TI>Pharmacokinetic and oncotic characteristics of high-dose hydroxyethyl starch compared with human albumin 5% in operative procedures</TI>
<TO>Pharmakokinetik und onkotisches verhalten von hochdosierter hydroxyathylstarke bei operativen eingriffen im vergleich zu humanalbumin 5%</TO>
<SO>Infusion Therapy and Transfusion Medicine</SO>
<YR>1998</YR>
<VL>25</VL>
<PG>212-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volta-2007" MODIFIED="2012-04-02 11:21:16 +0100" MODIFIED_BY="Frances Bunn" NAME="Volta 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-02 11:21:16 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volta CA, Alvisi V, Campi M, Marangoni E, Alvisi R, Castellazzi M, et al</AU>
<TI>Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study</TI>
<SO>Anesthesiology</SO>
<YR>2007</YR>
<VL>106</VL>
<NO>1</NO>
<PG>85-91</PG>
<IDENTIFIERS MODIFIED="2012-04-02 11:21:13 +0100" MODIFIED_BY="Frances Bunn">
<IDENTIFIER TYPE="PUBMED" VALUE="17197849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Sommoggy-1990" NAME="von Sommoggy 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Von Sommoggy St , Fraunhofer J, Jelen-Esselborn S, Stemberger A. Gerinnungsveranderungen bei aortofemoralem bifurkationsbypass: ist eine Volumen -und Plasmasubstitution mit hydroxyathylstarke allein moglich? Anaesthesist 1990;39:353-360&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Von Sommoggy S, Fraunhofer J, Jelen-Esselborn S, Stemberger A</AU>
<TI>Coagulation changes during aortofemural bifurcation bypass: is volume and plasma substitution possible with hydroxyethyl starch alone?</TI>
<TO>Gerinnungsveranderungen bei aortofemoralem bifurkationsbypass: ist eine Volumen -und Plasmasubstitution mit hydroxyathylstarke allein moglich?</TO>
<SO>Anaesthesist</SO>
<YR>1990</YR>
<VL>39</VL>
<NO>7</NO>
<PG>353-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wahba-1996" NAME="Wahba 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Wahba A, Sendtner E, Birnbaum DE. Fluid resuscitation with Haemaccel vs. human albumin following coronary artery bypass grafting. Thorac.cardiovasc surgeon 1996;44:178-183&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wahba A, Sendtner E, Birnbaum DE</AU>
<TI>Fluid resuscitation with Haemaccel vs. human albumin following coronary artery bypass grafting</TI>
<SO>The Thoracic and Cardiovascular Surgeon</SO>
<YR>1996</YR>
<VL>44</VL>
<NO>4</NO>
<PG>178-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997051433"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watkins-1990" NAME="Watkins 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Watkins J, Wild G, Appleyard TN, Hardy G. Complement activation by polystarch and gelatine volume expanders (letter) Lancet 1990;335(8683):233&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watkins J, Wild G, Appleyard TN, Hardy G</AU>
<TI>Complement activation by polystarch and gelatine volume expanders</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<NO>8683</NO>
<PG>233</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Woittiez-1997" NAME="Woittiez 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Hondebrink Y, Jeekel L, Oude Nijhuis J, Woittiez AJJ. Restoration of colloid osmotic pressure in hypoalbuminaemic patients. Intensive Care Medicine 1997; 23 (supp 1):S184&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hondebrink Y, Jeekel L, Oude Nijhuis J, Woittiez AJJ</AU>
<TI>Restoration of colloid osmotic pressure in hypoalbuminaemic patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>supp 1</NO>
<PG>S184</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Timmer B, Hondebrink Y, Oude Nijhuis J, Woittiez AJJ</AU>
<TI>Restoration of colloid osmotic pressure in hypoalbuminaemic patients</TI>
<SO>Netherlands Journal of Medicine</SO>
<YR>1998</YR>
<VL>52</VL>
<PG>A42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2011" MODIFIED="2012-05-29 18:54:05 +0100" MODIFIED_BY="[Empty name]" NAME="Yang 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-05-29 18:54:05 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yang J, Wang WT, Yan LN, Xu MQ, Yang JY</AU>
<TI>Alternatives to albumin administration in hepatocellular carcinoma patients undergoing hepatectomy: an open, randomized clinical trial of efficacy and safety</TI>
<SO>Chinese Medical Journal</SO>
<YR>2011</YR>
<VL>124</VL>
<NO>10</NO>
<PG>1458-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Boks-2007" MODIFIED="2012-05-16 11:15:15 +0100" MODIFIED_BY="Frances Bunn" NAME="Boks 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-05-16 11:15:15 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boks RH, Wijers MJ, Hofland J, Takkenberg JJM, Bogers AJJ</AU>
<TI>Low molecular starch versus gelatin plasma expander during CPB: does it make a difference?</TI>
<SO>Perfusion</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>5</NO>
<PG>333-8</PG>
<IDENTIFIERS MODIFIED="2012-05-16 11:15:05 +0100" MODIFIED_BY="Emma M Sydenham">
<IDENTIFIER MODIFIED="2012-05-16 11:15:05 +0100" MODIFIED_BY="Emma M Sydenham" TYPE="DOI" VALUE="10.1177/0267659107086656"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-1993" MODIFIED="2012-05-15 11:10:23 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Boldt 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-05-15 11:10:23 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Boldt J, Knothe C, Schindler E, Hammermann H, Dapper F, Hempelmann G. Volume replacement with hydroxyethyl starch solution in children. British Journal of Anaesthesia 1993; 70: 661-665.&lt;/p&gt;" NOTES_MODIFIED="2012-05-15 11:10:23 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Knothe C, Schindler E, Hammermann H, Dapper F, Hempelmann G</AU>
<TI>Volume replacement with hydroxyethyl starch solution in children</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1993</YR>
<VL>70</VL>
<NO>6</NO>
<PG>661-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-2000b" MODIFIED="2012-05-29 18:54:38 +0100" MODIFIED_BY="Anne Lawson" NAME="Boldt 2000b" YEAR="2000">
<REFERENCE MODIFIED="2012-05-29 18:54:38 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Lehmann A, Rompert R, Haisch G, Isgro F</AU>
<TI>Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass</TI>
<SO>Journal of Cardiothoracic and Vascular Anaesthesia</SO>
<YR>2000</YR>
<VL>14</VL>
<NO>3</NO>
<PG>264-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-2006" MODIFIED="2012-06-11 13:07:16 +0100" MODIFIED_BY="Frances Bunn" NAME="Boldt 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-06-11 13:07:16 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Schollhorn T, Mayer J, Piper S, Suttner S</AU>
<TI>The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2006</YR>
<VL>103</VL>
<PG>191-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boldt-2008" MODIFIED="2012-05-29 18:54:57 +0100" MODIFIED_BY="[Empty name]" NAME="Boldt 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-29 18:54:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Brosch C, Röhm K, Papsdorf M, Mengistu A</AU>
<TI>Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>4</NO>
<PG>457-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brehme-1993" MODIFIED="2012-05-29 18:55:35 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Brehme 1993" YEAR="1993">
<REFERENCE MODIFIED="2012-05-29 18:55:35 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Brehme S, Keyber G, Turowski A, Schmidt H. Haemorheologische wirkungen von hydroxyathylstarke 200/0.5, dextran 40, Oxypolygelatine und vollelekttrolytlosung uber 48 studen. Innere Medizin 1993;48:506-510&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:55:35 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brehme S, Keysser G, Turowski A, Schmidt H</AU>
<TI>Hemorheologic effects of hydroxyethyl starch 200/0.5, dextran 40, oxypolygelatine and full electrolyte sodium over 48 hours</TI>
<TO>Hamorheologische wirkungen von hydroxyathylstarke 200/0.5, dextran 40, oxypolygelatine und vollelekttrolytlosung uber 48 studen</TO>
<SO>Zeitschrift fur die Gesamte Innerve Medizin und ihre Grenzgebiete</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>10</NO>
<PG>506-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bremerich-2000" MODIFIED="2012-05-15 11:10:49 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Bremerich 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-05-15 11:10:49 +0100" MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bremerich DH, Lischke V, Asskali F, Forster H, Behne M</AU>
<TI>Pharmacodynamics and tolerability of acetyl starch as a new plasma volume expander in patients undergoing elective surgery</TI>
<SO>International Journal of Clinical Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>38</VL>
<NO>8</NO>
<PG>408-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charlet-1991" MODIFIED="2012-05-15 11:11:20 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Charlet 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-05-15 11:11:20 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Charlet P, Zerr C, Robert D, Merville C, Renouf P, khayat MC. Essais comparatifs des gelatines fluides sur l'hemostase dans la chirurgie cardiague de l'adulte. Cahiers d'Anesthesiologie 1991;39(4):233-238&lt;/p&gt;" NOTES_MODIFIED="2012-05-15 11:11:20 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charlet P, Zerr C, Robert D, Merville C, Renouf P, Khayat MC</AU>
<TI>Comparative trials of fluid gelatins on hemostasis in heart surgery in adults</TI>
<TO>Essais comparatifs des gelatines fluides sur l'hemostase dans la chirurgie cardiaque de l'adulte</TO>
<SO>Cahiers d'Anesthesiologie</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>4</NO>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Christ-1997" NAME="Christ 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Christ F, Niklas M, Kreimeier U, Lauterjung L, Peter K, Messmer K. Hyperosmotic-hyperoncotic solutions during abdominal aortic aneurysm (AAA) resection. Acta Anaesthesiol Scand 1997; 41:62-70.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Christ F, Niklas M, Kreimeier U, Lauterjung L, Peter K, Messmer K</AU>
<TI>Hyperosmotic-hyperoncotic solutions during abdominal aortic aneurysm (AAA) resection</TI>
<SO>Acta Anaesthesiologica Scandinavica</SO>
<YR>1997</YR>
<VL>41</VL>
<NO>1</NO>
<PG>62-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Emery-1992" NAME="Emery 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Emery EF, Greenough A, Gamsu HR. Randomised controlled trial of colloid infusions in hypotensive preterm infants. Archives of disease in childhood, 1992; 67:1185-1188.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Emery EF, Greenough A, Gamsu HR</AU>
<TI>Randomised controlled trial of colloid infusions in hypotensive preterm infants</TI>
<SO>Archives of Disease in Childhood,</SO>
<YR>1992</YR>
<VL>67</VL>
<NO>10(S)</NO>
<PG>1185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gan-1999" NAME="Gan 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gan TJ, Bennett-Guerrero E, Phillips-Bute B, Wakeling H, Moskowitz DM, Olufolabi Y et al</AU>
<TI>Hextend, a physiologically balanced plasma expander for large volume use in major surgery: a randomized phase III clinical trial</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1999</YR>
<VL>88</VL>
<NO>5</NO>
<PG>992-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Green-2010" MODIFIED="2012-05-15 13:43:32 +0100" MODIFIED_BY="Frances Bunn" NAME="Green 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-05-15 13:43:32 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Green RS, Zed PJ, McIntyre L</AU>
<TI>Pentastarch Resuscitation in Severe Sepsis and Septic Shock</TI>
<SO>Canadian Journal of Emergency Medicine</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>1</NO>
<PG>58-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haisch-2001a" MODIFIED="2012-06-11 13:07:32 +0100" MODIFIED_BY="Frances Bunn" NAME="Haisch 2001a" YEAR="2001">
<REFERENCE MODIFIED="2012-06-11 13:07:32 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F</AU>
<TI>Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation in cardiac surgical patients</TI>
<SO>Journal of Cardiothoracic and Vascular Anesthesia</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>3</NO>
<PG>316-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haisch-2001b" MODIFIED="2012-06-11 13:07:49 +0100" MODIFIED_BY="Frances Bunn" NAME="Haisch 2001b" YEAR="2001">
<REFERENCE MODIFIED="2012-06-11 13:07:49 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haisch G, Boldt J, Krebs C, Kumle B, Suttner S, Schulz A</AU>
<TI>The influence of intravascular volume therapy with a new hydroxyethyl starch preparation (6% HES 130/0.4) on coagulation in patients undergoing major abdominal surgery</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>3</NO>
<PG>565-71</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21124037"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hankeln-1990" MODIFIED="2012-05-15 11:11:36 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Hankeln 1990" YEAR="">
<REFERENCE MODIFIED="2012-05-15 11:11:36 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Hankeln K, Senker R, Beez M. Vergleichende Untersuchung zur intraoperativen Wirksamkeit von 5% Humanalbumin oder 10% Hydroxyathylstarke (HAES-steril) auf Hamodynamik und Sauerstofftransport bei 40 Patienten. Infusionstherapie 1990;17:135-140.&lt;/p&gt;" NOTES_MODIFIED="2012-05-15 11:11:36 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hankeln K, Senker R, Beez M</AU>
<TI>Comparative study of the intraoperative effectiveness of 5% human albumin or 10% hydroxyethyl starch (HAES-steril) on hemodynamics and oxygen transport in 40 patients</TI>
<TO>Vergleichende Untersuchung zur intraoperativen Wirksamkeit von 5% Humanalbumin oder 10% Hydroxyathylstarke (HAES-steril) auf Hamodynamik und Sauerstofftransport bei 40 Patienten</TO>
<SO>Infusionstherapie</SO>
<YR>1990</YR>
<VL>17</VL>
<NO>3</NO>
<PG>135-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harke-1976" MODIFIED="2012-05-15 11:11:42 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Harke 1976" YEAR="1976">
<REFERENCE MODIFIED="2012-05-15 11:11:42 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Harke H, Thoenies R, Margraf I, momsen W. The influence of different plasma substitutes on blood clotting and platelet function during and after surgery. Anaesthesist 1976;25:366-373.&lt;/p&gt;" NOTES_MODIFIED="2012-05-15 11:11:42 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harke H, Thoenies R, Margraf I, Momsen W</AU>
<TI>The influence of different plasma substitutes on blood clotting and platelet function during and after surgery</TI>
<TO>Der Einfluss verschiedener Plasmaersatzmittel auf Gerinnungssystem und Thrombocytenfunktion wahrend und nach operativen Eingriffen. Vorlaufige Ergebnisse einer klinischen Studie</TO>
<SO>Anaesthesist</SO>
<YR>1976</YR>
<VL>25</VL>
<NO>8</NO>
<PG>366-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiippala-1996" MODIFIED="2012-05-29 18:56:56 +0100" MODIFIED_BY="Anne Lawson" NAME="Hiippala 1996" YEAR="">
<REFERENCE MODIFIED="2012-05-29 18:56:56 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Hiippala S, Teppo AM. Perioperative volume effect of HES 120/0.7 compared with dextran 70 and ringer acetate. Annales Chirurgiae et Gynaecologiae, 1996;85: 333-339&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:56:56 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiippala S, Teppo AM</AU>
<TI>Perioperative volume effect of HES 120/0.7 compared with dextran 70 and Ringer acetate</TI>
<SO>Annales Chirurgiae et Gynaecologiae</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>4</NO>
<PG>333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Hopkins-1994" MODIFIED="2012-05-29 18:57:06 +0100" MODIFIED_BY="Frances Bunn" NAME="Hopkins 1994" YEAR="1994">
<REFERENCE MODIFIED="2012-05-29 18:57:06 +0100" MODIFIED_BY="Frances Bunn" NOTES="&lt;p&gt;Hopkins PM. 6% hydroxyethylstarch with 4% gelatine as peri-operative intravenous volume replacement in surgical patients. National Research Register, version 1/1998.&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:57:06 +0100" NOTES_MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Hopkins PM</AU>
<TI>6% Hydroxyethylstarch with 4% gelatine as peri-operative intravenous volume replacement in surgical patients</TI>
<SO>National Research Register</SO>
<YR>Version 1/1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huet-2000" MODIFIED="2012-05-29 18:57:35 +0100" MODIFIED_BY="Anne Lawson" NAME="Huet 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-05-29 18:57:35 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huet RCGG, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JAM, van Oeveren W, et al</AU>
<TI>A novel hydroxyethyl starch (Voluven(TM)) for effective perioperative plasma volume substitution in cardiac surgery</TI>
<SO>Canadian Journal of Anaesthesia</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>12</NO>
<PG>1207-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huttner-2000" MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="Frances Bunn" NAME="Huttner 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huttner I, Boldt J, Haisch G, Suttner S, Kumle B, Schulz H</AU>
<TI>Influence of different colloids on molecular markers of haemostasis and platelet function in patients undergoing major abdominal surgery</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>3</NO>
<PG>417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2004a" NAME="Jones 2004a" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones SB, Whitten CW, Monk TG</AU>
<TI>Influence of crystalloid and colloid replacement solutions on hemodynamic variables during acute normovolemic hemodilution</TI>
<SO>Journal of Clinical Anesthesia</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>1</NO>
<PG>11-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jovanovic-1997" MODIFIED="2012-05-29 18:58:11 +0100" MODIFIED_BY="Anne Lawson" NAME="Jovanovic 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-05-29 18:58:11 +0100" MODIFIED_BY="Anne Lawson" NOTES="&lt;p&gt;Jovanovic K, Filipovic N, Romic P, Surbatovic M. Hetastarch in replacement of circulation volume compared to haemaccel and dextran 70 in pre-hospital resuscitation of polytraumatised patients. Intensive Care Medicine 1997; 23 (supp 1):S184&lt;/p&gt;" NOTES_MODIFIED="2012-05-29 18:58:11 +0100" NOTES_MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jovanovic K, Filipovic N, Romic P, Surbatovic M</AU>
<TI>Hetastarch in replacement of circulation volume compared to haemaccel and dextran 70 in pre-hospital resuscitation of polytraumatised patients</TI>
<SO>Intensive Care Medicine</SO>
<YR>1997</YR>
<VL>23</VL>
<PG>S184</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Korttila-1984" MODIFIED="2012-05-15 11:12:44 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Korttila 1984" YEAR="1984">
<REFERENCE MODIFIED="2012-05-15 11:12:44 +0100" MODIFIED_BY="Emma M Sydenham" NOTES="&lt;p&gt;Kortilla K, Grohn P, Gordin A, Sundberg S, Salo H, Nissinen E, Mattila M. Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol. 1984;24:273-282.&lt;/p&gt;" NOTES_MODIFIED="2012-05-15 11:12:44 +0100" NOTES_MODIFIED_BY="Emma M Sydenham" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Korttila K, Grohn P, Gordin A, Sundberg S, Salo H, Nissinen E, et al</AU>
<TI>Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1984</YR>
<VL>24</VL>
<NO>7</NO>
<PG>273-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kotzampassi-2008" MODIFIED="2012-05-29 18:58:46 +0100" MODIFIED_BY="Frances Bunn" NAME="Kotzampassi 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-05-29 18:58:46 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kotzampassi K, Grosomanidis V, Andreopoulos K, Skourtis CH, Eleftheriadis E</AU>
<TI>Albumin versus colloids in colon surgery patients: preliminary results (Abstract no P229)</TI>
<SO>Critical Care</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>Suppl 2</NO>
<PG>P229</PG>
<IDENTIFIERS MODIFIED="2012-05-16 11:17:43 +0100" MODIFIED_BY="Emma M Sydenham">
<IDENTIFIER MODIFIED="2012-05-16 11:17:43 +0100" MODIFIED_BY="Emma M Sydenham" TYPE="DOI" VALUE="10.1186/cc6450"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Langeron-2001" MODIFIED="2012-05-29 18:59:07 +0100" MODIFIED_BY="Anne Lawson" NAME="Langeron 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-05-29 18:59:07 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Langeron ODM, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P</AU>
<TI>Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4) causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2001</YR>
<VL>92</VL>
<NO>4</NO>
<PG>855-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palumbo-2006" MODIFIED="2012-05-29 18:59:21 +0100" MODIFIED_BY="Anne Lawson" NAME="Palumbo 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-05-29 18:59:21 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palumbo</AU>
<TI>The effect of HES solution in critically ill patients</TI>
<SO>Minerva Anesthesiology</SO>
<YR>2006</YR>
<VL>72</VL>
<PG>655-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puri-1983" NAME="Puri 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Puri VK, Howard M, Paidipaty B, Singh S. Resuscitation in hypovolemia and shock: A prospective study of hydroxyethyl starch and albumin. Crit care med 1983;11(7):518-523).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puri VK, Howard M, Paidipaty B, Singh S</AU>
<TI>Resuscitation in hypovolemia and shock: a prospective study of hydroxyethyl starch and albumin</TI>
<SO>Critical Care Medicine</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>7</NO>
<PG>518-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rauch-2000" NAME="Rauch 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rauch S, Sefrin P</AU>
<TI>Comparison of hydroxyethyl starch solutions derived from potato and corn starch</TI>
<TO>Vergleich von Hydroxyethylstarkelosungen aus Kartoffel- und Maisstarke</TO>
<SO>Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>12</NO>
<PG>750-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rehm-2000" NAME="Rehm 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rehm M, Orth V, Scheingraber S, Kreimeier U, Brechtelsbauer H, Finsterer U</AU>
<TI>Acid-base changes caused by 5% albumin versus 6% hydroxyethyl starch solution in patients undergoing acute normovolemic hemodilution: a randomized prospective study</TI>
<SO>Anesthesiology</SO>
<YR>2000</YR>
<VL>93</VL>
<NO>5</NO>
<PG>1174-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romero-1999" MODIFIED="2012-05-10 09:00:51 +0100" MODIFIED_BY="Frances Bunn" NAME="Romero 1999" YEAR="1999">
<REFERENCE MODIFIED="2012-05-10 09:00:51 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romero J, Luna P, Fernandez B, Rojas E, Sarrano X, Alvarez H</AU>
<TI>The use of HAES-Steril 6% as a plasma expander after cardiopulmonary bypass in aortocoronary surgery</TI>
<TO>Uso de HAES esteril 6% como expansor plasmatico despues de la circulacion extracorporea en revascularizacion coronaria</TO>
<SO>Revista Mexicana de Anestesiologia</SO>
<YR>1999</YR>
<VL>22</VL>
<PG>160-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strauss-1985" NAME="Strauss 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Strauss RG, Stump DC, Henriksen A, Saunders R. Effects of hydroxyethyl starch and fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 1985;25(3):230-234.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strauss RG, Stump DC, Henriksen RA, Saunders R</AU>
<TI>Effects of hydroxyethyl starch and fibrinogen, fibrin clot formation, and fibrinolysis</TI>
<SO>Transfusion</SO>
<YR>1985</YR>
<VL>25</VL>
<NO>3</NO>
<PG>230-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vanhoonacker-2009" MODIFIED="2012-05-29 19:00:58 +0100" MODIFIED_BY="Frances Bunn" NAME="Vanhoonacker 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-05-29 19:00:58 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vanhoonacker J, Ongenae M, Vanoverschelde H, Donadoni R</AU>
<TI>Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for cardiopulmonary bypass priming: the effects on postoperative bleeding and volume expansion needs after elective CABG</TI>
<SO>Acta Anaesthesiologica Belgica</SO>
<YR>2009</YR>
<VL>60</VL>
<PG>91-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waxman-1989" NAME="Waxman 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Waxman K, Holness R, Tominaga G, Chela P, Grimes J. Hemodynamic and oxygen transport effects of pentastarch in burn resuscitation. Ann Surg 1989; 209(3):341-345&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waxman K, Holness R, Tominaga G, Chela P, Grimes J</AU>
<TI>Hemodynamic and oxygen transport effects of pentastarch in burn resuscitation</TI>
<SO>Annals of Surgery</SO>
<YR>1989</YR>
<VL>209</VL>
<NO>3</NO>
<PG>341-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yap-2007" MODIFIED="2012-04-02 10:03:52 +0100" MODIFIED_BY="Frances Bunn" NAME="Yap 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-04-02 10:03:50 +0100" MODIFIED_BY="Frances Bunn" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yap WW, Young D, Pathi V</AU>
<TI>Effects of gelatine and medium molecular weight starch as priming fluid in cardiopulmonary bypass - a randomised controlled trial</TI>
<SO>Perfusion</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>57-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-05-10 09:00:51 +0100" MODIFIED_BY="Frances Bunn"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-05-30 12:40:23 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-05-30 12:40:23 +0100" MODIFIED_BY="Emma M Sydenham">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Armstrong-1994" MODIFIED="2012-05-30 12:40:23 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Armstrong 1994" TYPE="BOOK">
<AU>Armstrong RF, Bullen C, Cohen SL, Singer M, Webb AR</AU>
<SO>Critical care algorithms</SO>
<YR>1994</YR>
<VL>Oxford Medical Publications</VL>
<PB>Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1997" NAME="Berlin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA</AU>
<TI>Does blinding of readers affect the results of meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>185-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boldt-1996" MODIFIED="2012-05-30 11:00:53 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Boldt 1996" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Heesen M, Muller M, Pabsdorf M, Hempelmann G</AU>
<TI>The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1996</YR>
<VL>83</VL>
<PG>254-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boldt-2009" MODIFIED="2012-05-29 19:02:38 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Boldt 2009" TYPE="JOURNAL_ARTICLE">
<AU>Boldt J, Suttner S, Brosch C, Lehmann A, Roehm K, Mengitsu A</AU>
<TI>Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2009</YR>
<VL>109</VL>
<PG>1752-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-05-30 11:36:13 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perel-2012" MODIFIED="2012-05-15 14:44:49 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Perel 2012" TYPE="COCHRANE_REVIEW">
<AU>Perel P, Roberts I</AU>
<TI>Colloids versus crystalloids for fluid resuscitation in critically ill patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2012-05-15 14:44:49 +0100" MODIFIED_BY="Emma M Sydenham">
<IDENTIFIER MODIFIED="2012-05-15 14:44:49 +0100" MODIFIED_BY="Emma M Sydenham" TYPE="DOI" VALUE="10.1002/14651858.CD000567.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reinhart-2011" MODIFIED="2012-05-29 19:04:01 +0100" MODIFIED_BY="[Empty name]" NAME="Reinhart 2011" TYPE="JOURNAL_ARTICLE">
<AU>Reinhart K, Takala J</AU>
<TI>Hydroxyethyl starches: what do we still know?</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2011</YR>
<VL>112</VL>
<PG>507-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-2011" MODIFIED="2012-05-15 14:43:15 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Roberts 2011" TYPE="COCHRANE_REVIEW">
<AU>Roberts I, Blackhall K, Alderson P, Bunn F, Schierhout G</AU>
<TI>Human albumin solution for resuscitation and volume expansion in critically ill patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>11</NO>
<IDENTIFIERS MODIFIED="2012-05-15 14:43:15 +0100" MODIFIED_BY="Emma M Sydenham">
<IDENTIFIER MODIFIED="2012-05-15 14:43:15 +0100" MODIFIED_BY="Emma M Sydenham" TYPE="DOI" VALUE="10.1002/14651858.CD001208.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shafer-2011" MODIFIED="2012-05-29 19:04:16 +0100" MODIFIED_BY="[Empty name]" NAME="Shafer 2011" TYPE="JOURNAL_ARTICLE">
<AU>Shafer SL</AU>
<TI>Shadow of doubt</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2011</YR>
<VL>112</VL>
<PG>498-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Traylor-1996" MODIFIED="2012-05-29 19:04:29 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Traylor 1996" TYPE="JOURNAL_ARTICLE">
<AU>Traylor RJ, Pearl RG</AU>
<TI>Crystalloid versus colloid: all colloids are not created equal</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>1996</YR>
<VL>83</VL>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vermeulen-1995" MODIFIED="2012-05-30 11:06:48 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Vermeulen 1995" TYPE="JOURNAL_ARTICLE">
<AU>Vermeulen LC Jr, Ratko TA, Erstad BL, Brecher ME, Matuszewski KA</AU>
<TI>A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solutions</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<NO>4</NO>
<PG>373-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yim-1995" MODIFIED="2008-07-18 18:03:11 +0100" MODIFIED_BY="Emma M Sydenham" NAME="Yim 1995" TYPE="JOURNAL_ARTICLE">
<AU>Yim JM, Vermeyken LC, Erstad BL, Matuszewski KA, Burnett DA, Vlasses PH</AU>
<TI>Albumin and nonprotein colloid solution use in US academic health centers</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<NO>22</NO>
<PG>2450-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2012-05-15 13:46:07 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-06-12 17:44:16 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-06-12 17:44:16 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akech-2006">
<CHAR_METHODS MODIFIED="2012-05-03 12:21:26 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised design. Fluid interventions allocated sequentially in blocks of 10</P>
<P>ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="[Empty name]">
<P>88 children over 3 months of age with severe malaria complicated by metabolic acidosis. Inclusion criteria: severe malaria, metabolic acidosis, and clinical feature of shock. Excluded if had pulmonary oedema, oedematous malnutrition, or papilloedema</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="[Empty name]">
<P>1) 4% Modified gelatin (n = 44)</P>
<P>2) 4.5% Albumin (n = 44)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-21 11:22:49 +0000" MODIFIED_BY="[Empty name]">
<P>Death</P>
<P>Resolution of shock and acidosis</P>
<P>Neurological sequelae at discharge</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-21 11:25:23 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention arms not blinded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 19:58:41 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Allison-1999">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Randomisation was based on date of admission<BR/>Analysis not ITT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Anne Lawson">
<P>45 patients with blunt trauma who required colloid infusion. Patients were excluded if they were less than 12 years old, did not require admission to the ITU, died within 24 hours, were pregnant or in renal failure<BR/>8 gelatin and 6 HES patients excluded after randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 19:58:41 +0100" MODIFIED_BY="Anne Lawson">
<P>1) HES (200/0.45 Pentaspan) (n = 24)<BR/>2) Gelatin (Gelofusine) (n = 21)<BR/>After 24 hours, colloid administration was at the discretion of the clinician</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Glasgow coma score<BR/>Volumes of blood and platelets infused<BR/>Haematological parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Anne Lawson">
<P>Data were collected until the patient left the ITU or for a maximum of 5 days. Main outcome of interest was capillary leak</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-11 11:44:51 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Arellano-2005">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. All participants, healthcare workers, and study personnel blinded to allocation<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Anne Lawson">
<P>50 adults undergoing surgical ablation of oropharyngeal cancer with free flap reconstruction (mean age 55 years). Exclusion criteria - ASA Physical Status Classification 3-4, cardiac insufficiency, pancreatitis, severe hepatic dysfunction, renal dysfunction, anaemia, coagulation abnormalities, ingestion of NSAID, or ASA within 10 days of surgery and previous major head and neck surgery with free flap reconstruction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-11 11:44:51 +0100" MODIFIED_BY="Emma M Sydenham">
<P>1) 5% HA (n = 25)<BR/>2) HES 264/0.45 (n = 25)<BR/>CVP was maintained between 7 mmHg and 10 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Anne Lawson">
<P>Clinical indices of coagulation<BR/>Number of units of blood transfused<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 24 hours. 1 patient in each group did not complete the study because planned surgical procedure was abandoned</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:10:36 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Asfar-2000">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Anne Lawson">
<P>34 septic, hypovolaemic, ventilated, and haemodynamically controlled patients<BR/>Inclusion criteria: patients aged over 16 years, systolic arterial pressure higher than 90 mmHg and hypovolaemia defined by PAOP of 12 mmHg or less<BR/>Patients were excluded if they had an overt haemodynamic, ventilatory, or acid base status instability. Sepsis was identified by either positive bacterial blood cultures, bronchoalveolar lavage, or clinical evidence of infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:29 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 16)<BR/>2) 4% MFG (n = 18)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:10:36 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 1 hour. 2 patients in the HES group were excluded because they experienced haemodynamic instability. The final analysis was made on remaining 16 patients. Information on allocation concealment obtained from study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:10:44 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Beards-1994">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 18:04:38 +0100" MODIFIED_BY="Anne Lawson">
<P>28 patients with hypovolaemia, mechanically ventilated for concurrent acute respiratory failure. Patients fulfilled the following inclusion criteria: age &gt;16 years, body weight between 50 kg and 85 kg, MAP &lt; 80 mmHg (or 30 mmHg less than previously recorded); PAOP &lt; 10 mmHg with oliguria (i.e. urine output &lt; 15 mL/hour)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:31 +0100" MODIFIED_BY="Anne Lawson">
<P>1) Rapid infusion of 500 mL MFG (n = 15)<BR/>2) Rapid infusion of 500 mL hetastarch (n = 13)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Oxygen variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:10:44 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 30 minutes for haemodynamic variables and until discharge for deaths. Information on allocation concealment was obtained on contact with the study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:19:32 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Berard-1995">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Anne Lawson">
<P>319 patients in a resuscitation service receiving medical (gastrointestinal haemorrhage) and surgical cases. Patients were excluded if they had had a prior allergic reaction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:32 +0100" MODIFIED_BY="Anne Lawson">
<P>1) Gelatin (n = 153)<BR/>2) HES (n = 146)<BR/>The prescribers chose the quantity of colloid, guided by normal practice</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 18:07:48 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Amount of colloid and RBCs given<BR/>Cost</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Frances Bunn">
<P>20 patients lost to follow-up, no explanation given. Follow-up to discharge. Information on method of randomisation was obtained on contact with the study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:19:33 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Beyer-1997">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. No blinding</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 18:01:58 +0100" MODIFIED_BY="Anne Lawson">
<P>48 patients undergoing major elective hip surgery with an expected blood loss of &gt; 1000 mL. Exclusion criteria were Hb concentration 11 g/dL or less; heart failure and coronary artery disease; MI within the past 6 months; hypertension (&gt; 180 mmHg systolic); impaired renal function; pregnancy; known hypersensitivity to HES or gelatin; patient taking drugs that may specifically affect blood viscosity, diuresis, or clotting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:33 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 3% MFG (n = 22)<BR/>2) 6% HES (n = 19)<BR/>Both groups also given RL. Fluids administered according to haemodynamic and clinical parameters</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:53:40 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (information on death was obtained by contact with the study author)<BR/>Haemodynamic variables<BR/>Packed cell volume, Hb, clotting times<BR/>Incidence of allergic reactions<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Frances Bunn">
<P>7 patients were lost to follow-up but only 5 were accounted for. Information on method of allocation concealment was obtained by contact with the author<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 19:59:32 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Boldt-1986">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial, using sealed opaque envelopes<BR/>Information on allocation concealment was obtained on contact with the study authors<BR/>Blinding not mentioned<BR/>Loss to follow-up not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Anne Lawson">
<P>55 patients undergoing elective aortocoronary bypass surgery<BR/>Exclusion criteria were ejection fraction &lt; 50% and LVEDP &gt;15 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 19:59:32 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 500 mL 20% HA (n = 15)<BR/>2) 500 mL 3% HES (n = 13)<BR/>3) 500 mL 3.5% Gelatin (n = 14)<BR/>A fourth group received no colloid (n = 13)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Incidence of anaphylactic shock<BR/>Amount blood transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up until discharge from ICU</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:19:39 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-1993a">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 18:05:01 +0100" MODIFIED_BY="Anne Lawson">
<P>75 men undergoing elective aortocoronary bypass grafting, who had a PCWP of &lt; 5 mmHg after induction of anaesthesia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:39 +0100" MODIFIED_BY="Anne Lawson">
<P>1) HA 5% (n = 15)<BR/>2) 6% HES, HMW (n = 15)<BR/>3) 6% HES, LMW (n = 15)<BR/>4) Gelatin 3.5% (n = 15)<BR/>5) No additional volume</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (information obtained on contact with author)<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 1 day. Information on allocation was obtained on contact with study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 17:52:57 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-1995">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Blinding of outcome assessors not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Anne Lawson">
<P>30 consecutive trauma patients (injury severity score &gt; 15) and 30 consecutive septic patients who underwent major surgery. Exclusions: patients suffering from renal failure requiring haemofiltration, severe liver dysfunction or coagulation abnormalities in their history were excluded as were patients who were receiving aspirin or other cyclooxygenase inhibitors</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 17:52:57 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% HES, LMW (15 trauma patients and 15 sepsis patients)<BR/>2) 20% HA (15 trauma patients and 15 sepsis patients)<BR/>Fluid was given to maintain CVP and PCWP between 12 mmHg and 16 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up at 5 days<BR/>Deaths were reported within the study period and later (time not specified). Information on allocation concealment was obtained on contact with the study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:30:39 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-1996a">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Outcome assessors blinded to treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Anne Lawson">
<P>30 trauma patients and 30 patients with from sepsis secondary to major general surgery. Exclusions were patients with renal impairment, liver insufficiency, disseminated intravascular coagulation, or septic shock</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 10:30:39 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% HES (n = 30)<BR/>2) 20% HA solution (n = 30)<BR/>All patients also received RL</P>
<P>Volume therapy was given to maintain PCWP between 12 mmHg and 18 mmHg<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up at 5 days and at discharge from ICU</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 11:13:48 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-1996b">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. The doctors giving the fluid were blinded to the solution but blinding of outcome assessors not mentioned. Loss to follow-up not reported<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 20:59:48 +0100" MODIFIED_BY="Anne Lawson">
<P>45 consecutive trauma patients transferred to the surgical ICU. Inclusion criteria: injury severity score of &gt; 15 points<BR/>All patients were haemodynamically stable before being admitted to the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 11:13:48 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% HES (n = 15)<BR/>2) 20% HA (n = 15)<BR/>3) Unspecified volume therapy regimen (n = 15)<BR/>The allocated solution was given to maintain CVP and or PAWP between 12 mmHg and 18 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Circulating adhesion molecules</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Deaths were reported within the study period and later (left ITU). Information on allocation concealment was obtained on contact with the study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:11:09 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-1996c">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Outcome variables were collected by an investigator who was blinded to the treatment. Loss to follow-up not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Anne Lawson">
<P>56 patients from the surgical ICU. 28 patients with an injury severity score &gt; 15 and 28 patients with sepsis secondary to major surgery. Patients with renal insufficiency, urine output &lt; 20 mL/hour, severe liver dysfunction, or disseminated intravascular coagulation were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:22:54 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% HES, LMW (14 trauma patients, 14 sepsis patients)<BR/>2) 20% HA (14 trauma patients, 14 sepsis patients)<BR/>Fluid was infused to maintain PCWP at 10 mmHg to 15 mmHg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:11:09 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 5 days<BR/>Deaths were reported within the study period and later (time not specified)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-12 17:42:38 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-1998">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Blinding of outcome assessors not mentioned<BR/>Loss to follow-up not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 20:26:44 +0100" MODIFIED_BY="Anne Lawson">
<P>150 traumatised patients (injury severity score &gt;15) and 150 postoperative patients with sepsis. Patients suffering from renal failure, severe liver insufficiency, or with major coagulation abnormalities were not included</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-12 17:42:38 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% HES, LMW (n = 150)<BR/>2) 20% HA (n = 150)</P>
<P>Both for 5 days to maintain the PAWP between 12 Torr and 15 Torr</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Organ function<BR/>Coagulation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Deaths were reported within the study period and after the study period (time not specified). Information on allocation concealment was obtained on contact with the authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:31:54 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-2000">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Anne Lawson">
<P>150 patients undergoing major abdominal surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 10:31:54 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES, LMW (n = 50)<BR/>2) 6% HES, MMW (n = 50)<BR/>3) 3% MFG (n = 50)<BR/>To keep MAP &gt; 70 mmHg and CVP between 10 mmHg and 14 mmHg<BR/>Volume was given perioperatively until the morning of the first postoperative day. For each hour of surgery 500 mL to 800 mL of crystalloids was routinely infused</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Blood loss<BR/>Blood transfused<BR/>Cost</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:11:15 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 1 postoperative day. Deaths recorded after study period. Information on allocation concealment was obtained on contact with the study authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:08:38 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-2001">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Volume therapy was done by doctors who did not know the aim of the study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Anne Lawson">
<P>75 patients undergoing major abdominal surgery<BR/>Volume was administered to keep the CVP between 8 mmHg and 12 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:08:38 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 25)<BR/>2) 6% HES (n = 25)<BR/>3) 4% MFG (n = 25)<BR/>All groups also received 500 mL of RL for each hour of surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Blood loss<BR/>Blood units transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Anne Lawson">
<P>There were no deaths in the study period (until first follow-up on first postoperative day. Deaths until discharge</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:19:51 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Brock-1995">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Anne Lawson">
<P>21 patients who had undergone cardiac surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:51 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% HES 200/0.5 in 7.2% saline (n = 7)<BR/>2) 5% HA (n = 7)<BR/>3) 6% HES in 0.9% saline (n = 7)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data obtained on contact with study author)<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Frances Bunn">
<P>Data on allocation concealment was obtained on contact with the study authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:11:31 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Brutocao-1996">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised double-blind controlled trial with pharmacy-controlled randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Anne Lawson">
<P>38 children aged 1 year or more who were undergoing surgical repair of a congenital heart disease. Exclusion criteria included amrinone therapy, renal disease, coagulopathy, or a known bleeding diathesis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:00:40 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% Albumin (n = 18)<BR/>2) 6% HES (n = 20)<BR/>Volume expansion was administered as clinically indicated to maintain adequate CVP, perfusion, and urine output. The total amount of colloid therapy was determined by care providers blinded to the randomisation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (information on death was obtained on contact with the study authors)<BR/>Haemodynamic variables<BR/>Coagulation variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:11:31 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up until discharge from hospital<BR/>9 children excluded post randomisation because they did not require colloid. Information on allocation concealment was obtained on contact with the study authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:19:54 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Carli-2000">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Not ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Anne Lawson">
<P>164 trauma patients. Patients were included if their SBP was &lt; 100 mmHg, associated with signs of hypoperfusion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:54 +0100" MODIFIED_BY="Anne Lawson">
<P>1) HES (Hesteril 6%) (n = 85)<BR/>2) Gelatin (Plasmion) (n = 79)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Anne Lawson">
<P>Glasgow coma score<BR/>Haemodynamic variables<BR/>Units of blood transfused<BR/>Adverse reaction</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Anne Lawson">
<P>There were 13 deaths from heart failure but these patients were excluded from the final analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:33:10 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Claes-1992">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
<P>Blinding not mentioned</P>
<P>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 10:33:10 +0100" MODIFIED_BY="Anne Lawson">
<P>20 patients undergoing brain tumour surgery and 20 patients undergoing transabdominal hysterectomy. Exclusion criteria: pre-existing coagulopathies, abnormal preoperative coagulation screening tests, intake of drugs affecting haemostasis within 2 weeks preoperatively, and liver or kidney dysfunction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:30:08 +0100" MODIFIED_BY="Anne Lawson">
<P>1000 mL of fluid for volume replacement, as<BR/>1) 6% HES (n = 19)<BR/>2) 5% HA solution in 0.9% saline (n = 21)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Coagulation variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:11:52 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 48 postoperative hours<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:12:01 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Diehl-1982">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Anne Lawson">
<P>60 patients undergoing coronary artery bypass</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:56 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 27)<BR/>2) 5% Albumin (n = 33) for volume expansion during the first 24 hours postoperatively. Neither hetastarch nor albumin was used intraoperatively or in the pump prime</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Coagulation data<BR/>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:12:01 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 7 postoperative days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:01:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dolecek-2009">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial, randomised according to computer-generated randomisation list</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="[Empty name]">
<P>56 patients with severe sepsis. Patients were included if they were 18 years or older and developed severe sepsis. Exclusion criteria: severe coagulopathy, pregnant, cardiac failure, acute renal failure, aortal aneurysm, severe aortal regurgitation or dysrhythmia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:01:19 +0100" MODIFIED_BY="[Empty name]">
<P>1) 20% Albumin (n = 30)</P>
<P>2) 6% HES (n = 26)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-21 12:34:09 +0000" MODIFIED_BY="[Empty name]">
<P>Death</P>
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up 28 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:30:52 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Du-Gres-1989">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 10:30:52 +0100" MODIFIED_BY="Anne Lawson">
<P>30 patients post cardiac surgery. Patients were included if they were haemodynamically stable, were without serious 'rhythm' problems, had MAP &lt; 90 mmHg, mean pulmonary artery pressure &lt; 20 mmHg and CVP &lt; 10 mmHg. Patients excluded if they needed blood transfusion, had a haematocrit &lt; 28% or Hb &lt; 9 g/100 mL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:19:59 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4% HA (n = 15)<BR/>2) Haemaccel (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 4 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-11 15:23:55 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Dytkowska-1998">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-11 15:23:55 +0100" MODIFIED_BY="Anne Lawson">
<P>40 patients post cardiac surgery. Patients were excluded if they had co-existing cardiogenic shock, renal failure with creatinine level &gt; 3.0 mg, or severe clotting disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 21:00:37 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 200/0 HAES 6% (n = 20)<BR/>2) Gelafundin (n = 20)<BR/>Colloids were administered to patients with diagnosed symptoms of hypovolaemia, during the first 24 hours postoperatively. Infusion rate was adjusted to patients needs but it did not exceed 1000 mL/hour</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic parameters<BR/>Biochemical parameters<BR/>Adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 2 hours<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 19:11:31 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Evans-2003">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Treatment blinded (fluid set up by independent operator and covered with opaque black bag)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="Anne Lawson">
<P>55 patients undergoing unilateral cemented hip replacement<BR/>Exclusion criteria: cardiac insufficiency, renal insufficiency, altered liver function, preoperative anaemia, preoperative coagulation abnormalities, chronic use of corticosteroids and diuretics</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:32 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4.5% HA (n = 13)<BR/>2) 4% Gelosulfine (n = 14)<BR/>3) Haemacel (n = 14)<BR/>2 L of fluid was infused during the operative period<BR/>A fourth group received normal saline (n = 14)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Total blood loss</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 19:11:31 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up before surgery, at the end of the surgery, and 2 hours postoperatively</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:09:55 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Falk-1988">
<CHAR_METHODS MODIFIED="2012-05-29 19:10:04 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="Anne Lawson">
<P>12 patients with septic shock. Patients were excluded from the study if the pretreatment PAWP &gt; 10 mmHg</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 21:09:55 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 250 mL of 5% Albumin (n = 6)<BR/>2) 250 mL of 6% HES (n = 6)<BR/>Given every 15 minutes until the PAWP was increased to 15 mmHg. The test infusion was then continued at 100 mL/hour to maintain PAWP at 15 mmHg for the next 24 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Clotting variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 24 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-11 15:35:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friedman-2008">
<CHAR_METHODS MODIFIED="2012-03-22 16:05:30 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:56:53 +0100" MODIFIED_BY="[Empty name]">
<P>34 haemodynamically stable adults with sepsis and suspected hypovolaemia. Exclusion criteria: pregnancy, terminal state, PAOP &gt; 12 mmHg, serum creatinine concentration &gt; 3 mg/dL, severe coagulation abnormalities, history of allergy to any IV fluid</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-11 15:35:01 +0100" MODIFIED_BY="[Empty name]">
<P>1) 400 mL 10% HES (n=11)</P>
<P>2) 400 mL 6% HES (n=10)</P>
<P>3) 4% HA (n=13)</P>
<P>All over 40 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-01 09:54:26 +0100" MODIFIED_BY="[Empty name]">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:12:24 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up 160 minutes. No data on mortality or blood transfused</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:39:27 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Fries-2004">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Treatment not blinded</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>60 patients undergoing primary knee replacement surgery<BR/>Exclusion criteria: contraindications for regional anaesthesia and puncture of the radial artery, any known allergies, primary and secondary haemostatic disorder<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 10:39:27 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4% Gelofusine (n = 20)<BR/>2) 6% HES (n = 20)<BR/>A third group received RL</P>
<P>Before administrating spinal anaesthesia all patients received 500 mL RL. All patient intraoperatively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 2 hours postoperatively</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:35:54 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Fulachier-1994">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>16 patients undergoing cardiac surgery (8 were undergoing valve replacement and 8 undergoing coronary bypass). Patients were excluded if they were &gt; 80 years of age, &lt; 18 years of age, had been included in other studies, had received colloids in the month preceding surgery, had coagulation abnormalities, or who were undergoing inotropic treatment</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:35:54 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 500 mL OF 4% solution of HA in RL (n = 8)<BR/>2) 500 mL of HES (n = 8) </P>
<P>until starting cardiopulmonary bypass</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 30 minutes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:35:51 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gahr-1981">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>20 patients with hypovolaemia following abdominal surgery for malignoma</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:35:51 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 500 mL HES 450/0.7 (n = 10)<BR/>2) 500 mL HA 5% (n = 10) </P>
<P>during the first 24 hours after the operation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic parameters<BR/>Coagulation data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 6 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:21:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallagher-1985">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="[Empty name]">
<P>10 patients after coronary artery bypass graft surgery<BR/>Exclusion criteria: patients with significant left main coronary artery stenosis, poor left ventricular function, or poor pulmonary function</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:34 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% Albumin (n = 5)<BR/>2) 6% HES (n = 5)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data on deaths from study author)<BR/>Haemodynamic data</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 1 day. Data on allocation obtained on contact with author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:07:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Godet-2008">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial. Computer-generated random list with randomisation in balanced blocks</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 10:07:47 +0100" MODIFIED_BY="[Empty name]">
<P>65 patients aged 18 years and over with renal dysfunction undergoing abdominal aortic surgery. Exclusion criteria: endovascular aortic surgery, preoperative serum creatinine &gt; 250 µmol/L, history or present diagnosis of severe hepatic insufficiency or coagulation disorders, dialysis, anuria, and post-transplant surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:35 +0100" MODIFIED_BY="[Empty name]">
<P>1) 6% HES (n = 32)</P>
<P>2) 3% Gelatin (n = 33)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-23 08:30:31 +0000" MODIFIED_BY="[Empty name]">
<P>Death</P>
<P>Haemodynamic variables</P>
<P>Renal safety (serum creatinine)</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="[Empty name]">
<P>Follow-up at 6 days and 3 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:36:25 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Gold-1990">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
<P>Colloid solution was blinded by covering with foil<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 20:36:25 +0100" MODIFIED_BY="Anne Lawson">
<P>40 surgical patients undergoing AAA surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:04:03 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 1 g/kg Albumin 5% solution (n = 20)<BR/>2) 1 g/kg Hetastarch 6% solution (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data on death was obtained on contact with the author)<BR/>Haemodynamic and coagulation variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up not specified. Information on allocation concealment was obtained by contact with the author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:04:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gombocz-2007">
<CHAR_METHODS MODIFIED="2012-04-30 15:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised double-blind study (does not specify who was blinded)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="[Empty name]">
<P>40 patients undergoing coronary bypass surgery or aortic valve replacement. Exclusion criteria: 'redo' operation, hepatic disease, renal dysfunction, immunological disease, steroid treatment, intake of aspirin or other cyclooxygenase inhibitor within 7 days of surgery, known allergy to volume expanders used in the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>1) 5.5% Gelatin (n = 20)</P>
<P>2) 6% Dextran 70 (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-23 08:51:54 +0000" MODIFIED_BY="[Empty name]">
<P>Death</P>
<P>Haemodynamic variables</P>
<P>Blood transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="[Empty name]">
<P>Final follow-up 44 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:04:25 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Gondos-2010">
<CHAR_METHODS MODIFIED="2012-03-26 09:57:55 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="Frances Bunn">
<P>200 postoperative haemodynamically stable hypovolaemic patients needing intensive care treatment because of general health status. Exclusion criteria: aged &lt; 18 years, active bleeding or shock, severe pulmonary oedema, known uraemia, anaphylactic reaction to colloid fluids, and life expectancy less than 24 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:04:25 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 4% Gelatin (n = 50)</P>
<P>2) 6% HES (n = 50)</P>
<P>2) 5% HA (n = 50)</P>
<P>A fourth group were given LR (n = 50)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 10:06:17 +0100" MODIFIED_BY="Frances Bunn">
<P>Death</P>
<P>Haemodynamic variables</P>
<P>Length of ICU stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>Final follow-up 10th postoperative day. Additional information on allocation obtained from study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:04:37 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Haas-2007">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Computer-generated randomisation list</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>42 children undergoing surgery (including craniofacial surgery, tumour resection and abdominal surgery and needing colloid replacement. Exclusion criteria: prematurity; emergency surgery; history of hereditary or acquired coagulopathy including renal, hepatic, and bone marrow disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:04:37 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 4% Modified gelatin (n = 14)</P>
<P>2) 5% Albumin (n = 14)</P>
<P>3) 6% HES (n = 14)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 10:19:44 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>Length of follow-up not clear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:01:15 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Hausdorfer-1986">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 21:01:15 +0100" MODIFIED_BY="Anne Lawson">
<P>30 children undergoing major surgery. During about 3 hours of surgery, the patients lost up to 15% of blood volume</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:40 +0100" MODIFIED_BY="Anne Lawson">
<P>1) HA 5% (n = 15)<BR/>2) HES 6% (n = 15)</P>
<P>with 14 mL/kg body weight each</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 24 hours postoperatively</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:21:41 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Hecht_x002d_Dolnik-2009">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Block randomisation with 8 patients in each block. Attending intensivists were blinded to randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>156 patients undergoing off-pump coronary artery bypass grafting. Exclusion criteria: history of cardiac surgery, primary bleeding disorders, end-stage renal disease, and pregnant patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:41 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 6% HES (n = 78)</P>
<P>2) 5% HA (n = 78)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 16:38:11 +0100" MODIFIED_BY="Frances Bunn">
<P>Death</P>
<P>PRBC transfused</P>
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>4 patients excluded after randomisation because they were converted to on-pump surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:21:41 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Hedstrand-1987">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>Postoperative care staff were blinded<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Anne Lawson">
<P>275 patients undergoing major surgery. Patients were excluded if they were known to have decreased serum albumin levels or expected to sustain plasma loss, or had pronounced cardiovascular disease</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:41 +0100" MODIFIED_BY="Anne Lawson">
<P>1) PPF (n = 142)<BR/>2) Dextran (n = 133)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Volume transfused<BR/>Complication rates<BR/>Serum albumin<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 1 month</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:05:10 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Hiippala-1995">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>Blinding not mentioned<BR/>3 patients lost to follow-up (explanation given)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>60 patients undergoing major abdominal or urological surgery. Patients who had used platelet-inhibiting drugs or had a diagnosed haemostatic defect were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:05:10 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 3% Dextrose (n = 15)<BR/>2) 4% HES (n = 15)<BR/>3) 6% HES (n = 15)<BR/>4) 5% Albumin (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Clotting variables<BR/>Blood loss</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 19:11:38 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 3 days postoperatively</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:21:43 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Huang-2005">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>No information given on blinding</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>20 patients with burns over 40% of total body surface area admitted 4 to 8 hours after injury</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:43 +0100" MODIFIED_BY="Anne Lawson">
<P>1) PPF (n = 9)<BR/>2) Gelofusine (n = 11)<BR/>In a third control group patients did not receive fluid resuscitation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 48 hours<BR/>No relevant outcome data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:05:30 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Huskisson-1993">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>27 children returning to the ICU following hypothermic open heart surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>1) Albumin<BR/>2) Gelatin<BR/>3) Hetastarch</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 20:05:30 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:05:55 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Inal-2010">
<CHAR_METHODS MODIFIED="2012-03-26 10:26:23 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn">
<P>30 hypovolaemic patients admitted to ICU. Exclusion criteria: pregnancy, haemodynamic instability, heart failure, renal failure, liver failure, known or suspected brain death</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:05:55 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 3.5% Polygeline (n = 15)</P>
<P>2) 6% HES (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 10:49:00 +0100" MODIFIED_BY="Frances Bunn">
<P>Death</P>
<P>Haemodynamic variables</P>
<P>Liver function</P>
<P>Length of ICU stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 30 minutes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:13:27 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Jin-2010">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn">
<P>36 patients undergoing surgery for gastric cancer. Exclusion criteria: cardiac or renal insufficiency, or both; altered liver function; preoperative anaemia or coagulation abnormality, or both; colloid allergy; use of anticoagulants or antiplatelets</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:05:59 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 6% HES (n = 12)</P>
<P>2) 4% Modified gelatin (n = 12)</P>
<P>3) RL (n = 12)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 11:39:46 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
<P>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:13:27 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 4 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:13:33 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Jones-2004">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Surgeons blinded to the fluid administered although the anaesthetist was aware of the fluid administered to a given patient<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Anne Lawson">
<P>40 adults scheduled to undergo radical retropubic prostatomy<BR/>Exclusion criteria: coagulation disorder, platelet count &lt; 100,000/mm<SUP>3</SUP>, preoperative Hb &lt; 12 g/dL, if anticoagulant therapy within 10 days of the surgery, aspirin or NSAID use &lt; 10 days before surgery or if they had documented allergy to any of the IV fluids used in the protocol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:06:12 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% HA (n = 10)<BR/>2) 6% Dextran 70 (n = 10)<BR/>3) 6% HES (n = 10)<BR/>A fourth group received RL<BR/>Haemodilution was done with the target of 9 g/dL<BR/>All patients underwent moderate haemodilution to a target of Hb 9 g/dL<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Blood loss and units transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:13:33 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 3 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:06:22 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Karanko-1987">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Patients were randomised in blocks of 4<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Anne Lawson">
<P>48 patients who had undergone coronary bypass surgery 20 hours earlier</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:06:22 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4% PPF (n = 15)<BR/>2) 6% Dextran 70 (n = 10)<BR/>3) 5.5% Oxypolygelatin (n = 12)<BR/>A fourth group (not randomly selected) acted as a control (n = 11)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data on death was obtained on contact with the author<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 28 hours. Information on allocation was obtained on contact with the author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:43:29 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Kirklin-1984">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:50:23 +0100" MODIFIED_BY="Frances Bunn">
<P>30 patients undergoing coronary artery operations. Patients were excluded if they had undergone previous cardiac operations, if they had severe coagulopathies, anaemia, or CRF</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 10:43:29 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 15)<BR/>2) 5% Albumin (n = 15)<BR/>Both fluids infused over 24 hours to maintain left arterial pressure between 6 mmHg and 12 mmHg and cardiac index &gt; 2.0 L/minute/m<SUP>2</SUP>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic and coagulation variables<BR/>Adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up until discharge from ICU<BR/>34 patients were originally included in the trial but data from 4 of them was not included in the final analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:06:43 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Lisander-1996">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>No loss to follow-up<BR/>Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>40 patients undergoing revision hip arthroplasty</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:06:43 +0100" MODIFIED_BY="Anne Lawson">
<P>1) Albumin 40 g/L (n = 20)<BR/>2) Dextran 70 60 g/L (n = 20)<BR/>Patients all received enoxaparin 40 mg/day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data obtained from contact with study author)<BR/>External blood loss<BR/>Red cell balance<BR/>Packed cell volume<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up until discharge from hospital. Information on allocation concealment was obtained on contact with the study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:06:53 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-London-1989">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>93 male cardiac surgical patients. Patients were excluded from the study if they had a significant coagulopathy or were anaemic (haematocrit value &lt; 30%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:06:53 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% Pentastarch in 0.9% saline (n = 50)<BR/>2) 5% HA in 0.9% saline (n = 44)<BR/>to provide volume expansion during the first 24 hours after cardiac operations</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Coagulation variables<BR/>Death<BR/>Length of stay</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>1 patient was treated twice with an 8-month interval. Follow-up until discharge from hospital</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:44:06 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Mahmood-2007">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Randomisation by blocks of 6 using random number table. The study was not double blind but person analysing data was blind to study group. ITT analysis</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 10:08:35 +0100" MODIFIED_BY="Frances Bunn">
<P>62 patients undergoing elective infrarenal AAA surgery. Exclusion criteria: preoperative serum creatinine of more than 177 µmol/L and left ventricular ejection fraction &lt; 40%. Also juxtarenal aneurysms and patients who had had a renal transplant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:52 +0100" MODIFIED_BY="Frances Bunn">
<P>1) HES 200/0.62 (n = 21)</P>
<P>2) HES 130/0.4 (n = 21)</P>
<P>3) Gelatin (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-02 11:42:49 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
<P>Deaths</P>
<P>Red cells infused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-30 10:44:06 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 5 days, but all-cause mortality reported for 30 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:44:20 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Mastroianni-1994">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Anne Lawson">
<P>34 patients undergoing open heart surgery were enrolled</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:07:12 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% Pentastarch. (n = 12)<BR/>2) 5% Albumin (n = 17)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Frances Bunn">
<P>Deaths<BR/>Haemodynamics variables<BR/>Clotting variables<BR/>Pulmonary oedema<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 20:44:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 7 days<BR/>4 patients in the pentastarch group, and 1 patient in the albumin group were excluded after randomisation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:44:40 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Mittermayr-2007">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Computer-generated randomisation list</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 20:44:40 +0100" MODIFIED_BY="Frances Bunn">
<P>66 patients undergoing major orthopaedic surgery (5 excluded from analysis because of pathological baseline measurements of fibrinogen and platelets)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:54 +0100" MODIFIED_BY="Frances Bunn">
<P>1) Gelatin (n = 21)</P>
<P>2) HES (n = 19)</P>
<P>A third group (n = 21) received RL</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 18:07:57 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
<P>RBCs transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:02:20 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Moggio-1983">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>No loss to follow-up<BR/>Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Frances Bunn">
<P>47 postoperative open heart surgery patients. Operations performed included coronary revascularisation, valve operations, and combined coronary and valve procedures. Patients with pre-existing hepatic or renal disease were not eligible for the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 21:02:20 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% Albumin in 0.9% saline (n = 23)<BR/>2) 6% HES in 0.9% saline (n = 24)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Clotting variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up not specified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:07:45 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Molnar-2004">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:51 +0100" MODIFIED_BY="Frances Bunn">
<P>30 hypovolaemic patients with ITBVI &lt; 850 in septic shock with ALI<BR/>Exclusion criteria: CVS failure (NYHA class IV), chronic respiratory failure (chronic hypoxia, hypercapnia) requiring renal replacement therapy, chronic liver failure or those with diabetes mellitus or with known aortic aneurysm</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:07:45 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 15)<BR/>2) 4% GEL (n = 15)<BR/>250 mL/15-minute boluses (max 1000 mL) were given until the end point ITBVI &gt; 900 mL/m<SUP>2</SUP>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 60 minutes after the end point was reached. Follow-up for deaths was not clear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:45:44 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Mukhtar-2009">
<CHAR_METHODS MODIFIED="2012-03-26 13:22:33 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 20:45:44 +0100" MODIFIED_BY="Frances Bunn">
<P>40 patients undergoing living donor liver transplantation. Exclusion criteria: retransplantation, history of previous upper abdominal surgery, portal vein thrombosis, &lt; 18 years old, primary renal dysfunction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:55 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 5% HA (n = 20)</P>
<P>2) 6% HES (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 13:29:03 +0100" MODIFIED_BY="Frances Bunn">
<P>Death</P>
<P>Haemodynamic variables</P>
<P>Renal function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Frances Bunn">
<P>Final follow-up 4 days postoperatively. Mortality given for 2 weeks postoperatively</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:46:50 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Munoz-1980">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not mentioned<BR/>No mention of loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>14 patients with shock due to haemorrhage or sepsis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-30 10:46:50 +0100" MODIFIED_BY="Anne Lawson">
<P>1) HES (Hespan)<BR/>2) 5% Albumin<BR/>Number in each group not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 4 hours post infusion</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:14:01 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Munsch-1988">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>40 consecutive patients undergoing elective coronary artery bypass graft surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:56 +0100" MODIFIED_BY="Anne Lawson">
<P>1) HES 6% (n = 20)<BR/>2) PPF (n = 20)<BR/>as their postoperative volume expander</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Clotting variables<BR/>Death<BR/>Adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:14:01 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 7 postoperative days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:14:14 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Niemi-2006">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not clear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Anne Lawson">
<P>45 patients post cardiac surgery<BR/>Exclusion criteria: preoperative coagulation disorders; renal or hepatic failure; or taking medication with coumarin anticoagulants, heparin, salicylic acids, or a combination within the previous 5 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:08:41 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4% HA (n = 15)<BR/>2) 4% Gelatine (n = 15)<BR/>3) 6% HES (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data on death obtained on contact with the author)<BR/>Clotting variables<BR/>Blood transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:14:14 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 1 postoperative day<BR/>54 patients gave consent but 9 later excluded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:14:30 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Ooi-2009">
<CHAR_METHODS MODIFIED="2012-03-26 13:51:21 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised single-blind controlled study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn">
<P>90 patients undergoing coronary artery bypass surgery. Exclusion criteria: repeat coronary artery bypass, congestive heart failure, recent antiplatelet therapy, coagulopathy, renal dysfunction, liver dysfunction, history of pancreatitis, and known hypersensitivity to HES</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:09:25 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 6% HES (n = 45)</P>
<P>2) 4% Gelatin (n = 45)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn">
<P>Death</P>
<P>PRBCs transfused</P>
<P>Postoperative bleeding and renal function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:14:30 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 1, 2, and 4 postoperative days. Final follow-up at 4 weeks. Information on allocation concealment obtained from study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:21:58 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Prien-1990">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not mentioned<BR/>Loss to follow-up not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn">
<P>18 patients undergoing modified Whipple's operation (hemipancreato-duodenectomy). Patients were eligible for the study if there was an absence of major organ dysfunction and serum protein, sodium, glucose, blood urea nitrogen, haematocrit, aPTT and PT times, and platelet times were within normal limits. Specific exclusion criteria included compensated myocardial insufficiency, chronic hypertension, chronic obstructive airways disease, and insulin-dependent diabetes mellitus</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:21:58 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 10% HES (n = 6)<BR/>2) 20% HA (n = 6)<BR/>A third group were given RL (n = 6)<BR/>All given as a volume replacement solution, which was given to maintain CVP at the preoperative level</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data on death was obtained on contact with the study author)<BR/>Haemodynamic variables<BR/>Clotting variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up unspecified<BR/>Study was intraoperative</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:09:50 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Rackow-1983">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn">
<P>18 patients with hypovolaemic and septic shock. Patients were excluded if they were &lt; 18 years of age, considered to be in a terminal state, or had a significant coagulopathy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:09:50 +0100" MODIFIED_BY="Anne Lawson">
<P>1) Albumin (n = 9)<BR/>2) HES (n = 9)<BR/>Patients received 250 mL of the treatment fluid every 15 minutes as a fluid challenge. The fluid challenge ended when the WP equalled 15 mmHg. Thereafter the treatment fluid was given in sufficient quantities to maintain the WP at 15 mmHg for the next 24 hours, at which point the study was completed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Respiratory variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Deaths given for study period and for length of hospital stay. Survival until discharge was used for the mortality data for this review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:02:56 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Rackow-1989">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>No loss to follow-up<BR/>Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>20 patients with severe sepsis and systemic hypoperfusion. Patients were excluded from the study if they were &lt; 21 years of age, pregnant, considered to be terminal, or they manifested spontaneous bleeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 21:02:56 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% Albumin (n = 10)<BR/>2) 10% HES (pentastarch) (n = 10)<BR/>Each group received 250 mL of the treatment fluid every 15 minutes until either the WP was 15 mmHg or less or a maximum volume of 2000 mL of study colloid was infused</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Clotting variables<BR/>Allergic reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up unspecified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:22:00 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Reine-2008">
<CHAR_METHODS MODIFIED="2012-03-26 14:08:41 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Computerised randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn">
<P>38 patients undergoing major orthopaedic, gastrointestinal, or gynaecological surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:00 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 20% HA (n = 19)</P>
<P>2) 6% HES (n = 19)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 14:12:48 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
<P>Changes in albumin binding capacity</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn">
<P>Final follow-up first postoperative day (approximately 22 hours)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-30 10:48:19 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Rittoo-2004">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding-not clear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-30 10:48:19 +0100" MODIFIED_BY="Anne Lawson">
<P>40 patients undergoing AAA surgery<BR/>Exclusion criteria: ejection fraction of &lt; 40% with poor pulmonary function with microalbuminuria and a creatinine concentration of &gt; 150 &#956;mol/L<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:01 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 20)<BR/>2) 4% Gelosulfine (n = 20)<BR/>All patients received crystalloid. Colloid infused to maintain stable heart rate, CVP 8 cmH<SUB>2</SUB>O to 10 cmH<SUB>2</SUB>O and steady MAP and urine output of<BR/>&gt; 40 mL/hour</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>Lung function<BR/>Adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 24 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:14:41 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Rosencher-1992">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>No mention of blinding<BR/>Loss to follow-up not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>32 patients undergoing total hip replacement</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:10:44 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4% Albumin (n = 16)<BR/>2) LMW HES (n = 16)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data obtained on contact with study author)<BR/>Bleeding<BR/>Clotting variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:14:41 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 5 postoperative days. Information on allocation concealment was obtained on contact with the study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-12 17:43:40 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Schortgen-2001">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Anne Lawson">
<P>129 patients with severe sepsis or septic shock over 18 years of age. Patients were excluded if they were pregnant, had a history of allergy to HES or gelatin, had severe acute or chronic renal dysfunction, or previous administration of HES or mannitol</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:11:06 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 65)<BR/>2) 3% Fluid-modified gelatin (n = 64)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-12 17:43:34 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data obtained on contact with study author)<BR/>Length of stay in ICU<BR/>Acute renal failure</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-12 17:43:40 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up while in ICU<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:22:03 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Schramko-2009">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn">
<P>45 patients undergoing elective primary cardiac surgery. Exclusion criteria: preoperative coagulation disorder; renal or hepatic failure; received warfarin, heparin, clopidogrel, or acetylsalicylic acid within 5 days before surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:03 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 6% HES 200/0.5 (n = 15)</P>
<P>2) 6% HES 130/0.4 (n = 15)</P>
<P>3) 4% HA (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 14:43:57 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
<P>PRBCs transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn">
<P>Final follow-up first postoperative morning. Mortality data obtained from study author (relates to study period only, inhospital mortality not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:14:53 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Schramko-2010">
<CHAR_METHODS MODIFIED="2012-04-30 15:37:08 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn">
<P>45 patients undergoing elective cardiac surgery. Exclusion criteria: known coagulation disorder; renal or hepatic failure; preoperative left ventricular ejection fraction &lt; 40%; received warfarin, heparin, clopidogrel, or acetylsalicylic acid within previous 5 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:11:30 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 6% HES (n = 15)</P>
<P>2) 4% Gelatin (n = 15)</P>
<P>3) Ringer's acetate (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-30 14:04:34 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
<P>Units of RBC and FFP transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:14:53 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 18 hours postoperatively. Mortality data obtained from study author (relates to study period only, inhospital mortality not available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:22:04 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Shatney-1983">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Anne Lawson">
<P>Controlled clinical trial. Patients were assigned to groups in an alternating fashion<BR/>No loss to follow-up<BR/>No mention of blinding</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Anne Lawson">
<P>32 patients with multisystem trauma or haemorrhagic shock, or both. Patients with cardiac arrest on hospital admission or during the first 30 minutes after admission were excluded from the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:04 +0100" MODIFIED_BY="Anne Lawson">
<P>1) PPF 5% solution (n = 16)<BR/>2) Hetastarch 6% (n = 16)<BR/>Study patients continued to receive the assigned colloid solution for the first 8 days whenever colloid was thought necessary</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Anne Lawson">
<P>Hepatic, pulmonary and renal function<BR/>Clotting variables<BR/>Volume of fluids infused<BR/>Deaths</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 8 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:22:05 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Standl-2008">
<CHAR_METHODS MODIFIED="2012-03-26 15:27:55 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Randomisation in blocks of 4 using a 1:1 ratio</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn">
<P>82 children younger than 2 years of age undergoing non-cardiac surgery. Exclusion criteria: intracranial bleeding within 6 weeks prior to randomisation, ASA risk score &gt; 3, pre-existing severe organ insufficiencies, coagulation abnormalities and Hb below critical age-appropriate levels</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:05 +0100" MODIFIED_BY="Frances Bunn">
<P>1) HES 130/0.4 (n = 41)</P>
<P>2) 5% HA (n = 41)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 15:32:05 +0100" MODIFIED_BY="Frances Bunn">
<P>Death</P>
<P>Haemodynamic variables</P>
<P>Coagulation variables</P>
<P>RBC transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn">
<P>Final follow-up first postoperative day</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-12 17:43:46 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Stockwell-1992">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>No loss to follow-up<BR/>Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Anne Lawson">
<P>475 patients admitted to the ICU. Patients were excluded from the study if they were &lt; 18 years or if admitted for cardiac monitoring or cardiac thrombolytic therapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:11:59 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4.5% Albumin (n = 226)<BR/>2) Synthetic colloid polygeline (Haemaccel) (n = 249)<BR/>for IV volume replacement</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-12 17:43:44 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Length of stay in ICU<BR/>Incidence of renal failure<BR/>Pulmonary oedema</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-12 17:43:46 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up until discharge from ICU</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:22:06 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Stoddart-1996">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised blinded trial<BR/>Anaesthetist unaware of intervention<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:25:49 +0100" MODIFIED_BY="Anne Lawson">
<P>30 neonates undergoing major surgery. They were excluded if the body weight &lt; 2 kg or &gt; 5 kg; preoperative Hb &lt; 14 g/dL; they had previously received blood or colloid; or they had suspected major cardiac, renal, metabolic, or chromosomal abnormalities. Neonates were withdrawn from the study if either blood or &gt; 40 mL/kg of colloid was required either during or within the first 24 hour after surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:06 +0100" MODIFIED_BY="Anne Lawson">
<P>1) HA 4.5% (n = 15)<BR/>2) Haemaccel (n = 15)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Plasma albumin<BR/>Hb<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 24 hours postoperatively. Information on allocation concealment was obtained on contact with the study author<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:14:00 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Tollofsrud-1995">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>No loss to follow-up<BR/>Blinding not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Anne Lawson">
<P>30 patients undergoing elective coronary artery bypass surgery. Patients with left ventricular ejection fraction &lt; 40%, valvular heart disease, ventricular aneurysm, arrhythmia, diabetes mellitus, renal failure, or lung disease were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:14:00 +0100" MODIFIED_BY="Anne Lawson">
<P>1) Polygeline (Haemaccel) (n = 10)<BR/>2) Dextran 70 (n = 10)<BR/>3) Albumin 40 (n = 10)<BR/>A fourth group received RL (n = 10)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Respiratory data<BR/>Cost of fluid regimens<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 48 hours during and after surgery. Information on allocation concealment was obtained on contact with the study authors</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:14:09 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Van-der-Linden-2004">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Anne Lawson">
<P>110 patients (average age 63 years) undergoing cardiac surgery under cardiopulmonary bypass (elective coronary artery or single valve surgery). Exclusion criteria: undergoing combined cardiac surgery or redo operations, history of allergic reactions to starches or gelatins, significant liver or renal dysfunction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:14:09 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 55)<BR/>2) 3.5% Urea-lined gelatine (n = 55)<BR/>If additional colloid required 4.5% HA given</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Blood transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 18 hours after surgery</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-06-11 15:54:15 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Van-der-Linden-2005">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>Blinding unclear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-11 15:29:14 +0100" MODIFIED_BY="Anne Lawson">
<P>132 patients with a preoperative left ventricular ejection fraction &gt; 35% undergoing elective primary cardiac surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:09 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES 130/0.4 (48.9 ± 17.2 mL/kg) (n = 64)<BR/>2) 3% GEL (48.9 ± 14.6 mL/kg) (n = 68)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-11 15:54:15 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Blood loss</P>
<P>Blood transfused</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:15:34 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up until 5 postoperative days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:14:29 +0100" MODIFIED_BY="Emma M Sydenham" STUDY_ID="STD-Veneman-2004">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Anne Lawson">
<P>61 critically ill hypoalbuminic patients (serum concentration &lt; 20 g/L)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:14:29 +0100" MODIFIED_BY="Emma M Sydenham">
<P>1) Albumin (n = 15)<BR/>2) HES 10% 500 mL (n = 15)<BR/>3) HES 10% 1000 mL (n = 15)<BR/>A fourth group received saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables<BR/>Adverse events (from study author)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 72 hours postoperatively, mortality 30 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:14:51 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Verheij-2006">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 18:22:10 +0100" MODIFIED_BY="Anne Lawson">
<P>67 patients undergoing either vascular (n = 28) or cardiac surgery (n = 40)<BR/>Exclusion criteria: age &gt; 79 years and known anaphylactoid reactions to colloids<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:14:51 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 4% Gelatine (n = 16)<BR/>2) 6% HES (n = 18)<BR/>3) 5% HA (n = 18)<BR/>A fourth group received normal saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up not clear</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:22:12 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Vogt-1994">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>40 patients undergoing major surgery. Exclusion criteria included anaemia and renal, liver, and coagulation disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:12 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% HA (n = 20)<BR/>2) 6% HES (n = 20)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Coagulation<BR/>Haematological parameters<BR/>Blood loss and blood intake</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>-</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 19:11:41 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Vogt-1996">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>The patients were divided into 2 groups using random numbers<BR/>Blinding not mentioned<BR/>No loss to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>41 patients undergoing total hip arthroplasty during the perioperative period. Exclusion criteria: weight &lt; 60 kg, age &lt; 18 years, ASA grade &gt; 3, haematocrit &lt; 34% or &gt; 44%, history of coagulopathies or a Quick's prothrombin test of &lt; 75%, PTT &gt; 45 seconds, platelet count &lt; 100,000/mm<SUP>3</SUP>, impaired liver function and renal failure</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:12 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 6% HES (n = 20)<BR/>2) 5% HA (n = 21)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic and clotting variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 19:11:41 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 6 hours postoperatively</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:15:51 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Vogt-1999">
<CHAR_METHODS MODIFIED="2012-05-29 17:45:11 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:45:11 +0100" MODIFIED_BY="Anne Lawson">
<P>50 patients undergoing radical prostatectomy or cystectomy with bladder replacement<BR/>Exclusion criteria: weight &lt; 60 kg; age &lt; 21 years; ASA 1 or 2; Hb &lt; 12 g/dL; history of clotting disorders, liver function disorders, advanced renal insufficiency, or hypoproteinaemia</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 17:34:06 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% HA<BR/>2) 6% HES 200/0.5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:34:07 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Blood loss</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:15:51 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 3 days</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:15:02 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Volta-2007">
<CHAR_METHODS MODIFIED="2012-05-29 17:34:22 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled study. List of random numbers generated by computer. Patients were managed postoperatively by anaesthetists who were masked to the aims of the study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:34:47 +0100" MODIFIED_BY="Frances Bunn">
<P>36 patients undergoing major abdominal surgery for colon cancer. Exclusion criteria: aged &lt; 18, cardiac insufficiency, kidney dysfunction, altered liver function, preoperative anaemia, preoperative coagulation abnormalities, and long-term use of corticosteroids or NSAIDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:15:02 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 3.4% Poligeline (n = 12)</P>
<P>2) HES 130/0.4 (n = 12)</P>
<P>A third group received RL (n = 12)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-04-02 14:31:34 +0100" MODIFIED_BY="Frances Bunn">
<P>Haemodynamic variables</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:35:00 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 72 hours</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 18:22:14 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-von-Sommoggy-1990">
<CHAR_METHODS MODIFIED="2012-05-29 17:35:09 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation<BR/>No loss to follow-up<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:35:12 +0100" MODIFIED_BY="Anne Lawson">
<P>24 patients undergoing infrarenal aortofemoral bifurcation grafting</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:14 +0100" MODIFIED_BY="Anne Lawson">
<P>1) FFP and 5% HA (n = 13)<BR/>2) HES 200 10% and HES 450 6% (n = 11)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:35:19 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodynamic variables<BR/>Clotting variables<BR/>Influence on organ function</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:35:32 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 6 hours postoperatively</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:57:26 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Wahba-1996">
<CHAR_METHODS MODIFIED="2012-05-29 17:35:51 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Computerised system was used for randomisation<BR/>Blinding not mentioned<BR/>Loss to follow-up not mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:36:04 +0100" MODIFIED_BY="Anne Lawson">
<P>20 patients who had had coronary artery bypass grafting. Patients with abnormal left-ventricular function as judged from cine-angiography were excluded as were patients on anticoagulants &lt; 10 days before the operation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:15:15 +0100" MODIFIED_BY="Anne Lawson">
<P>1) 5% Albumin (n = 10)<BR/>2) Haemaccel (n = 10)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:36:20 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data on death were obtained on contact with the study author)<BR/>Haemodynamic variables<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 20:57:26 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up 2 weeks. Data on method of allocation concealment were obtained on contact with the study author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:57:44 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Watkins-1990">
<CHAR_METHODS MODIFIED="2012-05-29 17:36:43 +0100" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial. No information given on method of randomisation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:36:44 +0100" MODIFIED_BY="Anne Lawson">
<P>12 patients undergoing major surgery</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:15:21 +0100" MODIFIED_BY="Anne Lawson">
<P>1) LMW polystarch<BR/>2) Polygelatine (Haemaccel)<BR/>for postoperative volume replacement</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:36:52 +0100" MODIFIED_BY="Anne Lawson">
<P>Death<BR/>Adverse reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 20:57:44 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up 24 hours after infusion</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 20:15:29 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Woittiez-1997">
<CHAR_METHODS MODIFIED="2012-05-29 17:37:04 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:37:19 +0100" MODIFIED_BY="Anne Lawson">
<P>60 patients who had developed hypoalbuminaemia (&lt; 20 g/L) after major surgery<BR/>2 patients died after randomisation and before treatment started. These were excluded from the analysis<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 20:15:29 +0100" MODIFIED_BY="Anne Lawson">
<P>1) Albumin 20% (300 mL/24 hours) (n = 15)<BR/>2) HES 10% (500 mL/24 hours) for 3 days (n = 27)<BR/>Aim was to restore COP<BR/>A third group received saline (n = 16)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-05-29 17:38:06 +0100" MODIFIED_BY="Anne Lawson">
<P>Death (data on death obtained on contact with the study author)<BR/>Changes in fluid balance, serum albumin, COP, and clinical signs of oedema were followed daily<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 17:38:07 +0100" MODIFIED_BY="Anne Lawson">
<P>Follow-up unspecified</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-05-29 21:16:06 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Yang-2011">
<CHAR_METHODS MODIFIED="2012-05-29 17:38:12 +0100" MODIFIED_BY="Frances Bunn">
<P>Randomised controlled trial. Computer-generated random numbers</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-29 17:38:42 +0100" MODIFIED_BY="Frances Bunn">
<P>90 patients aged 18 to 75 years with hepatocellular carcinoma scheduled for hepatectomy - received fluids postoperatively. Exclusion criteria: renal insufficiency requiring dialysis, cardiac insufficiency, steroid therapy, pre-existing signs of bacteraemia, and known allergic reactions to starch preparations</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-05-29 18:22:22 +0100" MODIFIED_BY="Frances Bunn">
<P>1) 20% HA (n = 30)</P>
<P>2) 6% HES (n = 30)</P>
<P>3) LR (n = 30)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-26 16:54:24 +0100" MODIFIED_BY="Frances Bunn">
<P>Death</P>
<P>Haemodynamic variables</P>
<P>Liver function</P>
<P>Inflammatory response parameters</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-29 21:16:06 +0100" MODIFIED_BY="Frances Bunn">
<P>Follow-up until hospital discharge</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AAA: abdominal aortic aneurysm; ALI: acute lung injury; aPPT: activated partial thromboplastin time; ASA: American Society of Anesthesiologists; COP: colloid osmotic pressure; CRF: chronic renal failure; CVP: central venous pressure; CVS: cardiovascular system; EVLW: extravascular lung water; FFP: fresh frozen plasma; HA: human albumin; Hb: haemoglobin; HES: hydroxyethyl starch; HMW: high molecular weight; ICU: intensive care unit; ITBVI: intrathoracic blood volume index; ITT: intention to treat; IV: intravenous; LMW: low molecular weight; LVEDP: left ventricular end diastolic pressure; MMW: medium molecular weight; MAP: mean arterial pressure; MFG: modified fluid gelatin; MI: myocardial infarction; NSAID: non-steroidal anti-inflammatory drug; NYHA: New York Heart Association; PAWP: pulmonary artery wedge pressure; PAOP: pulmonary artery occlusion pressure; PCWP: pulmonary capillary wedge pressure; PPF: plasma protein fraction; PRBC: packed red blood cell; PT: prothrombin time; RBC: red blood cell; RL: Ringer's lactate; SBP: systolic blood pressure; WP: wedge pressure.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-06-11 13:08:52 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:24:53 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boks-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:24:53 +0100" MODIFIED_BY="Frances Bunn">
<P>Pump priming for patients undergoing cardiac surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:24:56 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Boldt-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:24:56 +0100" MODIFIED_BY="Anne Lawson">
<P>Pre-bypass volume loading</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:31 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Boldt-2000b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:31 +0100" MODIFIED_BY="Anne Lawson">
<P>Compares 2 starches with each other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-11 13:08:38 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-11 13:08:38 +0100" MODIFIED_BY="Frances Bunn">
<P>The paper was retracted by the journal as Institutional Review Board approval could not be verified</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:25:11 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Boldt-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:25:11 +0100" MODIFIED_BY="Frances Bunn">
<P>The paper was retracted by the journal as Institutional Review Board approval could not be verified</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:25:13 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Brehme-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:25:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodilution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:29 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Bremerich-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:29 +0100" MODIFIED_BY="Anne Lawson">
<P>Compares 2 different starches (acetyl starch with hydroxyethyl starch)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-30 11:18:30 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Charlet-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-30 11:18:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Study compared 2 different gelatins with each other and not with other colloids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:27:13 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Christ-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:27:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomised trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:23 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Emery-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Compares 20% and 4.5% albumin with each other and not with other colloids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:26 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gan-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Compares Hextend (a plasma volume expander based upon 6% hetastarch) with 6% hetastarch in saline (HES)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:20 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Green-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:20 +0100" MODIFIED_BY="Frances Bunn">
<P>Compares HES versus ringers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-11 13:08:44 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Haisch-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-11 13:08:44 +0100" MODIFIED_BY="Frances Bunn">
<P>The paper was retracted by the journal as Institutional Review Board approval could not be verified</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-11 13:08:46 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Haisch-2001b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-11 13:08:46 +0100" MODIFIED_BY="Frances Bunn">
<P>The paper was retracted by the journal as Institutional Review Board approval could not be verified</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:27:34 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Hankeln-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:27:34 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodilution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:27:35 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Harke-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:27:35 +0100" MODIFIED_BY="Anne Lawson">
<P>Unable to find out if a randomised controlled trial. Methodology unclear</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:27:52 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Hiippala-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:27:52 +0100" MODIFIED_BY="Anne Lawson">
<P>Patients were expected to have minimal blood loss</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:27:56 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Hopkins-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:27:56 +0100" MODIFIED_BY="Frances Bunn">
<P>Insufficient information to include in review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:13 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Huet-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Compares 2 starches with each other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-11 13:08:52 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Huttner-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-11 13:08:52 +0100" MODIFIED_BY="Frances Bunn">
<P>The paper was retracted by the journal as Institutional Review Board approval could not be verified</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:05 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Jones-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:05 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodilution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:41 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Jovanovic-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:41 +0100" MODIFIED_BY="Anne Lawson">
<P>Does not mention if study was randomised. Unable to contact author for further information</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:46 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Korttila-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:46 +0100" MODIFIED_BY="Anne Lawson">
<P>Healthy volunteers and cross-over trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:48 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Kotzampassi-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:48 +0100" MODIFIED_BY="Frances Bunn">
<P>Not clear how many participants were in each group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:52 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Langeron-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:52 +0100" MODIFIED_BY="Anne Lawson">
<P>Compares 2 starches with each other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:28:53 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Palumbo-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:28:53 +0100" MODIFIED_BY="Anne Lawson">
<P>Authors do not report the number of patients randomised to each group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:08 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Puri-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:08 +0100" MODIFIED_BY="Anne Lawson">
<P>There is no mention of a method of randomisation. Just reports "Twenty-five patients studied in each group were well matched"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:12 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Rauch-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:12 +0100" MODIFIED_BY="Anne Lawson">
<P>Compares 2 starches with each other</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:15 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Rehm-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:15 +0100" MODIFIED_BY="Anne Lawson">
<P>Haemodilution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:16 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Romero-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:16 +0100" MODIFIED_BY="Frances Bunn">
<P>Does not mention randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:17 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Strauss-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Healthy volunteers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:18 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Vanhoonacker-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:18 +0100" MODIFIED_BY="Frances Bunn">
<P>Pump priming for cardiac surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:19 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Waxman-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:19 +0100" MODIFIED_BY="Anne Lawson">
<P>Cross-over study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-29 18:29:21 +0100" MODIFIED_BY="Frances Bunn" STUDY_ID="STD-Yap-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-29 18:29:21 +0100" MODIFIED_BY="Frances Bunn">
<P>Pump priming cardiac surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-05-10 09:00:51 +0100" MODIFIED_BY="Frances Bunn" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-11 13:08:02 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Akech-2006">
<DESCRIPTION>
<P>Inadequate. Authors report that allocation of intervention was not concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Allison-1999">
<DESCRIPTION>
<P>Inadequate. Randomisation was based on date of admission (on even dates patients received HES)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:33 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Arellano-2005">
<DESCRIPTION>
<P>Adequate. Study colloids placed in masked container by nurse not involved in other aspects of trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Asfar-2000">
<DESCRIPTION>
<P>Adequate. Allocation using sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:32 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Beards-1994">
<DESCRIPTION>
<P>Inadequate. Allocation by alternation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Berard-1995">
<DESCRIPTION>
<P>Inadequate. 'A set of 200 tickets (type 1) and another set of 200 tickets (type 2) were mixed in a box. One ticket was drawn at random for each patient'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:31 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Beyer-1997">
<DESCRIPTION>
<P>Adequate. Allocation was by a list of random numbers read by someone not entering patients into the trial (closed list)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 12:23:11 +0100" MODIFIED_BY="Emma M Sydenham" RESULT="UNKNOWN" STUDY_ID="STD-Boldt-1986">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 12:23:14 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-1993a">
<DESCRIPTION>
<P>Adequate. Allocation by sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-1995">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-1996a">
<DESCRIPTION>
<P>Adequate. Allocation by sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-1996b">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-1996c">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:30 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-1998">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:29 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-2000">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 20:27:27 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Boldt-2001">
<DESCRIPTION>
<P>Adequate. 'Closed envelope system'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Brock-1995">
<DESCRIPTION>
<P>Inadequate. Allocation by list of random numbers read by someone entering patients into the trial (open list)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Brutocao-1996">
<DESCRIPTION>
<P>Adequate. Pharmacy-controlled randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:28 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Carli-2000">
<DESCRIPTION>
<P>Unclear. 'Each centre received instructions from the coordinating Institute on the treatment to give the patient'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Claes-1992">
<DESCRIPTION>
<P>Unclear. No information given on method of randomisation or allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Diehl-1982">
<DESCRIPTION>
<P>Inadequate. Patients were allocated to groups according to their hospital identification number</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 12:24:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dolecek-2009">
<DESCRIPTION>
<P>Sealed opaque sequentially numbered envelopes (information obtained from authors)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Du-Gres-1989">
<DESCRIPTION>
<P>Unclear. No information given on method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:27 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Dytkowska-1998">
<DESCRIPTION>
<P>Unclear. No information given on method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 12:24:59 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Evans-2003">
<DESCRIPTION>
<P>Unclear - 'sealed envelopes'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Falk-1988">
<DESCRIPTION>
<P>Unclear. No information given on method of randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Friedman-2008">
<DESCRIPTION>
<P>Unclear - sealed, opaque envelope assignment (does not say if sequentially numbered)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Fries-2004">
<DESCRIPTION>
<P>Unclear. No information given on method of randomisation or allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Fulachier-1994">
<DESCRIPTION>
<P>Unclear. No information given on method of randomisation or allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Gahr-1981">
<DESCRIPTION>
<P>Unclear. No information given on method of randomisation or allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:25 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Gallagher-1985">
<DESCRIPTION>
<P>Adequate. Computerised system - patient details were entered before treatment assignment was revealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Godet-2008">
<DESCRIPTION>
<P>Adequate. Investigator received a set of envelopes. Envelope only opened when the patient arrived at pre-induction anaesthesia room</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Gold-1990">
<DESCRIPTION>
<P>Inadequate. Randomisation by alternation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gombocz-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-30 10:45:04 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Gondos-2010">
<DESCRIPTION>
<P>Adequate - 'randomised by blinded envelope technique - each centre had got 20 closed, opaque envelopes which were sequentially numbered'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Haas-2007">
<DESCRIPTION>
<P>Unclear. No information given on method of allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Hausdorfer-1986">
<DESCRIPTION>
<P>Unclear. No information given on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:23 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Hecht_x002d_Dolnik-2009">
<DESCRIPTION>
<P>Adequate. 'Sealed envelopes, attending anaesthetist opened the envelope linked to the patient's study number in the operating room when the procedure was underway'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Hedstrand-1987">
<DESCRIPTION>
<P>Unclear. No information given on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Hiippala-1995">
<DESCRIPTION>
<P>Unclear. No information given on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Unclear. No information given on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:22 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Huskisson-1993">
<DESCRIPTION>
<P>Unclear. No information given on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Inal-2010">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 12:27:22 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Jin-2010">
<DESCRIPTION>
<P>Unclear - 'closed envelopes'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:21 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Jones-2004">
<DESCRIPTION>
<P>Unclear. No information given on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Karanko-1987">
<DESCRIPTION>
<P>Inadequate. Paper was put into a hat and taken out by an independent person</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Kirklin-1984">
<DESCRIPTION>
<P>Unclear. No information given on allocation concealment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 12:27:40 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Lisander-1996">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Emma M Sydenham" RESULT="UNKNOWN" STUDY_ID="STD-London-1989">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:20 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Mahmood-2007">
<DESCRIPTION>
<P>Adequate 'sealed envelops allocating the fluid type' were opened on the morning of surgery. Recruitment, randomisation, and concealment were carried out by the trial coordinator</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Emma M Sydenham" RESULT="UNKNOWN" STUDY_ID="STD-Mastroianni-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Mittermayr-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:19 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Moggio-1983">
<DESCRIPTION>
<P>Inadequate. Randomised according to the last digit of their hospital identification numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Emma M Sydenham" RESULT="UNKNOWN" STUDY_ID="STD-Molnar-2004">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Mukhtar-2009">
<DESCRIPTION>
<P>Unclear 'sealed envelope' (does not say if opaque or sequentially numbered)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:18 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Munoz-1980">
<DESCRIPTION>
<P>Unclear. No information given on method of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Munsch-1988">
<DESCRIPTION>
<P>Unclear. No information given on method of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Niemi-2006">
<DESCRIPTION>
<P>Unclear. Allocation by closed envelope (not enough information provided to classify as adequate)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Ooi-2009">
<DESCRIPTION>
<P>Adequate 'sealed envelopes' - on contact study author confirmed that envelopes opaque and sequentially numbered</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:17 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Prien-1990">
<DESCRIPTION>
<P>Unclear. No information on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Rackow-1983">
<DESCRIPTION>
<P>Unclear. No information on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 21:03:03 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Rackow-1989">
<DESCRIPTION>
<P>Unclear. No information on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Reine-2008">
<DESCRIPTION>
<P>Adequate, 'randomisation process was handled by the hospital's office for clinical research'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Rittoo-2004">
<DESCRIPTION>
<P>Unclear. Allocation by sealed envelopes (not enough information provided to classify as adequate)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:16 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Rosencher-1992">
<DESCRIPTION>
<P>Adequate. Sequentially numbered, sealed, opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Schortgen-2001">
<DESCRIPTION>
<P>Adequate. Allocation was by sealed opaque envelopes serially numbered and used in sequence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Schramko-2009">
<DESCRIPTION>
<P>Adequate 'closed envelopes were prepared before the beginning of the study'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Schramko-2010">
<DESCRIPTION>
<P>Adequate 'closed envelopes were prepared before the beginning of the study by a person who did not take part in the treatment of the study subjects'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:15 +0100" MODIFIED_BY="Frances Bunn" RESULT="NO" STUDY_ID="STD-Shatney-1983">
<DESCRIPTION>
<P>Inadequate. Patients assigned by alternation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 21:03:40 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Standl-2008">
<DESCRIPTION>
<P>Adequate 'sealed randomisation envelopes that were opened by the investigator only after final enrolment of the patient'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Stockwell-1992">
<DESCRIPTION>
<P>Unclear. No information given on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:14 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Stoddart-1996">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Tollofsrud-1995">
<DESCRIPTION>
<P>Adequate. Sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Linden-2004">
<DESCRIPTION>
<P>Unclear. Patients were randomly allocated by opening an envelope (not enough information provided to classify as adequate)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:13 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Van-der-Linden-2005">
<DESCRIPTION>
<P>Unclear. No information given on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Veneman-2004">
<DESCRIPTION>
<P>Adequate. Allocation by sealed envelopes kept outside of hospital</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Verheij-2006">
<DESCRIPTION>
<P>Adequate. Hospital pharmacy assigned patients via sealed enveloped method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:12 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Vogt-1994">
<DESCRIPTION>
<P>Unclear. No information given on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:45:11 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Vogt-1996">
<DESCRIPTION>
<P>Unclear. No information given on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:34:13 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Vogt-1999">
<DESCRIPTION>
<P>Unclear. No information given on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:35:02 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Volta-2007">
<DESCRIPTION>
<P>Unclear. Data on allocation not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-03 12:30:38 +0100" MODIFIED_BY="Emma M Sydenham" RESULT="YES" STUDY_ID="STD-Wahba-1996">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:36:55 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Watkins-1990">
<DESCRIPTION>
<P>Unclear. No information given on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:38:09 +0100" MODIFIED_BY="Frances Bunn" RESULT="YES" STUDY_ID="STD-Woittiez-1997">
<DESCRIPTION>
<P>Adequate. Allocation by sequentially numbered sealed opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:38:57 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2011">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-29 17:35:39 +0100" MODIFIED_BY="Frances Bunn" RESULT="UNKNOWN" STUDY_ID="STD-von-Sommoggy-1990">
<DESCRIPTION>
<P>Unclear. No information given on allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-18 17:56:29 +0100" MODIFIED_BY="Emma M Sydenham"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-16 19:25:25 +0100" MODIFIED_BY="Emma M Sydenham">
<COMPARISON ID="CMP-001" MODIFIED="2012-10-16 19:25:25 +0100" MODIFIED_BY="Emma M Sydenham" NO="1">
<NAME>Albumin or PPF versus HES</NAME>
<DICH_OUTCOME CHI2="4.786468922006058" CI_END="1.3139196222132232" CI_START="0.8598263983997658" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0628935866559628" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="122" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.11856879848330266" LOG_CI_START="-0.06558922530024798" LOG_EFFECT_SIZE="0.026489786591527342" METHOD="MH" MODIFIED="2012-10-16 19:25:25 +0100" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="0.9937851107025046" P_Q="1.0" P_Z="0.5728541769196536" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="31" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="832" TOTAL_2="887" WEIGHT="99.99999999999997" Z="0.5638530063568497">
<NAME>Death</NAME>
<GROUP_LABEL_1>Albumin</GROUP_LABEL_1>
<GROUP_LABEL_2>Hydroxyethyl starch</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Albumin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Starch</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:25 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16273" O_E="0.0" SE="0.0" STUDY_ID="STD-Boldt-1993a" TOTAL_1="15" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.51077932597227" CI_START="0.410165341167152" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.54540353224961" LOG_CI_START="-0.38704104015436036" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2011-02-11 16:16:24 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16274" O_E="0.0" SE="0.5477225575051662" STUDY_ID="STD-Boldt-1995" TOTAL_1="30" TOTAL_2="30" VAR="0.30000000000000004" WEIGHT="4.401926679154402"/>
<DICH_DATA CI_END="3.0028281703186757" CI_START="0.550501437554572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.47753048144390436" LOG_CI_START="-0.2592415425937682" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2011-02-11 16:16:24 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16275" O_E="0.0" SE="0.4327835340000672" STUDY_ID="STD-Boldt-1996a" TOTAL_1="30" TOTAL_2="30" VAR="0.1873015873015873" WEIGHT="6.162697350816162"/>
<DICH_DATA CI_END="19.775299481351468" CI_START="0.20227253720086952" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.296123069267743" LOG_CI_START="-0.6940630779397805" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2011-02-11 16:16:24 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16276" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Boldt-1996b" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="0.8803853358308803"/>
<DICH_DATA CI_END="2.311461368779981" CI_START="0.534107088229724" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.36388663951501277" LOG_CI_START="-0.2723716583936625" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2011-02-11 16:16:23 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16277" O_E="0.0" SE="0.3737412737209254" STUDY_ID="STD-Boldt-1996c" TOTAL_1="28" TOTAL_2="28" VAR="0.13968253968253969" WEIGHT="7.923468022477922"/>
<DICH_DATA CI_END="1.9028155574806211" CI_START="0.8317812625194992" EFFECT_SIZE="1.2580645161290323" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" LOG_CI_END="0.2793966935679005" LOG_CI_START="-0.07999086718344749" LOG_EFFECT_SIZE="0.09970291319222653" MODIFIED="2011-02-11 16:16:22 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16278" O_E="0.0" SE="0.21110603218245882" STUDY_ID="STD-Boldt-1998" TOTAL_1="150" TOTAL_2="150" VAR="0.044565756823821336" WEIGHT="27.29194541075729"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:21 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16280" O_E="0.0" SE="0.0" STUDY_ID="STD-Brock-1995" TOTAL_1="7" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16281" O_E="0.0" SE="0.0" STUDY_ID="STD-Brutocao-1996" TOTAL_1="18" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:21 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16282" O_E="0.0" SE="0.0" STUDY_ID="STD-Diehl-1982" TOTAL_1="33" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8265671022232148" CI_START="0.1827620568045421" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.26163563142883606" LOG_CI_START="-0.7381139630378877" LOG_EFFECT_SIZE="-0.23823916580452575" MODIFIED="2012-03-22 15:49:41 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.5872578606300599" STUDY_ID="STD-Dolecek-2009" TOTAL_1="30" TOTAL_2="26" VAR="0.34487179487179487" WEIGHT="5.659620016055659"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16283" O_E="0.0" SE="0.0" STUDY_ID="STD-Gallagher-1985" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:20 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16284" O_E="0.0" SE="0.0" STUDY_ID="STD-Gold-1990" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5325039443390018" CI_START="0.4176171959387969" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.18540160097346" LOG_CI_START="-0.3792216269895728" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-03-26 10:08:06 +0100" MODIFIED_BY="Frances Bunn" ORDER="109" O_E="0.0" SE="0.33166247903553997" STUDY_ID="STD-Gondos-2010" TOTAL_1="50" TOTAL_2="50" VAR="0.11" WEIGHT="13.205780037463205"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-26 16:41:45 +0100" MODIFIED_BY="Frances Bunn" ORDER="121" O_E="0.0" SE="0.0" STUDY_ID="STD-Hecht_x002d_Dolnik-2009" TOTAL_1="78" TOTAL_2="78" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:20 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16285" O_E="0.0" SE="0.0" STUDY_ID="STD-Kirklin-1984" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.053924418783321" CI_START="0.05332583563659308" EFFECT_SIZE="0.5681818181818182" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7820369946333986" LOG_CI_START="-1.2730623302616983" LOG_EFFECT_SIZE="-0.2455126678141498" MODIFIED="2011-02-11 16:16:19 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16286" O_E="0.0" SE="1.2071755163491047" STUDY_ID="STD-London-1989" TOTAL_1="44" TOTAL_2="50" VAR="1.4572727272727273" WEIGHT="1.6483810543216482"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:19 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16287" O_E="0.0" SE="0.0" STUDY_ID="STD-Mastroianni-1994" TOTAL_1="18" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="14.903914722906746" CI_START="0.06709646549862758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1733003569528007" LOG_CI_START="-1.1733003569528007" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-26 13:30:52 +0100" MODIFIED_BY="Frances Bunn" ORDER="113" O_E="0.0" SE="1.378404875209022" STUDY_ID="STD-Mukhtar-2009" TOTAL_1="20" TOTAL_2="20" VAR="1.9" WEIGHT="0.8803853358308803"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:18 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16288" O_E="0.0" SE="0.0" STUDY_ID="STD-Munsch-1988" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:18 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16289" O_E="0.0" SE="0.0" STUDY_ID="STD-Niemi-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.859796643732878" CI_START="0.01619743512551825" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8363112413898837" LOG_CI_START="-1.7905537508292084" LOG_EFFECT_SIZE="-0.47712125471966244" MODIFIED="2011-02-11 16:16:18 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16290" O_E="0.0" SE="1.5430334996209192" STUDY_ID="STD-Prien-1990" TOTAL_1="6" TOTAL_2="6" VAR="2.380952380952381" WEIGHT="1.3205780037463204"/>
<DICH_DATA CI_END="2.5274792947174864" CI_START="0.5697376049764865" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.40268760650763846" LOG_CI_START="-0.24432511441238877" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2011-02-11 16:16:17 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16291" O_E="0.0" SE="0.3800584750330461" STUDY_ID="STD-Rackow-1983" TOTAL_1="9" TOTAL_2="9" VAR="0.1444444444444445" WEIGHT="4.401926679154402"/>
<DICH_DATA CI_END="2.402530460804138" CI_START="0.41622781326372665" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.38066890263622855" LOG_CI_START="-0.3806689026362286" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:17 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16292" O_E="0.0" SE="0.447213595499958" STUDY_ID="STD-Rackow-1989" TOTAL_1="10" TOTAL_2="10" VAR="0.20000000000000004" WEIGHT="4.401926679154402"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16293" O_E="0.0" SE="0.0" STUDY_ID="STD-Rosencher-1992" TOTAL_1="16" TOTAL_2="16" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-02 09:30:27 +0100" MODIFIED_BY="Frances Bunn" ORDER="127" O_E="0.0" SE="0.0" STUDY_ID="STD-Schramko-2009" TOTAL_1="15" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.231237209631626" CI_START="0.23633749432049936" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6264673732269029" LOG_CI_START="-0.6264673732269029" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-11 16:16:16 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16294" O_E="0.0" SE="0.7359800721939872" STUDY_ID="STD-Shatney-1983" TOTAL_1="16" TOTAL_2="16" VAR="0.5416666666666666" WEIGHT="2.641156007492641"/>
<DICH_DATA CI_END="71.55844228907183" CI_START="0.12577132357972595" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8546608781135627" LOG_CI_START="-0.9004183686742377" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2012-03-26 15:35:20 +0100" MODIFIED_BY="Frances Bunn" ORDER="119" O_E="0.0" SE="1.618347187425374" STUDY_ID="STD-Standl-2008" TOTAL_1="41" TOTAL_2="41" VAR="2.619047619047619" WEIGHT="0.44019266791544015"/>
<DICH_DATA CI_END="1.550379950547752" CI_START="0.5096321430827142" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="0.19043814346392832" LOG_CI_START="-0.29274318835869095" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="16295" O_E="0.0" SE="0.2838231060987733" STUDY_ID="STD-Veneman-2004" TOTAL_1="15" TOTAL_2="30" VAR="0.08055555555555555" WEIGHT="10.564624029970563"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16296" O_E="0.0" SE="0.0" STUDY_ID="STD-Verheij-2006" TOTAL_1="18" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.0473186836373296" CI_START="0.5993118014928754" EFFECT_SIZE="1.1076923076923078" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.3111854497816084" LOG_CI_START="-0.22234717020478253" LOG_EFFECT_SIZE="0.04441913978841291" ORDER="16297" O_E="0.0" SE="0.31339970200906897" STUDY_ID="STD-Woittiez-1997" TOTAL_1="15" TOTAL_2="27" VAR="0.09821937321937324" WEIGHT="8.175006689858176"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-26 16:58:37 +0100" MODIFIED_BY="Frances Bunn" ORDER="123" O_E="0.0" SE="0.0" STUDY_ID="STD-Yang-2011" TOTAL_1="30" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-001.02" MODIFIED="2012-06-11 13:07:16 +0100" MODIFIED_BY="Frances Bunn" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO">
<NAME>Blood/red cells transfused (skewed or inadequate data)</NAME>
<TR>
<TH>
<P>Notes</P>
</TH>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2012-05-30 11:38:37 +0100" MODIFIED_BY="Anne Lawson" ORDER="32" STUDY_ID="STD-Arellano-2005">
<TR>
<TD>
<P>HA group received median of 1 unit each; HES median of 3 units each</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:38:47 +0100" MODIFIED_BY="Anne Lawson" ORDER="33" STUDY_ID="STD-Boldt-1998">
<TR>
<TD>
<P>Total units of red blood cells transfused given for each group (Hetastarch 356, albumin 371). No means, medians, or measures of variation given</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:55:46 +0100" MODIFIED_BY="Anne Lawson" ORDER="34" STUDY_ID="STD-Brock-1995">
<TR>
<TD>
<P>The amount of blood derivatives ('blutderivate') was given in millilitres as a mean and standard deviation (SD). In the 10% starch group the mean was 379 (SD 483), in the 6% starch group the mean was 243 (SD 192) and in the 5% albumin group the mean was 171 (SD 236)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:56:21 +0100" MODIFIED_BY="Anne Lawson" ORDER="35" STUDY_ID="STD-Brutocao-1996">
<TR>
<TD>
<P>Packed red cell transfusion is given in mL/kg. In the HES group the mean was 0.3, the SD 1.3, and the range of 0 to 6.4. In the albumin group the mean was 1.1, the SD 3.7, and the range 0 to 13.1</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:41:26 +0100" MODIFIED_BY="Anne Lawson" ORDER="36" STUDY_ID="STD-Claes-1992">
<TR>
<TD>
<P>Blood transfused was not recorded. Authors state "none of the patients lost an abnormally large quantity of blood or experienced a clinically perceptible coagulation disorder"</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:42:07 +0100" MODIFIED_BY="Anne Lawson" ORDER="37" STUDY_ID="STD-Diehl-1982">
<TR>
<TD>
<P>18% (n = 5) of the albumin group and 15% (n = 5) of the HES group received banked blood during their stay. Blood transfused was recorded as mean number of units per person. In the albumin group this was 0.37 units per person and in the HES group this was 0.36 units per person</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:57:07 +0100" MODIFIED_BY="Anne Lawson" ORDER="38" STUDY_ID="STD-Falk-1988">
<TR>
<TD>
<P>Packed red blood cells transfused at 24 hours was given in millilitres. The albumin group received a mean of 375 with a standard error of the mean (SEM) of 244 and the HES group received a mean of 700 with an SEM 228</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:57:25 +0100" MODIFIED_BY="Anne Lawson" ORDER="39" STUDY_ID="STD-Gallagher-1985">
<TR>
<TD>
<P>Amount of blood products transfused postoperatively was given as a mean in millilitres with the SEM. For the albumin group the mean was 560 (SEM 149.2) and for the starch group the mean was 566 (SEM 72.6)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:57:32 +0100" MODIFIED_BY="Anne Lawson" ORDER="40" STUDY_ID="STD-Gold-1990">
<TR>
<TD>
<P>Packed red blood cells is given in units. The albumin group received a mean of 2.05 and the HES group received a mean of 2.50</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:44:46 +0100" MODIFIED_BY="Frances Bunn" ORDER="41" STUDY_ID="STD-Hecht_x002d_Dolnik-2009">
<TR>
<TD>
<P>Data given as mean number of units (SD)</P>
<P>RBC: HES 1.13 (2.52), HA 0.40 (0.89), P = 0.0002</P>
<P>Platelets: HES 0.35 (0.77), HA 0.13 (0.38), P = 0.0001</P>
<P>FFB: HES 0.56 (1.24), HA 0.15 (0.56), P value not significant</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:58:09 +0100" MODIFIED_BY="Anne Lawson" ORDER="42" STUDY_ID="STD-Hiippala-1995">
<TR>
<TD>
<P>Amount of red cell concentrates transfused was given as a mean and SD of millilitres per kilogram body weight (mL/kgBW). For albumin the mean was 20 (SD 14), for 4% HES the mean was 20 (SD 14) and for 6% HES the mean was 25 (SD 17)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:47:33 +0100" MODIFIED_BY="Anne Lawson" ORDER="43" STUDY_ID="STD-Jones-2004">
<TR>
<TD>
<P>HA group received mean of 0.5 units (range 0 units to 1 unit), HEs group received mean of 1 unit (range of 0 units to 2 units)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:52:58 +0100" MODIFIED_BY="Anne Lawson" ORDER="44" STUDY_ID="STD-Kirklin-1984">
<TR>
<TD>
<P>The amount of red cells given up to the first 24 hours postoperatively was recorded. In the HES group the mean was 430 with a standard error of 90, and in the albumin group the mean is 440 with a standard error of 76</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:54:29 +0100" MODIFIED_BY="Anne Lawson" ORDER="45" STUDY_ID="STD-London-1989">
<TR>
<TD>
<P>Total postoperative blood transfused is given in millilitres. In the albumin group the figures are given as 838 mL (630 mL) and the HES group 894 mL (600 mL). It does not report what the figures represent (they may be mean and SD). Intraoperatively the blood given in the albumin group was 400 mL (346 mL) and in the HES group 336 mL (400 mL)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:58:30 +0100" MODIFIED_BY="Anne Lawson" ORDER="46" STUDY_ID="STD-Mastroianni-1994">
<TR>
<TD>
<P>The mean of packed red cells given was recorded in millilitres. For pentastarch the mean was 167 and for albumin it was 234. Another figure was given 163 for pentastarch and 148 for albumin but it was not clear what this represented</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:58:46 +0100" MODIFIED_BY="Frances Bunn" ORDER="47" STUDY_ID="STD-Mukhtar-2009">
<TR>
<TD>
<P>Reported as units of PRBCs, mean and range. Intraoperatively HA 4 (0 to 6), HES 4 (0 to 10), postoperatively HA 4 (0 to 8), HES 2 (0 to 8)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:59:26 +0100" MODIFIED_BY="Anne Lawson" ORDER="48" STUDY_ID="STD-Munsch-1988">
<TR>
<TD>
<P>The amount of whole blood transfused was given as a median volume. For the albumin group it was 830 mL (range 260 mL to 1800 mL), and for the HES group it was 830 mL (range 50 mL to 1840 mL)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 11:59:41 +0100" MODIFIED_BY="Anne Lawson" ORDER="49" STUDY_ID="STD-Niemi-2006">
<TR>
<TD>
<P>The mean and SD of number of RBC units transfused was given. HA mean 0.2 (SD 0.6), HES mean 0.3 (SD 0.6)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:00:40 +0100" MODIFIED_BY="Anne Lawson" ORDER="50" STUDY_ID="STD-Prien-1990">
<TR>
<TD>
<P>The mean and SEM for the amount of packed red cells given was recorded. For the albumin group the mean was 1.2 (SEM 0.7). In the HES group the mean was 1.8 (SEM 0.7)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:00:45 +0100" MODIFIED_BY="Anne Lawson" ORDER="51" STUDY_ID="STD-Rackow-1983">
<TR>
<TD>
<P>Total amount of blood transfused was given in millilitres at the end of the maintenance period. For the albumin group the mean was 363.9 (SEM 186) and for the starch group the mean was 757.1 (SEM 201)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:00:50 +0100" MODIFIED_BY="Anne Lawson" ORDER="52" STUDY_ID="STD-Rackow-1989">
<TR>
<TD>
<P>No data on units transfused. The authors say "there was no evidence of clinical bleeding"</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:00:52 +0100" MODIFIED_BY="Anne Lawson" ORDER="53" STUDY_ID="STD-Shatney-1983">
<TR>
<TD>
<P>The amount of red blood cells transfused was given in a graphical form not figures</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:01:31 +0100" MODIFIED_BY="Frances Bunn" ORDER="54" STUDY_ID="STD-Standl-2008">
<TR>
<TD>
<P>Data given as mean number of units with SD</P>
<P>RBC: HES 52.2 (139.2), 53.4 (155.9)</P>
<P>FFP: HES 22.4 (117.9), HA 25.2 (90.7)</P>
<P>No significant difference between groups</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:01:52 +0100" MODIFIED_BY="Anne Lawson" ORDER="55" STUDY_ID="STD-Vogt-1994">
<TR>
<TD>
<P>Amount of EK given was recorded as a mean and SD of the millilitres given. For the albumin group it was 1138 (SD 763.5), and for the HES group it was 944.4 (SD 466.2)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:05:14 +0100" MODIFIED_BY="Anne Lawson" ORDER="56" STUDY_ID="STD-Vogt-1996">
<TR>
<TD>
<P>The mean and SD of packed red blood cells transfused was given for the end of surgery and at 6 hours. For the albumin group at the end of surgery the mean was 798 (SD 1147) and at 6 hours it was 1333 (SD 1399). For the HES group at the end of surgery the mean was 763 (SD 923) and at 6 hours the mean was 1538 (SD 1074)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:06:05 +0100" MODIFIED_BY="Anne Lawson" ORDER="57" STUDY_ID="STD-Vogt-1999">
<TR>
<TD>
<P>Amount of packed red blood cells was given as mean and SD. In the HES group the mean was 1510 mL (SD 765 mL) and in the albumin group the mean was 1410 mL (SD 946 mL)</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:06:08 +0100" MODIFIED_BY="Anne Lawson" ORDER="58" STUDY_ID="STD-von-Sommoggy-1990">
<TR>
<TD>
<P>The trialists report 'no increased bleeding in the HES group'</P>
</TD>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-10-16 19:21:41 +0100" MODIFIED_BY="Emma M Sydenham" NO="2">
<NAME>Albumin or PPF versus gelatin</NAME>
<DICH_OUTCOME CHI2="3.9713362205879865" CI_END="1.2136207395621517" CI_START="0.6523897724407379" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8898054608240569" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="70" I2="24.458675031150417" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.0840829894995361" LOG_CI_START="-0.18549285604280974" LOG_EFFECT_SIZE="-0.050704933271636804" METHOD="MH" MODIFIED="2012-10-16 19:21:41 +0100" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="0.2645760537939321" P_Q="1.0" P_Z="0.4609367462064796" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="403" TOTAL_2="421" WEIGHT="100.0" Z="0.7373052496671401">
<NAME>Death</NAME>
<GROUP_LABEL_1>Albumin or PPF</GROUP_LABEL_1>
<GROUP_LABEL_2>Gelatin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Albumin or PPF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Gelatin</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1132559774467066" CI_START="0.018331959296650702" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.04659503568302807" LOG_CI_START="-1.7367911157115419" LOG_EFFECT_SIZE="-0.8450980400142568" MODIFIED="2012-03-21 11:36:49 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.0475698532329945" STUDY_ID="STD-Akech-2006" TOTAL_1="44" TOTAL_2="44" VAR="1.0974025974025974" WEIGHT="10.269609420243228"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-10 16:24:59 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16323" O_E="0.0" SE="0.0" STUDY_ID="STD-Boldt-1993a" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.008837696708396" CI_START="0.49780029598138337" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.302944849505161" LOG_CI_START="-0.302944849505161" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-26 10:08:55 +0100" MODIFIED_BY="Frances Bunn" ORDER="110" O_E="0.0" SE="0.3559026084010437" STUDY_ID="STD-Gondos-2010" TOTAL_1="50" TOTAL_2="50" VAR="0.12666666666666668" WEIGHT="17.605044720416963"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16324" O_E="0.0" SE="0.0" STUDY_ID="STD-Karanko-1987" TOTAL_1="15" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16325" O_E="0.0" SE="0.0" STUDY_ID="STD-Niemi-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.4216143696841521" CI_START="0.6916478481535008" EFFECT_SIZE="0.9915929203539823" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" LOG_CI_END="0.1527818046699192" LOG_CI_START="-0.16011496989459856" LOG_EFFECT_SIZE="-0.003666582612339713" ORDER="16326" O_E="0.0" SE="0.18379711424321157" STUDY_ID="STD-Stockwell-1992" TOTAL_1="226" TOTAL_2="249" VAR="0.03378137920413216" WEIGHT="69.8024580142848"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16327" O_E="0.0" SE="0.0" STUDY_ID="STD-Tollofsrud-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.842616666677241" CI_START="0.012999478214868448" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.835222210870207" LOG_CI_START="-1.8860740794586417" LOG_EFFECT_SIZE="-0.5254259342942175" ORDER="16328" O_E="0.0" SE="1.5985029115730547" STUDY_ID="STD-Verheij-2006" TOTAL_1="18" TOTAL_2="16" VAR="2.5552115583075334" WEIGHT="2.3228878450550154"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16329" O_E="0.0" SE="0.0" STUDY_ID="STD-Wahba-1996" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-002.02" MODIFIED="2012-06-11 15:46:56 +0100" MODIFIED_BY="Anne Lawson" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO">
<NAME>Blood/red cells transfused (skewed or inadequate data)</NAME>
<TR>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2012-05-30 12:07:35 +0100" MODIFIED_BY="Anne Lawson" ORDER="68" STUDY_ID="STD-Evans-2003">
<TR>
<TD>
<P>No data on amount of units transfused. Author reports that there was no significant difference in the median total blood loss between the groups (P = 0.5587)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:07:47 +0100" MODIFIED_BY="Anne Lawson" ORDER="69" STUDY_ID="STD-Niemi-2006">
<TR>
<TD>
<P>The mean and standard deviation (SD) of RBC units transfused was given. HA mean 0.2 (SD 0.6), Gel mean 0.2 (SD 0.4)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-06-11 15:46:56 +0100" MODIFIED_BY="Anne Lawson" ORDER="70" STUDY_ID="STD-Stockwell-1992">
<TR>
<TD>
<P>The volume of blood products given was recorded as a mean with the range also given. In the albumin group the mean was 1.45 L (range 0-29) and in the haemacell group the mean was 1.39 L (range 0 L to 66 L) (P = 0.65, Mann-Whitney U test)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:41:03 +0100" MODIFIED_BY="Anne Lawson" ORDER="71" STUDY_ID="STD-Tollofsrud-1995">
<TR>
<TD>
<P>The amount of erthrocytes given was recorded as a mean and SD. In the albumin group the mean was 240 (SD 310), and in the polygeline group the mean was 490 (SD 548)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-10-16 19:21:59 +0100" MODIFIED_BY="Anne Lawson" NO="3">
<NAME>Albumin or PPF versus dextran</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="33.09301746200066" CI_START="0.4241409525059634" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7464788732394365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="1.519736368469899" LOG_CI_START="-0.37248979264591564" LOG_EFFECT_SIZE="0.5736232879119917" METHOD="MH" MODIFIED="2012-10-16 19:21:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.23470909356259362" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="187" TOTAL_2="173" WEIGHT="100.0" Z="1.1883156549722196">
<NAME>Death</NAME>
<GROUP_LABEL_1>Albumin or PPF</GROUP_LABEL_1>
<GROUP_LABEL_2>Dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Albumin or PPF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="33.09301746200066" CI_START="0.4241409525059634" EFFECT_SIZE="3.7464788732394365" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.519736368469899" LOG_CI_START="-0.37248979264591564" LOG_EFFECT_SIZE="0.5736232879119917" ORDER="16334" O_E="0.0" SE="1.1115030137099908" STUDY_ID="STD-Hedstrand-1987" TOTAL_1="142" TOTAL_2="133" VAR="1.235438949486392" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16335" O_E="0.0" SE="0.0" STUDY_ID="STD-Karanko-1987" TOTAL_1="15" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16336" O_E="0.0" SE="0.0" STUDY_ID="STD-Lisander-1996" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16337" O_E="0.0" SE="0.0" STUDY_ID="STD-Tollofsrud-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-003.02" MODIFIED="2012-05-30 12:37:47 +0100" MODIFIED_BY="Anne Lawson" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO">
<NAME>Blood/red cells transfused (skewed or inadequate data)</NAME>
<TR>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2012-05-30 12:12:28 +0100" MODIFIED_BY="Anne Lawson" ORDER="76" STUDY_ID="STD-Hedstrand-1987">
<TR>
<TD>
<P>The perioperative and postoperative amount of red blood cells transfused was reported as a mean and standard deviation (SD) of units given. For the plasma group the mean was 5.2 (SD 4.8) and for the dextran group the mean was 5.8 (SD 4.4)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:13:00 +0100" MODIFIED_BY="Anne Lawson" ORDER="77" STUDY_ID="STD-Hiippala-1995">
<TR>
<TD>
<P>Amount of red cell concentrates transfused was given as a mean and SD of millilitre per kilo gram body weight (mL/kgBW). For albumin the mean was 20 (SD 14) and for dextran the mean was 19 (SD 12)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:13:12 +0100" MODIFIED_BY="Anne Lawson" ORDER="78" STUDY_ID="STD-Jones-2004">
<TR>
<TD>
<P>Mean of 0.5 unit HA (range 0 to 1), mean of 1 for DEX (range 0 to 2)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:14:08 +0100" MODIFIED_BY="Anne Lawson" ORDER="79" STUDY_ID="STD-Lisander-1996">
<TR>
<TD>
<P>Total red blood cells transfused is given. For the albumin group the mean was 2.3 (SD1.6), in the dextran group the mean was 3.8 (SD 2.4). Red cells autotransfused was also given as 312 (SD 184) in the albumin group and 383 (SD 259) in the dextran group</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:37:44 +0100" MODIFIED_BY="Anne Lawson" ORDER="80" STUDY_ID="STD-Tollofsrud-1995">
<TR>
<TD>
<P>Erythrocytes given was recorded as mean and SD. The mean for the albumin group was 240 (SD 310) and the mean for the dextran group was 390 (SD 417)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-10-16 19:24:49 +0100" MODIFIED_BY="Emma M Sydenham" NO="4">
<NAME>Modified gelatin versus HES</NAME>
<DICH_OUTCOME CHI2="8.613441137683642" CI_END="1.2550521235497691" CI_START="0.8356062893361884" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.024074922983141" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="115" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.09866176286882397" LOG_CI_START="-0.0779982998864129" LOG_EFFECT_SIZE="0.010331731491205542" METHOD="MH" MODIFIED="2012-10-16 19:24:49 +0100" MODIFIED_BY="Emma M Sydenham" NO="1" P_CHI2="0.8014718224694788" P_Q="1.0" P_Z="0.8186731882348426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="758" TOTAL_2="854" WEIGHT="100.0" Z="0.22925183320870177">
<NAME>Death</NAME>
<GROUP_LABEL_1>Gelatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Hydroxyethyl starch</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Gelatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Starch</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.82976889241327" CI_START="0.0162496050423134" EFFECT_SIZE="0.3787878787878788" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9459493366395004" LOG_CI_START="-1.7891571903791628" LOG_EFFECT_SIZE="-0.42160392686983106" MODIFIED="2011-02-16 12:42:19 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16343" O_E="0.0" SE="1.6066151129664257" STUDY_ID="STD-Allison-1999" TOTAL_1="21" TOTAL_2="24" VAR="2.581212121212121" WEIGHT="1.2085631775876016"/>
<DICH_DATA CI_END="1.7599754089691437" CI_START="0.646473679109073" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.24550659973255007" LOG_CI_START="-0.189449152532063" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="16344" O_E="0.0" SE="0.2554951619459316" STUDY_ID="STD-Asfar-2000" TOTAL_1="18" TOTAL_2="16" VAR="0.0652777777777778" WEIGHT="9.112695617104375"/>
<DICH_DATA CI_END="2.624608365044303" CI_START="0.4120995781333429" EFFECT_SIZE="1.04" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4190645086603422" LOG_CI_START="-0.38499783006278143" LOG_EFFECT_SIZE="0.01703333929878037" MODIFIED="2011-02-16 12:42:19 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16345" O_E="0.0" SE="0.47231019793873086" STUDY_ID="STD-Beards-1994" TOTAL_1="15" TOTAL_2="13" VAR="0.22307692307692312" WEIGHT="4.610590044368285"/>
<DICH_DATA CI_END="1.4864019607393257" CI_START="0.6126135245312088" EFFECT_SIZE="0.954248366013072" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.172136269535538" LOG_CI_START="-0.21281341960186137" LOG_EFFECT_SIZE="-0.020338575033161683" MODIFIED="2011-02-16 12:42:20 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16346" O_E="0.0" SE="0.22612135293100166" STUDY_ID="STD-Berard-1995" TOTAL_1="153" TOTAL_2="146" VAR="0.051130866251346614" WEIGHT="27.3045618841599"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16347" O_E="0.0" SE="0.0" STUDY_ID="STD-Beyer-1997" TOTAL_1="22" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 12:42:20 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16348" O_E="0.0" SE="0.0" STUDY_ID="STD-Boldt-1993a" TOTAL_1="15" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.246996764009346" CI_START="0.07114529769008528" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.7956712809783175" LOG_CI_START="-1.14785379908968" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-02-16 12:42:21 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16349" O_E="0.0" SE="1.1416362526362471" STUDY_ID="STD-Boldt-2000" TOTAL_1="50" TOTAL_2="100" VAR="1.3033333333333332" WEIGHT="1.7212869498974932"/>
<DICH_DATA CI_END="15.497590118068155" CI_START="0.027585888492494208" EFFECT_SIZE="0.6538461538461539" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.1902641704416415" LOG_CI_START="-1.5593130236267296" LOG_EFFECT_SIZE="-0.18452442659254403" MODIFIED="2011-02-16 12:42:21 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16350" O_E="0.0" SE="1.6151152544223812" STUDY_ID="STD-Boldt-2001" TOTAL_1="25" TOTAL_2="50" VAR="2.6085972850678734" WEIGHT="0.8718206629350939"/>
<DICH_DATA CI_END="6.492780573709726" CI_START="0.1450906143826609" EFFECT_SIZE="0.9705882352941176" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8124307259534104" LOG_CI_START="-0.8383606802821456" LOG_EFFECT_SIZE="-0.012964977164367649" MODIFIED="2012-03-23 08:33:10 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.9696830435720155" STUDY_ID="STD-Godet-2008" TOTAL_1="34" TOTAL_2="33" VAR="0.9402852049910874" WEIGHT="1.7469777998959632"/>
<DICH_DATA CI_END="1.5325039443390018" CI_START="0.4176171959387969" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.18540160097346" LOG_CI_START="-0.3792216269895728" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2012-03-26 10:09:43 +0100" MODIFIED_BY="Frances Bunn" ORDER="111" O_E="0.0" SE="0.33166247903553997" STUDY_ID="STD-Gondos-2010" TOTAL_1="50" TOTAL_2="50" VAR="0.11" WEIGHT="12.909652124231199"/>
<DICH_DATA CI_END="2.7514307510854565" CI_START="0.363447271789593" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4395585868182921" LOG_CI_START="-0.4395585868182921" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-26 10:55:17 +0100" MODIFIED_BY="Frances Bunn" ORDER="112" O_E="0.0" SE="0.5163977794943223" STUDY_ID="STD-Inal-2010" TOTAL_1="15" TOTAL_2="15" VAR="0.2666666666666667" WEIGHT="4.303217374743733"/>
<DICH_DATA CI_END="28.493253958782347" CI_START="1.392961297344789" EFFECT_SIZE="6.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.4547420489462985" LOG_CI_START="0.14393904996086487" LOG_EFFECT_SIZE="0.7993405494535817" MODIFIED="2012-04-02 11:45:13 +0100" MODIFIED_BY="Frances Bunn" ORDER="129" O_E="0.0" SE="0.7699721701835351" STUDY_ID="STD-Mahmood-2007" TOTAL_1="20" TOTAL_2="42" VAR="0.5928571428571427" WEIGHT="1.1105077096112859"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-02 13:48:23 +0100" MODIFIED_BY="Frances Bunn" ORDER="131" O_E="0.0" SE="0.0" STUDY_ID="STD-Mittermayr-2007" TOTAL_1="21" TOTAL_2="19" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2916748550289214" CI_START="0.5376310003564291" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.11115320527048951" LOG_CI_START="-0.2695156973657391" LOG_EFFECT_SIZE="-0.0791812460476248" MODIFIED="2011-02-16 12:42:23 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16354" O_E="0.0" SE="0.22360679774997902" STUDY_ID="STD-Molnar-2004" TOTAL_1="15" TOTAL_2="15" VAR="0.05000000000000002" WEIGHT="10.32772169938496"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 12:42:23 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16355" O_E="0.0" SE="0.0" STUDY_ID="STD-Niemi-2006" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-26 14:00:38 +0100" MODIFIED_BY="Frances Bunn" ORDER="115" O_E="0.0" SE="0.0" STUDY_ID="STD-Ooi-2009" TOTAL_1="45" TOTAL_2="45" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.5505137843779224" CI_START="0.713626661031288" EFFECT_SIZE="1.0518973214285714" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="28" LOG_CI_END="0.19047563155538816" LOG_CI_START="-0.14652893312397763" LOG_EFFECT_SIZE="0.021973349215705255" ORDER="16356" O_E="0.0" SE="0.19795814949215904" STUDY_ID="STD-Schortgen-2001" TOTAL_1="64" TOTAL_2="65" VAR="0.03918742895035998" WEIGHT="23.911210962917114"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-04-02 09:31:03 +0100" MODIFIED_BY="Frances Bunn" ORDER="128" O_E="0.0" SE="0.0" STUDY_ID="STD-Schramko-2010" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 12:42:24 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16357" O_E="0.0" SE="0.0" STUDY_ID="STD-Van-der-Linden-2004" TOTAL_1="55" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="68.13700837382474" CI_START="0.11721629223877801" EFFECT_SIZE="2.8260869565217392" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.83338306149981" LOG_CI_START="-0.9310120202492845" LOG_EFFECT_SIZE="0.45118552062526274" MODIFIED="2011-02-16 12:42:24 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16358" O_E="0.0" SE="1.6238193549957651" STUDY_ID="STD-Van-der-Linden-2005" TOTAL_1="68" TOTAL_2="64" VAR="2.6367892976588627" WEIGHT="0.4431671624736084"/>
<DICH_DATA CI_END="72.7468601168141" CI_START="0.13869966871039935" EFFECT_SIZE="3.176470588235294" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8618142531442754" LOG_CI_START="-0.857924576254886" LOG_EFFECT_SIZE="0.5019448384446945" ORDER="16359" O_E="0.0" SE="1.5975880513134" STUDY_ID="STD-Verheij-2006" TOTAL_1="16" TOTAL_2="17" VAR="2.5522875816993467" WEIGHT="0.4180268306893912"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-02-16 12:42:25 +0000" MODIFIED_BY="Emma M Sydenham" ORDER="16360" O_E="0.0" SE="0.0" STUDY_ID="STD-Watkins-1990" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-004.02" MODIFIED="2012-06-11 15:56:49 +0100" MODIFIED_BY="Frances Bunn" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO">
<NAME>Blood/red cells transfused (skewed or inadequate data)</NAME>
<TR>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2012-05-30 12:26:19 +0100" MODIFIED_BY="Anne Lawson" ORDER="103" STUDY_ID="STD-Allison-1999">
<TR>
<TD>
<P>The mean volume of packed red blood cells (PRBC) transfused was given for each day up to and including the 5th day. For the first postoperative day the hydroxyethyl starch (HES) group received a total of 3067 mL of PRBCs and the gelatine group received 2643 mL of PRBCs</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:15:23 +0100" MODIFIED_BY="Anne Lawson" ORDER="104" STUDY_ID="STD-Berard-1995">
<TR>
<TD>
<P>Blood transfused was given in units, 2.6 units for the gel group and 2.5 units for the HES group (presumably this figure is mean)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:15:28 +0100" MODIFIED_BY="Anne Lawson" ORDER="105" STUDY_ID="STD-Beyer-1997">
<TR>
<TD>
<P>Blood transfused is given in graphical form and not figures</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:26:28 +0100" MODIFIED_BY="Anne Lawson" ORDER="106" STUDY_ID="STD-Boldt-2000">
<TR>
<TD>
<P>The amount of PRBC transfused is given as the total number of units for each group<BR/>By the first post operative day the number of units of PRBCs transfused was: </P>
<P>HES 70: 38 units, </P>
<P>HES 200: 40 units, </P>
<P>Gelatin: 44 units</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:26:37 +0100" MODIFIED_BY="Anne Lawson" ORDER="107" STUDY_ID="STD-Boldt-2001">
<TR>
<TD>
<P>The amount of PRBC transfused is given as the total number of units for each group<BR/>By the first post operative day the number of units of PRBCs transfused was:<BR/>HES 200: 18 units,<BR/>HES 130: 16 units,<BR/>Gelatin 18 units</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:20:46 +0100" MODIFIED_BY="Anne Lawson" ORDER="108" STUDY_ID="STD-Carli-2000">
<TR>
<TD>
<P>The amount of PRBC transfused is given as the total number of units for each group<BR/>1 unit of blood was given in the gel group and 0 units of blood were given in the starch group<BR/>
</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:24:06 +0100" MODIFIED_BY="Frances Bunn" ORDER="109" STUDY_ID="STD-Mahmood-2007">
<TR>
<TD>
<P>Amount of red cells and FFP is given as median number of units (range)</P>
<P>Red cells: HES 200/0.62 = 7.0 (4.5 to 10), HES 130/0.4 = 6.0 (4.0 to 8.0), gelatin = 7.0 (5.25 to 9.75). P = 0.360 (no statistical difference between groups)</P>
<P>FFP: HES 200/0.62 = 4 (0 to 6), HES 130/0.4 = 2 (0 to 5), gelatine = 4 (0 to 7). P = 0.420 (no statistical difference between groups)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:24:25 +0100" MODIFIED_BY="Frances Bunn" ORDER="110" STUDY_ID="STD-Mittermayr-2007">
<TR>
<TD>
<P>Total red cells units transfused</P>
<P>Gelatin n = 13, HES n = 9</P>
<P>Number of patients transfused</P>
<P>Gelatin n = 8/21, HES n = 3/19</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:26:44 +0100" MODIFIED_BY="Anne Lawson" ORDER="111" STUDY_ID="STD-Niemi-2006">
<TR>
<TD>
<P>The mean and SD of red blood cell (RBC) units transfused was given. </P>
<P>Gel mean 0.2 (SD 0.4), HES 0.3 (0.6)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:25:34 +0100" MODIFIED_BY="Frances Bunn" ORDER="112" STUDY_ID="STD-Ooi-2009">
<TR>
<TD>
<P>Data reported as number of patients who received at least 1 unit</P>
<P>PRBCs: HES = 40, gelatin = 42. P = 0.46</P>
<P>FFP: HES = 17, gelatin = 24. P = 0.14</P>
<P>No statistical difference between groups</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:27:19 +0100" MODIFIED_BY="Frances Bunn" ORDER="113" STUDY_ID="STD-Schramko-2009">
<TR>
<TD>
<P>Data given as number of units of RBC and FFP transfused</P>
<P>RBC: HES 200/0.5 = 11, HES 130/0.4 = 5, HA = 5</P>
<P>FFP: HES 200/0/5 = 1, HES 130/0.4 = 1, HA = 0</P>
<P>No significant difference between groups</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:27:30 +0100" MODIFIED_BY="Frances Bunn" ORDER="114" STUDY_ID="STD-Schramko-2010">
<TR>
<TD>
<P>Data given as number of units of RBC and FFP transfused</P>
<P>HES group received 15 units of RBC and 2 units of FFP</P>
<P>Gel group received 21 units of RBC and 2 units of FFP</P>
<P>No significant difference between groups</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:27:53 +0100" MODIFIED_BY="Anne Lawson" ORDER="115" STUDY_ID="STD-Van-der-Linden-2004">
<TR>
<TD>
<P>HES group received total of 12 units of PRBC, GEL group received 3 units of PRBC</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-06-11 15:56:49 +0100" MODIFIED_BY="Frances Bunn" ORDER="116" STUDY_ID="STD-Van-der-Linden-2005">
<TR>
<TD>
<P> No of patients receiving allogenic blood in each group</P>
<P>HES group n= 24, GEL n= 21 </P>
<P>No of units of PRBC (median and range) </P>
<P>HES 0 (range 0-6), Gel 0 (range 0-6)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-10-16 19:22:54 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Modified gelatin versus dextran</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-10-16 19:22:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>Gelatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Dextran</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Gelatin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dextran</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-03-23 16:09:11 +0000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.0" STUDY_ID="STD-Gombocz-2007" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16373" O_E="0.0" SE="0.0" STUDY_ID="STD-Karanko-1987" TOTAL_1="12" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="16374" O_E="0.0" SE="0.0" STUDY_ID="STD-Tollofsrud-1995" TOTAL_1="10" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-005.02" MODIFIED="2012-05-30 12:38:09 +0100" MODIFIED_BY="Frances Bunn" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Blood/red cells transfused (skewed or inadequate data)</NAME>
<TR>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2012-05-30 12:31:20 +0100" MODIFIED_BY="Frances Bunn" ORDER="120" STUDY_ID="STD-Gombocz-2007">
<TR>
<TD>
<P>Units of red blood cells transfused</P>
<P>Dextran (group A): mean 1.8 (standard deviation (SD) 1.3)</P>
<P>Oxypolygelatin (group B): mean 1.6 (SD 1.2)</P>
<P>P = 0.548</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA MODIFIED="2012-05-30 12:38:09 +0100" MODIFIED_BY="Anne Lawson" ORDER="121" STUDY_ID="STD-Tollofsrud-1995">
<TR>
<TD>
<P>Erythrocytes given was recorded as mean and SD</P>
<P>Polygeline: mean 490 (SD 548)</P>
<P>Dextran: 390 (SD 417)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-05-30 12:38:38 +0100" MODIFIED_BY="Emma M Sydenham" NO="6">
<NAME>HES versus dextran</NAME>
<OTHER_OUTCOME COLS="5" ID="CMP-006.01" MODIFIED="2012-05-30 12:38:38 +0100" MODIFIED_BY="Emma M Sydenham" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Blood/red cells transfused (skewed or inadequate data)</NAME>
<TR>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
<TH/>
<TH/>
</TR>
<OTHER_DATA MODIFIED="2012-05-30 12:32:39 +0100" MODIFIED_BY="Anne Lawson" ORDER="122" STUDY_ID="STD-Hiippala-1995">
<TR>
<TD>
<P>Amount of red cell concentrates transfused in millilitres/kilogram body weight (mL/kgBW) was given as a mean and standard deviation</P>
<P>Dextran mean 19 (SD 12)</P>
<P>4% Starch mean 20 (SD 14)</P>
<P>6% Starch mean 25 (SD 17)</P>
</TD>
<TD/>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2012-06-12 17:41:27 +0100" MODIFIED_BY="Emma M Sydenham"/>
<APPENDICES MODIFIED="2012-05-29 19:09:06 +0100" MODIFIED_BY="Emma M Sydenham">
<APPENDIX ID="APP-01" MODIFIED="2012-05-29 19:09:06 +0100" MODIFIED_BY="Emma M Sydenham" NO="1">
<TITLE MODIFIED="2008-07-18 17:53:53 +0100" MODIFIED_BY="Emma M Sydenham">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2012-05-29 19:09:06 +0100" MODIFIED_BY="Emma M Sydenham">
<TABLE COLS="1" ROWS="9">
<TR>
<TD>
<P>
<B>Cochrane Injuries Specialised Register (searched: 1 December 2011)</B>
<BR/>1. (colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*)<BR/>2. (fluid* or volume or plasma or rehydrat* or blood or oral) and (replac* or therapy or substitut* or restor* or resuscitat* or rehydrat*)<BR/>3. 1 and 2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Cochrane Central Register of Controlled Trials 2011, issue 4 (<I>The Cochrane Library</I>)</B>
<BR/>#1 MeSH descriptor Colloids explode all trees in MeSH products<BR/>#2 MeSH descriptor Plasma explode all trees in MeSH products<BR/>#3 MeSH descriptor Albumins explode all trees in MeSH products<BR/>#4 (colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*)<BR/>#5 (#1 OR #2 OR #3 OR #4)<BR/>#6 MeSH descriptor Fluid Therapy explode all trees in MeSH products<BR/>#7 MeSH descriptor Plasma Volume explode all trees<BR/>#8 (fluid* or volume or plasma or rehydrat* or blood or oral) near1 (replac* or therapy or substitut* or restor* or resuscitat* or rehydrat*)<BR/>#9 (#6 OR #7 OR #8)<BR/>#10 (#5 AND #9)<BR/>#11 (#10), from 2007 to 2011</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>MEDLINE (Ovid) (1948 to November Week 3 2011)</B>
<BR/>1. exp Albumins/<BR/>2. exp plasma/<BR/>3. exp colloids/<BR/>4. (colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*).ti,ab.<BR/>5. 1 or 2 or 3 or 4<BR/>6. Exp Plasma volume/<BR/>7. Exp Fluid Therapy/<BR/>8. ((fluid* or volume or plasma or rehydrat* or blood or oral) adj1 (replac* or therapy or substitut* or restor* or resuscitat* or rehydrat*)).ab,ti.<BR/>9. 6 or 7 or 8<BR/>10. 5 and 9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>EMBASE (Ovid) (1974 to 2011 Week 47)</B>
<BR/>1. exp ALBUMIN/<BR/>2. exp HYDROCOLLOID/<BR/>3. exp PLASMA/<BR/>4. (colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*).ti,ab.<BR/>5. 1 or 2 or 3 or 4<BR/>6. exp Fluid Therapy/<BR/>7. exp Plasma volume/<BR/>8. ((fluid* or volume or plasma or rehydrat* or blood or oral) adj1 (replac* or therapy or substitut* or restor* or resuscitat* or rehydrat*)).ab,ti.<BR/>9. 6 or 7 or 8<BR/>10. 5 and 9<BR/>11. exp Randomized Controlled Trial/<BR/>12. exp controlled clinical trial/<BR/>13. randomi?ed.ab,ti.<BR/>14. placebo.ab.<BR/>15. *Clinical Trial/<BR/>16. randomly.ab.<BR/>17. trial.ti.<BR/>18. 11 or 12 or 13 or 14 or 15 or 16 or 17<BR/>19. exp animal/ not (exp human/ and exp animal/)<BR/>20. 18 not 19<BR/>21. 10 and 20<BR/>22. (2007* or 2008* or 2009* or 2010* or 2011*).em.<BR/>23. 21 and 22<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>ISI Web of Science: Science Citation Index Expanded (1970 to 1 December 2011),</B>
<BR/>
<B>ISI Web of Science: Conference Proceedings Citation Index-Science (1990 to 1 December 2011)</B>
<BR/>#1 Topic=((colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*)) AND Topic=((fluid* or volume or plasma or rehydrat* or blood or oral) NEAR/1 (replac* or therapy or substitut* or restor* or resuscitat* or rehydrat*))<BR/>#2 TS=((singl* OR doubl* OR trebl* OR tripl*) NEAR/1 (blind* OR mask*)) OR TS=((clinical OR control* OR placebo OR random*) NEAR/1 (trial* or group* or study or studies or placebo or controlled)) NOT TI=(Animal* or rat or rats or rodent* or mouse or mice or murine or dog or dogs or canine* or cat or cats or feline* or rabbit or rabbits or pig or pigs or porcine or swine or sheep or ovine* or guinea pig*)<BR/>#3 #1 and #2<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>CINAHL (EBSCO) (1982 to 2011)</B>
<BR/>S1. (fluid* or volume or plasma or rehydrat* or blood or oral) N3 (replac* or therapy or substitut* or restor* or resuscitat* or rehydrat*)<BR/>S2. colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*<BR/>S3. S1 and S2 (limit to Publication Type: Randomized Controlled Trial)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] (searched 1 December 2011: Limit-Humans, published in the last 90 days)</B>
<BR/>#1((randomized controlled trial[pt] OR controlled clinical trial[pt]) OR (randomized OR randomised OR randomly OR placebo[tiab]) OR (trial[ti]) OR ("Clinical Trials as Topic"[MeSH Major Topic])) NOT (("Animals"[Mesh]) NOT ("Humans"[Mesh] AND "Animals"[Mesh]))<BR/>#2 (fluid* or volume or plasma or rehydrat* or blood or oral) and (replac* or therapy or substitut* or restor* or resuscitat* or rehydrat*)<BR/>#3 (colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*)<BR/>#4 (("Albumins"[Mesh]) OR "Colloids"[Mesh]) OR "Plasma"[Mesh]<BR/>#5 #3 or #4<BR/>#6 #1 and #2 and #5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>NRR up to issue 1, 2007</B>
<BR/>#1 (colloid* or albumin* or albumen* or plasma* or starch* or dextran* or gelofus* or hemacc* or haemacc* or hydrocolloid*)<BR/>#2 ((plasma* or fluid* or volum*) and (therap* or restor* or resuscita* or substitut* or replac*))<BR/>#3 #1 and #2<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>ZETOC searched on 23 March, 2007</B>
<BR/>Colloid* fluid* resusc*<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>